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Urinary tract infection (UTI) caused by uropathogenic Escherichia coli (UPEC) is 
a substantial economic and societal burden – a formidable public health issue.  Despite 
significant advances in our understanding of the biology of UPEC, the mechanism by 
which the host successfully responds to UTI and a full comprehension of genetic loci that 
influence susceptibility are not yet in place.  While there is an appreciation for the role of 
classic innate immune responses that occur during UPEC-mediated UTI, there is a clear 
disconnect regarding how these factors stimulate acquired immunity that facilitates 
bacterial clearance upon reinfection.  Unraveling the molecular details of this process is 
vital to understanding the host response to UTI and developing a successful vaccine to 
prevent human UTI.   
Herein, the immune response to and efficacy of outer membrane iron receptor 
proteins delivered intranasally is demonstrated.  Correlates of protection – the 
immunoglobulin “class switch index” and relative abundance of bladder urinary IgA – 
were identified by testing the immune responses to vaccination with both successful and 
unsuccessful vaccine candidates.  In these experiments, splenocytes from mice vaccinated 
intranasally secreted high concentrations of the proinflammatory cytokine IL-17A in 
response to in vitro restimulation.  From this observation, a study was conducted using 
IL-17A
-/-
 mice as a murine model of ascending UTI to determine the role of IL-17A in 




While IL-17A appeared to be dispensable for the development of adaptive immune 
responses that result in enhanced clearance, IL-17A was clearly important to control the 
bacterial burdens of primary infection.  Minimally, both -positive cells and an 
inflammatory monocyte population appear to represent sources of IL-17A.  Not 
surprisingly, IL-17A was found to play a role in regulating inflammatory responses in the 
murine bladder, crucial events for efficient clearance of UPEC during acute infection.  
These results advance our understanding of the innate immune response to UPEC-
mediated UTI, and provide a means to more efficiently evaluate future vaccine 






Chapter 1  
Introduction 
1.1 Urinary tract infection (UTI) 
UTI, one of the most common infections in humans, occurs by an ascending route 
(Figure 1.1).  Bacteria present in fecal matter inoculate the periurethral area, then the 
bladder (191, 277, 461), causing symptoms clinically termed cystitis.  Left untreated, 
bacteria ascend the ureters to the kidney and establish a secondary infection, acute 
pyelonephritis.  At this juncture, there is risk of permanent renal scarring and bacteria can 
access the bloodstream (449).  UTIs are divided into two broad categories: complicated 
and uncomplicated.  Complicated UTI occurs due to anatomic, functional, or 
pharmacologic factors that predispose an individual to infection.  Often these infections 
are caused by organisms other than E. coli, are resistant to many antibiotics (228), and 
spread to other parts of the body.  Uncomplicated UTI occurs in otherwise healthy 
individuals that lack any urinary anatomical abnormalities (192). 
1.1.1 Epidemiological statistics regarding UTI 
In their lifetime, it is estimated that 40% of women and 12% of men will 
experience a symptomatic UTI, with incidences peaking in their early twenties or after 
age eighty-five, respectively (100, 292).  In the year 2000, UTIs accounted for more than 




Figure 1.1  Ascending UTI.  UPEC access the urethra, colonize the bladder, ascend 
the ureters, colonize the kidney, and penetrate the kidney epithelia to enter the blood.  




percent of nosocomial infections are complicated UTI, a direct result of urinary 
catheterization (398).  Recurrence of UTI is a prevalent issue in the clinic.   
Approximately 25% of all women presenting with symptomatic UTI will experience 
another infection within six to twelve months (100, 292).  The cause of recurrent 
infection is a hotly debated topic in the UTI community.  Although UTI is not typically 
thought of as a life-threatening disease [only 1% were fatal in one study of nosocomial 
UTI (398)], 15% to 30% of all bacteremia and sepsis cases result from bacterial 
pyelonephritis (337).  In the United States alone, the estimated annual societal cost of 
UTI is more than three billion dollars (247).   
1.1.2 Risk factors of UTI 
Risk factors for uncomplicated UTI are not always straightforward; however, 
epidemiological studies suggest that frequency of UTI can be attributed to sexual 
intercourse (49) and the use of spermicides (74, 75, 124) or antibiotics (382).  In all age 
groups, women are more likely to experience a UTI than men, a fact attributed to 
differences in anatomy (101).  Both sexes appear to be at high risk of UTI, regardless of 
age, in the event of hospitalization or catheterization (101).  Young women in particular 
have a well-recognized association between recent vaginal intercourse and incidence of 
UTI (49).  Suggested independent risk factors in this group of individuals include the use 
of spermicides with condoms or diaphragms, as opposed to an oral contraceptive (169).  
The mechanism of action responsible for the association of sexual intercourse and 
spermicides use with UTI is believed to be disruption of the normal vaginal flora 




vaginal and/or urethral meatus (389).  Similar to uncomplicated UTI, the factors 
predisposing certain women to recurrence are not clear.  Recurrent UTI patients often 
receive repeated antibiotic treatments, potentially leading to deleterious alterations of the 
normal microbiota (72) and contributing to the generation of antibiotic-resistant strains 
(130).   
1.2 Bladder biology 
 The bladder mucosa is a transitional epithelium with large, highly differentiated, 
multinuclear superficial facet or umbrella cells lining the luminal surface (Figure 1.2A 
and B) (13).  The apical side of umbrella cells, exposed to the lumen of the bladder, 
consists of a detergent-insoluble membrane containing a family of integral membrane 
proteins termed uroplakins (13).  Uroplakins are partly responsible for the barrier 
function of the uroepithelium, and act as receptors for FimH, the tip adhesin of UPEC 
type 1 fimbriae (472).  Beneath the basement membrane of the transitional epithelium lies 
the lamina propria, consisting of fibroblasts and blood vessels, and the site of edema and 
cellular infiltrate in response to infection (Figure 1.2).  Like other surface epithelia of the 
body, the bladder mucosa is a impermeable barrier that is responsible for preventing 
passive diffusion of ions, solutes, and toxic metabolites (13).  The bladder epithelium, 
however, must accomplish these tasks in the atmosphere of cyclical expansion and 
contraction to store and excrete urine waste, respectively (13).  These dynamic 
fluctuations are achieved on a gross level by unfolding of the mucosal surface and on a 
molecular level by cellular membrane dynamics.  Regarding these membrane dynamics, 





Figure 1.2  Histological and schematic views of the murine bladder.  (A)  
Hematoxylin and eosin (H&E) stained section from a healthy wild type C57BL/6 
female mouse.  Magnification, 200x.  Bar = 100 m.  (B)  Schematic 
representation of bladder physiology shown in (A).  (C and D)  H&E-stained 
sections from wild type C57BL/6 mice that were (C) left untreated or (D) 
infected for 48 hours.  Magnification, 40x.  Bar = 500 m.  Artwork in (B) 




endo- and exocytosed at a rate that provides additional membrane surface area during 
expansion (13). 
1.3 Uropathogenic Escherichia coli (UPEC) 
Escherichia coli is by far the most common etiological agent identified in patients 
experiencing uncomplicated UTI (129, 271) and is responsible for 80% of UTIs in 
women (70, 130, 271) and 70% of acute pyelonephritis cases in men (70).  UPEC are not 
a completely random assortment of fecal E. coli.  They appear to be a particular subset of 
strains, 75% of which belong to only six O-serogroups (208).  UPEC is a member of a 
broader class of pathogenic E. coli, the extraintestinal pathogenic E. coli (ExPEC) (347), 
a grouping of E. coli strains that cause diseases other than gastroenteritis (346).  Another 
defining feature of ExPEC is that they typically lack type III secretion systems utilized by 
diarrheagenic E. coli to inject host cells with an array of virulence effectors (267, 450, 
451).  UPEC strains themselves express an assortment of virulence and fitness factors 
which aid in successful colonization of the mammalian urinary tract (Figure 1.3) (193, 
208).   
1.3.1 UPEC virulence and fitness factors 
 To date, there are 14 bone fide virulence factors that have been shown, by 
molecular Koch’s postulates (92), to aid in UPEC colonization.  They are: type 1 fimbriae 
(66), Dr fimbriae (123), TonB (419), -hemolysin (HlyA) (385), cytotoxic necrotizing 
factor (CNF)-1 (336), K2 capsule (52), PhoU (53), DegS (332), Deg P (333), FliC (365), 
RfaH (284), pckA (9), dppA (9), and OmpR (366).  UPEC strains containing mutations in 




Figure 1.3  UPEC virulence and fitness factors.  A schematic depicting the 
major classes of virulence and fitness factors utilized by UPEC during UTI.  




or co-challenge) that could be complemented in trans.  It should be noted that loss and 
complementation of the phenotype caused by the mutation of hlyA was shown 
histologically, and there was no difference in the ability to colonize the urine or bladder 
by wild type and isogenic hlyA strains (385).  Generally speaking, the requirement for 
these gene products reflects the environmental challenges presented by the urinary tract: 
osmotic stress, nutrient/metabolic restrictions, fluid flow, iron sequestration, and host 
immune factors (i.e., complement).  The inclusion of transcriptional regulators (RfaH) 
and proteins involved in sigma factor activity (DegS) also reflect the need to alter global 
transcriptional profiles to acclimate to the urinary tract.  The inclusion of both hemolysin 
and CNF-1 illuminates the importance of toxins in UTI pathogenesis.  Moreover, the 
genome of CFT073, a model UPEC (270), revealed the presence of seven putative 
autotransporter proteins (450).  Autotransporter proteins are members of the type V 
secretion system (161), and with respect to UPEC, have pleiotropic functions both in vivo 
and in vitro (159, 305, 437, 439).  The secreted autotransporters toxin (Sat) has both 
vacuolation and cytopathic effects on cell lines, and can cleave a number of host proteins 
that may contribute to the progression of UTI (131, 133, 252).  Lastly, several of the 
aforementioned genes are encoded within large genomic elements termed “pathogenicity 
islands,” acquired by UPEC via horizontal gene transfer (39, 60, 132, 248, 304, 328, 
407).  These islands are comprised of a number of genes that facilitate UPEC survival in 
both the gut and the urinary tract, including those regulated by iron, biosynthetic and 
metabolic operons, and genes encoding secretion systems, motility and adherence 




1.3.2 Adherence and motility 
Adherence is critical for establishment of UTI (451).  UPEC stains have an 
impressive repertoire of factors that enable attachment to the uroepithelium.  Fimbriae are 
filamentous organelles that allow bacterial cells adhere to a number of different tissue 
surfaces or cell types.  To date, at least four types of fimbriae are known to be expressed 
by uropathogenic strains of E. coli.  They include P (pap), type 1 (fim), S (sfa), and F1C 
(foc) fimbriae.  Each type of fimbriae is encoded by at least one cluster of genes whose 
products are involved in synthesis and regulation (276).  Uropathogenic strains also 
encode the highly heterologous family of Afa and Dr adhesins (314, 373) that mediate 
adherence to both urinary and intestinal niches (211, 373).  Lastly, in addition to a 
number of uncharacterized non-polymeric adhesins that bind an assortment of host 
proteins, UpaG and antigen 43 autotransporter proteins have been shown to facilitate 
adherence to the extracellular matrix and be important for persistence in the urinary tract 
(437, 439). 
Regulation of UPEC fimbriae expression is a complex process.  Fimbrial 
expression is known to phase-vary, and expression of the different fimbrial operons must 
be coordinated with respect to each other and the environment (387, 388).  Additionally, 
expression of fimbriae appears to influence flagellin expression and bacterial motility 
(234).  Indeed, flagellar synthesis is negatively regulated during constitutive expression 
of fimbriae; however, the converse – fimbrial regulation in response to flagellar 
expression – does not appear to occur (234).  Nonetheless, flagella are essential for 
propagation of the infection from the bladder to the kidneys (230, 232, 454).  Using 




demonstrated that flagella confer a fitness
 
advantage for colonization (232) and 
persistence (454) in the urinary tract.  In an elegant study looking at transcriptional 
activity from the fliC promoter using a luminescence reporter system in vivo, Lane et al. 
provided direct evidence that flagella are expressed at the time [four to six hours post 
infection (hpi)] and location (ureters) corresponding to UPEC ascension from the bladder 
to the kidneys (230). 
1.3.3 UPEC iron acquisition systems 
Iron is essential for UPEC growth and survival in the urinary tract.  Sequenced 
genomes reveal that functional redundancy appears to be the theme for iron uptake by 
UPEC (Figure 1.4) (50, 60, 450).  UPEC secretes several classes of siderophores: low 
molecular weight iron-chelating molecules that scavenge iron in the ferric (oxidized) 
form in the urinary tract (47, 290).  In addition to aerobactin, enterobactin, salmochelin, 
and yersiniabactin siderophores, UPEC outer membrane (OM) receptors can also acquire 
iron bound by host heme/hemoglobin (46, 125).  Energy for uptake of iron-bound 
substrates by highly-specific OM proteins is derived from the electrochemical potential 
of the inner (cytoplasmic) membrane; this energy is transmitted to the OM by the TonB-
ExbB-ExbD system (46, 125).  Transcription of iron-related proteins is controlled by Fur, 
a master regulator that exerts its activity based on its iron-bound state (146).  Mutation of 
genes in several of the iron-uptake loci results in colonization defects during co-challenge 
with wild type in the mouse model, emphasizing the fitness advantage afforded by these 
systems (136, 195, 345, 348).  However, mutation of any single iron uptake system does 





Figure 1.4  Putative and established outer membrane receptors utilized 
for iron acquisition by E. coli CFT073.  Depicted are outer membrane 
receptors functioning in several different iron uptake systems, categorized by 




redundancy of iron acquisition systems in UPEC. 
1.3.4 UPEC central metabolism and pathogenesis 
The metabolism field is generating an enriched understanding of bacterial 
pathogenesis by recognizing the importance of genes that are not classically associated 
with virulence (i.e. toxins and adherence organelles) (9, 91, 199).  Specific to UTI, 
infection studies using bacterial mutants in key metabolic pathway enzymes revealed that 
the preferred carbon source for UPEC in the urinary tract is peptides, and that anaplerotic 
pathways (reactions that replenish metabolites) are also important (9).  On the host side, 
genes important for glucose import were upregulated by the uroepithelium of C3H/HeJ 
mice experiencing UTI, possibly for either nutrient sequestration or energy to combat 
infection (334).  The former prospect is unlikely, given that UPEC does not chemotax 
toward glucose in vitro (231) or utilize glucose as a primary carbon source in vivo (9).  
These data imply that, as a requisite for survival in the urinary tract, UPEC strains may 
have specifically evolved to use carbon sources other than glucose.  These results indicate 
that nutrient acquisition is a crucial aspect of bacterial pathogenesis and the host response 
that may influence the outcome of UTI. 
A role for metabolism involving D-serine has also been uncovered in the 
regulation of gene expression during UTI (151, 340).  D-serine is present in high 
concentrations in human urine (179), and UPEC strains commonly encode a catabolic 
enzyme, D-serine deaminase (DsdA), that converts D-serine to pyruvate and ammonium 
(273, 340).  Interestingly, a dsdA mutant exhibits a hypervirulent phenotype in the 




expression of genes directly involved in urinary tract survival – flagella, fimbriae, 
hemolysin, an OM porin, a heat shock protein, and a dipeptide transporter (151, 340).  It 
is not known if increased virulence gene expression in the dsdA mutant is a result of 
direct transcription changes in response to intracellular accumulation of D-serine or 
indirect effects due to altered metabolic processes. 
1.4 Treatments for UTI 
1.4.1 Antibiotics 
UTIs are typically treated with antimicrobial therapy; however, it is well 
established that treatment of bacterial infection with antibiotics selects for antibiotic 
resistance, a fact also applies to UPEC.  Of equal but underappreciated importance, 
selection of host commensal bacteria by antibiotic treatment could potentially serve as a 
resistance reservoir for UPEC strains (103), thus making resistance an important factor in 
the appropriate antibiotic choice for UTI treatment.  However, the choice of an 
antimicrobial agent for treatment of UTI is generally made empirically, especially in 
outpatient cases.  In some geographical regions, both ampicillin (197) and trimethoprim-
sulfamethoxazole have generated levels of bacterial resistance that render them 
inadequate for empirical treatment (279, 423).  Fluoroquinolones are the preferred agent 
to treat complicated UTI, in addition to being an alternative for uncomplicated UTI (351, 
397).  Not surprisingly, increased use of fluoroquinolones has also correlated with 
elevated levels of fluoroquinolone resistance (70).   




There has also been interest in non-antibiotic prophylactic treatments for UTI.  
Several reports indicate estrogen treatment of post-menopausal women alleviates 
recurrent UTI by virtue of its ability to restore a pre-menopausal vaginal pH (<4.5) and 
bacterial lactobacilli microbiota (45, 192, 309, 322, 331).  These results, however, are 
controversial (56, 214).  Prophylactic treatment for UTI using cranberry juice, while 
seemingly effective, has been somewhat anecdotal.  One study, however, showed 
substantial clinical evidence – a daily cranberry juice regimen given to 153 women 
reduced bacteriuria and pyuria by 42% (18).  Proposed mechanisms of action include 
acidification of urine (104) and interference with fimbriae expression or binding to the 
uroepithelium (311).  Pre- and post-coital bladder voiding appears to be associated with 
prevention of sexual intercourse-associated UTI, although data regarding this practice 
and the incidence of UTI are conflicting (102, 169).  Additionally, several studies have 
report that post-coital prophylactic treatment with antibiotics was found to be a successful 
means to prevent recurrent UTI (259, 399, 400). 
1.4.3 Proposed new treatments 
Specific targeting of particular virulence mechanisms is an exciting avenue of 
treatment with recent indications of translational use.  Cyclic adenosine monophosphate 
(cAMP) was shown to play a role in both the cytokine response to and inhibition of 
invasion events by UPEC (392, 394).  Forskolin, a drug causing increases in intracellular 
cAMP, was proposed as an effective treatment for the remove of UPEC contained in 
fusiform vesicles, which are the specialized vesicles dynamically endo- and exocytosed 




UPEC harbored in intracellular vesicles, rendering the bacteria susceptible to immune 
responses and antibiotics (37).  Similarly, exposing the bladder to protamine sulfate, a 
highly cationic protein, removes bound and intracellular UPEC by causing umbrella cells 
to exfoliate (280), unfortunately with a significant level of discomfort in volunteers (245).  
In addition to a number of non-specific chemical treatments (435), both small-molecule 
inhibitors (42) and specific antibody directed against FimH (412) have shown potential in 
that they interfere with FimH binding to its natural ligand in the urinary tract, the 
glycoprotein uroplakin Ia (263, 472).   
Vaccine initiatives for UTI  
While antibiotic therapy remains the standard treatment for UTI, overuse leads to 
deleterious alterations of the normal host microbiota (72) and selection for resistant 
strains (70, 103, 129, 130, 197, 279), prompting the need for vaccine-mediated 
prevention of UTI.  Despite a relatively in-depth knowledge base for UPEC physiology 
and virulence mechanisms [reviewed in (74, 193, 208, 451)], no licensed vaccine to 
prevent UTI exists in the United States.  A more thorough understanding of the 
mechanisms involved in the natural immune response to UTI, however, may direct a new 
approach to harness these responses in a vaccination setting.  Nonetheless, small 
successes have been observed in both animal models and in clinical trials.  These efforts 
are summarized in the following sections and in Table 1.1.  
1.4.4 Vaccines based on O- and K-antigens 
 Early vaccine studies targeted the lipopolysaccharide (LPS) side chain (O)-




Table 1.1  Previously tested vaccines for UPEC-mediated UTI. 
Category/ 




















O-antigen R B, SC ND
f 
H B (436) 
OMP 
fractions 
Swiss IM, O CFA
 
C, H B (238) 
Adherence       














CFA, IFA H B, K (236) 
FimHt BALB/c IM, IN CFA, IFA, 
CpG 
H B (317) 





CFA, IFA H B (412) 
P fimbria BALB/c IM, 
SC 
CFA, IFA H K, U (293, 
294, 360) 




Pap peptides BALB/c IM, 
SC 
CFA, IFA H U, K (360) 
Toxin       
Denatured 
HlyA 




      
Denatured 
IroN 
BALB/c SC ND H K (349) 
Native ChuA CBA/J IN CT C, H - (7) 
Native Iha CBA/J IN CT C, H - (7) 
Native IroN CBA/J IN CT C, H - (7) 
Native Hma CBA/J IN CT C, H B, K (7) 
Native IreA CBA/J IN CT C, H B, K (7) 
Native IutA CBA/J IN CT C, H B, K (7) 
Complex       
SolcoUrovac BALB/c IP, V MO C B, K (432) 
SolcoUrovac C57BL/6 IP, V MO C B, K (432) 
SolcoUrovac Swiss IP ND H ND (223) 
SolcoUrovac R IP AP ND K (222) 








Uro-Vaxom BALB/c IP, O ND C, H ND (21, 180, 
367) 




Live (L), live 
attenuated  
(LA), or killed 
(K) E. coli  
      
L NU14 C57BL/6
J 
TU ND C, H B (416) 




IN ND H ND (344) 








B ND ND B (35) 
K J96 BALB/c IM, 
SC 
CFA H - (294) 
K P678-54 BALB/c IM, 
SC 
CFA H - (294) 
K O6 R V IFA N B, K (433) 
K 1677 P V MO, MDP H U (425, 
431) 
a
 If tested in mice, strain specified; R=rats; P=Non-human primates; H=humans 
b 
B= bladder, IM=intramuscular, IN=intranasal, IP=intraperitoneal, O=oral, SC=subcutaneous, 
TU=transurethrally, V=vaginal 
c
 AP=Aluminum phosphate, CFA=complete Freund’s adjuvant, CpG= CpG oligodeoxynucleotides, 
CT=cholera toxin, IFA=incomplete Freund’s adjuvant, MDP=muramyl di-peptide, MO=Mineral oil (for 
vaginal route only) 
d
 C=cellular or H=humoral 
e 
K=reduction in kidney colonization/histopathology, B= reduction bladder colonization, -=no protection, 
Y=significant decrease in UTI incidence, U= reduction of UTI as determined by urinalysis 
f







UTI isolates (90, 403, 451), and O-antigen-specific antibodies demonstrate an anti-
adhesive effect (403).  Despite this finding and the fact that antigen-specific antibodies 
were detected in their urine, mice injected (subcutaneously or directly into the bladder) 
with O-antigen displayed only a modest reduction in bacterial colonization upon 
challenge (436).  Additionally, significant structural heterogeneity may represent an 
insurmountable obstacle for development of an O-antigen-based vaccine.   
Similar to the trends regarding particular O-antigen serotypes and uropathogenic 
strains, a number of virulence determinants associated with UTI appear to be associated 
with strains that have the K1 serotype (90).  There is evidence that capsular antigen 
specific antibodies are generated in response to UTI (145, 201), and the protective nature 
of K-specific antibodies has been demonstrated in an mice challenged the intraperitoneal 
(i.p.) route with E. coli (202).  Studies specific to UTI, however, have shown that K- 
specific antibodies have only a minor role in preventing E. coli from binding to human 
epithelial cells (403).  Considering that adherence is a key virulence determinant for 
uropathogenicity (79, 443), this result was not promising.  Lastly, a study evaluating 
antibody responses in mice intranasally vaccinated with a killed E. coli lacking capsule 
and O-antigen demonstrated that these surface features actually obstruct optimal humoral 
responses to other surface proteins (344). 
1.4.5 Vaccines based on kidney-specific virulence and fitness factors:  
P fimbriae and -hemolysin   
Later studies involved vaccines directed against particular virulence factors.  P 
fimbriae (also known as P-pili) are adherence organelles that play a role in kidney 




P fimbriae are the proposed minimal factors required for colonization of and 
dissemination from the kidney (293).  There are convincing data using both murine (293, 
294, 360) and primate models (338, 339) that vaccination against P fimbriae or HlyA 
prevents renal colonization and damage.  Additionally, to overcome P fimbrial allelic 
variability, linear peptide sequences that generated cross-reactive antibodies were 
evaluated as protective antigens (300, 360).  While P-fimbriae vaccination strategies were 
shown to decrease colonization levels in the kidney upon challenge, -hemolysin 
vaccination specifically protects mice from renal injury after challenge (293).  Beyond 
this study, the secretion system of E. coli -hemolysin, a prototypical type I system with 
secretion mediated by the HlyB, HlyD, and TolC proteins, has been used to deliver 
heterologous vaccine antigens from several different bacterial, parasitic, and viral 
antigens with some success (116).  Despite these successes, vaccines targeting P fimbriae 
may not be effective because of the kidney tropism of this fimbriae type.  In other words, 
while complicated UTI risk patients may avoid kidney damage and risk of bacteremia as 
a result of a vaccine based on P fimbria and HlyA, patients at risk of uncomplicated 
cystitis may benefit more from a vaccine that targets antigens expressed in the bladder, 
the site of initial infection.   
1.4.6 Vaccines based on bladder specific virulence factors:  
Type 1 fimbriae 
Type 1 fimbria is a bone fide virulence factor of UPEC and, in contrast to P 
fimbria, is critical for bladder colonization (15, 66, 127, 412).  Animals vaccinated with 
various components of type 1 fimbriae had increased levels of antigen-specific antibodies 




Unfortunately, type 1 fimbriae are subject to phase variation, allowing UPEC to evade 
immune responses by modulating gene expression (81, 388).  Additionally, since non-
pathogenic isolates also express type 1 fimbriae (140, 193), targeting this population may 
result in detrimental disruption of the host microbiota.  Targeting uropathogenic strains 
expressing type 1 fimbriae may also select for strains of E. coli that have been described 
to adhere to the epithelia by alternative adherence systems (233) or other mechanisms 
altogether (443).   Also of note, both P and type 1 fimbriae were not necessary for 
colonization of the human neurogenic bladder, indicating the need for alternative targets 
in certain high-risk patient groups (181).   
1.4.7 Vaccines targeting proteins involved in iron acquisition 
 Iron is essential for nearly all organisms (112, 468) and UPEC encode a battery of 
genes whose products are involved in iron acquisition.  Vaccination with UPEC OM 
protein (OMP) fractions that are enriched for iron receptors protects against experimental 
sepsis in both turkey and a murine models (41, 78).  Additionally, mice vaccinated 
subcutaneously with denatured IroN, an OMP siderophore receptor and urovirulence 
factor (348), had both increased levels of antigen-specific serum IgG and significantly 
reduced kidney colonization upon challenge (349).  Undetectable levels of IgA in the 
bladder mucosa may explain why IroN-vaccinated animals were not protected from 
cystitis (349).  This study also demonstrated an important caveat in generating an 
effective vaccine for UTI: systemic and mucosal antibodies are necessary to protect both 
the bladder and kidney from infection, respectively (349).  Chapter 2 describes a recent 




identify PASivE vaccine candidates: UPEC proteins that are pathogen-specific, antigenic, 
surface-exposed, and in vivo-expressed (Table 1.2) (7, 380).  Strikingly, the top targets 
identified by this approach were all OMPs functioning in iron uptake.  Intranasal 
vaccination with three of six candidates afforded protection from cystitis and 
pyelonephritis (7), suggesting that combining antigenic motifs found in these proteins 
may be an effective multivalent vaccine for UTI. 
1.4.8 Complex vaccines  
 Vaccines consisting of bacterial components or whole cells have also been 
assessed.  Often, these types of vaccines result in adverse affects and non-protective 
immune responses (192).  Nonetheless, they have been the focus of several studies over 
the last few decades.  Transurethral immunization of mice with a live-attenuated UPEC 
strain lacking the ability to persist in the urinary tract resulted in heterologous protection 
(35), a potential platform for further development.  In addition, SolcoUrovac (of the 
former Solco Basle Ltd./ICN Pharmaceuticals/Valeant Pharmaceuticals) is a whole-cell 
vaccine containing ten heat-killed uropathogenic strains, including six E. coli, and one 
each of Proteus mirabilis, Morganella morganii, Enterococcus faecalis, and Klebsiella 
pneumoniae (223).  SolcoUrovac has been tested in mice (223, 432), non-human primates 
(430), and in clinical trials (126, 171, 174, 350, 426-429).  Although SolcoUrovac 
showed efficacy in the kidneys in rats immunized intramuscularly and challenged by i.p. 
injection (222), the results of this study are non-translatable since there are clear toxicity 
concerns when delivering unknown levels of LPS systemically in humans.  In response to 




Table 1.2  Screens used to identify PASivE UPEC vaccine candidates. 
Criteria Screen(s) Reference 
Pathogen-
specific 
Comparative genomic hybridization (CGH) (248) 
In silico comparative genomics (60) 
Southern blot (137) 
Antigenic 
Two-dimensional SDS-PAGE and Western blot (137) 




In silico mining for genes containing predicted OM 
protein signatures (transmembrane domains, signal 
peptide cleavage sites, etc.) 
(D. Rasko, 
unpublished) 
Identification of surface peptides by limited 




Gene expression microarray (386) 
Two-dimensional fluorescence difference gel 
electrophoresis (2D-DIGE) 
(8) 
IVIAT (P. Vigil et al., 
unpublished) 




Quantitative metabolomics (162) 





in human clinical trials (426-429).  While safe, vaginal vaccination with SolcoUrovac did 
not result in appreciable increases in local specific antibody (427, 429, 430), nor did it 
afford long-term protection levels in women with recurrent UTI (427, 429).  Reasons for 
this result may include but not be limited to strain-specific (non-heterologous) immune 
responses, destruction of immunogenic antigens during vaccine preparation, and the lack 
of a mucosal adjuvant.  Human leukocyte antigen (HLA) genes, encoding major 
histocompatibility (MHC) complexes present on the surface of immune cells and 
responsible for antigen presentation in humans, influence an individual’s ability to 
recognize and respond to pathogens.  SolcoUrovac was not efficacious in women with the 
HLA-DR2 phenotype (174), indicating that this or other UPEC vaccine formulations may 
not be efficacious in this patient population. 
Uro-Vaxom (Om-89, OM Pharma) is a daily oral capsule containing a lyophilized 
mix of membrane proteins from eighteen E. coli strains (134, 409).  The formulation 
elicits a number of immunological effects in vitro (359, 444, 458, 459) and generates 
specific antibodies in mice and humans (21, 71, 180, 367).  As of 2002, twelve studies 
had been completed testing the efficacy of Uro-Vaxom (29), and in general, patients 
receiving Uro-Vaxom exhibited a reduced frequency of UTI than those receiving a 
placebo (28, 71, 134, 241, 251, 362, 409).  Unfortunately, complications can occur due to 
toxicity, and the exact mechanism of action is difficult to delineate.  The necessity of 
daily administration of Uro-Vaxom also presents supply and compliance issues.   
1.5 Innate host defenses to UPEC-mediated UTI 




Uroepithelial adherence is critical for establishment of UTI (451).  UPEC strains 
possess an impressive repertoire of adhesins that enable them to aggregate and adhere to 
cell surfaces (160, 211, 314, 373, 439).  Consequently, the first line of host defense 
against UTI is concentrated on preventing UPEC adherence to the bladder mucosa.  The 
luminal surface of the bladder is lined with highly sulfated and anionic 
glycosaminoglycans that contribute to bladder wall impermeability and afford an 
antimicrobial anti-adherence property (183, 245, 307, 308, 310, 377).  Intuitively, urine 
flow seems to be a convenient defense mechanism; however, FimH binds to mannose 
moieties using “catch-bonds,” interactions that are actually strengthened by the sheer 
stress induced by urine flow (413).   
1.5.2 Urothelial cell apoptosis 
More active mechanisms such as umbrella cell exfoliation (14, 82, 108, 262, 277, 
278, 298) also function to remove adherent UPEC.  Exfoliation occurs by an apoptosis-
like mechanism that is promoted by FimH (216, 277).  An in vitro investigation of the 
apoptotic cascades suggested that FimH acts like a tethered toxin, inducing cellular 
events consistent with activation of both extrinsic
 
(death receptor) and intrinsic 
(mitochondrial) apoptotic pathways, with cross-talk between the two signaling cascades 
mediated by the pro-apoptotic Bid protein (215).  UPEC-induced urothelial cell death 
correlates with increased bladder cell differentiation and is also dependent on expression 
of the uroplakin IIIa receptor, a terminal differentiation marker (281, 414).  Nuclear 
factor of kappa light polypeptide gene enhancer in B-cells (NF- B) is a transcription 




genetic programs (26, 447).  UPEC, independent of type 1 fimbriae, is able to suppress 
NF- B and thereby promotes host cell apoptosis (216).  Given the role for apoptotic cell 
exfoliation in UPEC host defense, promoting this sloughing activity may appear counter-
productive for the bacteria.  Nonetheless, cellular apoptosis may be an acceptable side 
effect of inhibiting the proinflammatory gene expression and the ensuing cellular 
responses initiated by NF- B.  
1.5.3 Tamm-Horsfall protein (THP) 
THP (a.k.a., mucoprotein, uromucoid, uromodulin) was first described in the early 
1950s as a high molecular weight protein present in human urine (408); its ability to bind 
E. coli type 1 fimbriae was not recognized until some thirty years later (299, 301, 306).  
THP was shown to be associated with (and thus secreted by) cells of the ascending limb 
of the loop of Henle and the distal convoluted tubule in the kidney (378).  A detailed 
biochemical analysis revealed that soluble THP from both mouse and human urine was 
able to bind type 1 fimbriae by virtue of its mannose moieties, inhibiting fimbrial 
interaction with uroplakin Ia and Ib receptors (269, 302).  THP was also shown to bind 
efficiently to S fimbriae (306).  Definitive studies using THP
-/-
 mice confirmed the ability 
to help control bacterial burdens in the lower urinary tract.  Compared to wild type mice, 
bacteria were present for longer durations and in higher numbers in the urine of THP
-/-
 
mice, and at twenty-four hpi, bladder bacterial burdens were increased in THP
-/- 
mice (27, 
268).  The use of lower inocula for infection exacerbated the phenotype (268), and there 
was no phenotype attributable to UPEC expressing P fimbriae (27, 268), further evidence 




as an innate-adaptive immunoregulatory molecule that can activate dendritic cells (DCs), 
as exemplified by surface marker expression, cytokine secretion, and the ability to 
stimulate T cells (353).  Both the aberrant presence of the THP itself and the generation 
of anti-THP-specific antibodies have implicated THP in many urological diseases (99, 
289, 353, 370).  The connection between UTI-induced THP expression and THP-
mediated renal disease is currently unexplored (109).    
1.5.4 Innate recognition of UPEC 
1.5.4.1 UPEC recognition by TLR4 
The late Charlie Janeway originally described the concept of pathogen-associated 
molecular patterns (PAMPs) being recognized by pattern recognition receptors (PRR) on 
host cells (420).  Upon successful adherence to the uroepithelium, PAMP recognition by 
toll-like receptors (TLRs) (190, 258) generates signaling cascades to direct innate and 
adaptive immune responses (75, 391).  It has been known for over two decades that 
C3H/HeJ mice, harboring a mutation in the Toll/Interleukin (IL)-1 receptor (TIR) domain 
of TLR4 (319), cannot resolve UTI as efficiently as LPS-responsive C3H/HeN 
counterparts (405).  In accordance, TLR4
-/-
 mice had significantly higher bacterial 
burdens in their bladders  compared to similarly-infected wild type mice (16).  This 
clearance defect is the result of both insufficient downstream cytokine and chemokine 
production and neutrophil recruitment (139, 170, 312, 374).  Data from mouse chimeras 
disclosed that TLR4 on both stromal and hematopoietic cells is critical for normal 
inflammatory responses and clearance of UPEC in the bladder (356) and kidney (312).  




demonstrated by studies of human patients.  Asymptomatic bacteriuria (ABU) is the 
presence of bacteria in urine specimens with no clinical presentation (symptoms) of acute 
UTI (271).  Children with low TLR4 expression on their neutrophils display the ABU 
carrier state, lacking both inflammation and bacterial clearance (325).  A similar response 
is exhibited by C3N/HeJ (LPS-non-responsive) mice following UPEC inoculation (324).  
While no mutations or polymorphisms of the TLR4 gene appeared to explain the 
expression defect in the affected children, there were alterations in the level of adaptor 
and regulatory protein expression that may affect TLR4 expression (325). 
1.5.4.1.1 UPEC molecular ligands recognized by TLR4 
TLR4-mediated signaling in the urinary tract does not appear to be the result of 
the archetypal interaction with LPS.  Both the role of LPS in and the molecular trigger of 
TLR4 signaling by UPEC are topics of debate (19, 158, 357).  Studies using the A498 
human kidney cell line indicate that TLR4 signaling in response to UPEC requires P 
fimbriae and can be mediated independently of LPS (106, 156, 158).  Mechanistic details 
regarding this phenomenon include P fimbriae binding to surface glycosphingolipids 
(GSLs) and subsequent release of the GSL membrane-anchoring domain, ceramide (95).  
Ceramide appears to act as a TLR4 agonist and the putative intermediate for TLR4 
signaling initiated by P fimbriae (95).  In contrast to LPS-independent signaling by P 
fimbriae, there appears to be a cooperative stimulation of TLR4 by LPS and type 1 
fimbriae (157, 358).  This cooperative stimulation directly correlates with the level of 
cluster of differentiation (CD)14 expression on bladder cells (357).  CD14 is an accessory 




Immunohistochemical (IHC) analysis of human bladder biopsies revealed that CD14 
expression is localized to the submucosa (158), suggesting that uroepithelial cells 
exposed to the lumen have little to no CD14 expression and therefore may not respond 
efficiently to LPS alone.  These results support a role for both independent and 
cooperative TLR4 stimulation by UPEC fimbriae.  Lastly, the FimH tip adhesin of type 1 
fimbriae was recently shown to directly interact with TLR4, an additional means for LPS-
independent stimulation by UPEC fimbriae (16, 275).   
1.5.4.1.2 Signaling downstream of TLR4 
Infection of knockout mice has revealed critical roles for myeloid differentiation 
primary response protein 88 (MyD88), TIR domain-containing adaptor inducing IFN-  
(TRIF), and TRIF-related adaptor molecule (TRAM) in signaling for UPEC clearance 
(96).  It is also apparent that different fimbrial types influence the corresponding 
downstream signaling pathways (96).  Regardless of the fimbrial type involved in 
stimulation, all pathways involving these adaptor molecules result in activation of NF- B 
and proinflammatory gene expression.  Song and colleagues identified an accompanying 
proinflammatory bladder cell signaling pathway that is also dependent on TLR4, but 
results in a spike in intracellular calcium levels (394).  This calcium spike leads to 
adenylyl cyclase 3-mediated increases in cAMP, protein kinase A (PKA) activation, 
phosphorylation of the cAMP response element–binding protein transcription factor 
(CREB), and proinflammatory gene expression (394).  In response to UPEC inoculation, 




translocation to the nucleus (two hours) and can also be activated by TLR2 and TLR3 
ligands (394).   
1.5.4.2 UPEC recognition by other TLRs   
Other TLR pathways have been implicated in host defense during UTI (Figure 
1.5).  TLR2
-/-
 mice appear to respond normally to acute UTI  (324).  Conversely,  
TLR11
-/-
 mice are more susceptible to UPEC kidney infection compared to wild type 
mice (469).  The TLR11 ligand is a profilin-like molecule that was isolated from 
Toxoplasma gondii (463).  While structurally-related
 
proteins are present in other 
apicomplexan protozoa (463), a UPEC-encoded homolog has yet to be identified.  The 
fact that there is a stop codon in the open reading frame of human genomic and cell line 
tlr11 sequences may help explain acute and recurrent UTI susceptibility in humans (469).  
In contrast to the kidney-specific role for TLR11 during UTI (469), TLR5 appears to play 
a UPEC-recognition role in the bladder (10).  TLR5 recognizes flagellin, the structural 
subunit of flagella (152), which are essential for UPEC motility in the urinary tract (230, 
232, 454).  Flagellar expression peaks at four to six hours post inoculation, coinciding 
with UPEC ascension of the ureters (230).  At this time point, there is TLR5-dependent 
induction of inflammatory cytokines and chemokines (10).  By day five post inoculation, 
TLR5
-/-
 mice have increased inflammation and bacterial burdens compared to wild type 
controls (10), highlighting the importance of early recognition of UPEC by TLR5 to 
contain the infection. 
1.5.4.3 Non-TLR UPEC recognition 








Figure 1.5  TLRs important in UTI host defense.  Depicted are the three 
TLRs and their proposed or confirmed ligands have been definitively 
shown (through the use of knockout mice) to play a role in recognition of 
UPEC and host defense during UTI.  Note that the UPEC-specific ligand 




UPEC exposure, the cytoplasmic tail of uroplakin IIIa undergoes phosphorylation and 
intracellular calcium levels
 
increase, important events for uroepithelial cell apoptosis and 
exfoliation (415).  Although uroplakin Ia is thought to be the main receptor for UPEC 
FimH in vivo (263, 412, 455), type 1 fimbriae may bind to a number of host molecules, 
including uroplakin complexes (415), extracellular matrix proteins (225, 320, 390), CD 
molecules (24, 115, 213), and integrins (87).  The role of the CD44 receptor and its 
ligand, hyaluronic acid (HA) polysaccharide, in experimental UTI has been elucidated 
(342).  Although UPEC themselves do not appear to express HA, they can bind it in vitro 
(342).   Typically involved in cell-cell and cell-extracellular matrix interactions, HA 
accumulates in the urinary tract in response to infection, and likely facilitates the 
interaction between UPEC and CD44 (342).  This interaction was shown to potentiate 
UPEC migration across the epithelium in a Transwell system and be important for murine 
kidney colonization (342).  CD44 expression is ubiquitous throughout the uroepithelium 
and CD44
-/-
 mice were more resistant to UTI, likely due to the inability of the bacteria to 
efficiently penetrate the kidneys (342).  Neutrophil migration and cytokine secretion was 
found to be independent of CD44, indicating that this surface receptor likely does not 
play a role in innate immune recognition (342).  However, because of its role in 
lymphocyte activation, it would be interesting to see if there are deficiencies in the 
adaptive immune response in CD44
-/-
 mice.  Lastly, there are still unidentified players in 
inflammation and clearance of UPEC.   For example, LPS-responsive C3H/OuJ mice 
were found to be equally susceptible to UTI as non-LPS responsive C3H/HeJ mice, yet 
demonstrated elevated levels of inflammation (170), revealing a susceptibility locus to 




1.5.4.4 UPEC defenses against host recognition 
UPEC has evolved mechanisms to counter host recognition and signaling.  
Clinical UPEC isolates encode the gene for TcpC, which has structural homology to the 
TIR domain of human TLR1 and binds to MyD88, thereby inhibiting cytokine responses 
(64).  While other sequenced genomes of UPEC and ExPEC model strains do not appear 
to encode the tcpC gene (34), a molecular epidemiology survey revealed the presence of 
the gene in clinical isolates is associated with severity of UTI; that is, 40% of 
pyelonephritis isolates encoded homologous genes as compared to only 21% cystitis, 
16% ABU, and 8% commensal (64).  TcpC-mediated interference with MyD88 signaling 
is an immune evasion strategy particular to acute pathogens; targeting this major 
signaling “hub” rapidly deteriorates innate immune responses (48).  UPEC also encodes 
genes that modify bacterial proteins to evade detection.   Billips and colleagues noted that 
a type 1-fimbriated K12 strain elicited more robust cytokine secretion from cultured 
urothelial cells than UPEC strains (33).  The authors used a genetic screen to isolate 
bacterial mutants that resulted in enhanced secretion of IL-8 from bladder epithelial cell 
lines (34).  They identified a peptidoglycan permease (ampG) and an O-antigen ligase 
gene (waaL) – enzymes that modify PRR targets – responsible for the dulled cytokine 
secretion in response to uropathogenic strains (34).  A similar screen also identified the 
rfa/rfb operons and surA, encoding genes important for LPS biosynthesis and OMP 
biogenesis, respectively (182).  These results suggest that UPEC utilizes gene products 
that modify bacterial membrane (especially LPS) to evade immune recognition and 
highlight the potential importance of TLR stimulation involving fimbriae and other 




1.5.5 Host iron sequestration and active inhibition of UPEC iron acquisition 
Considering the essential role of iron in both host and pathogen cellular processes, 
there are remarkably low concentrations of free iron in mammalian hosts.  This is not 
only a mechanism to avoid iron toxicity; it is a way to prevent the growth and 
establishment of infection by invading pathogens.  Indeed, as early as the 19
th
 century it 
was noticed that supplementing tuberculosis sufferers with iron worsened the outcome of 
disease, a notion that was later confirmed in experimental animal models (329).   
That E. coli strains causing UTI have several functionally redundant systems 
dedicated to iron uptake (50, 60, 450) suggests that the urinary tract, like other host 
niches, is an iron-limited environment requiring dedicated acquisition systems for 
survival (25).  For instance, enterobactin, a siderophore encoded by UPEC, can bind free 
ferric ions with a higher affinity than transferrin (93), a host iron transport protein 
responsible for regulating the free iron concentration in serum (330, 445).  A transferrin 
family member, lactoferrin, evokes antimicrobial activity by sequestering iron over a 
range of pH (445).  Lactoferrin is secreted by kidney cells (3) and found in other bodily 
secretions and neutrophil granules (69), thus could be involved in combating UTI.  Both 
transferrin and lactoferrin have been shown to mediate direct antimicrobial activity by 
disrupting Gram-negative bacterial membranes (83, 124).   
In addition to iron sequestration, there are host factors that directly counter the 
action of siderophores.  Early studies indicated that serum albumin, alone or in concert 
with other serum proteins, can impede bacterial siderophore function (218).  In addition, 
the 24 kDa mammalian protein lipocalin 2 (Lcn2) can bind and sequester enterobactin 




enterobactin-dependent propagation of E. coli in vitro, and Lcn2
-/-
 mice are unable to 
control systemic E. coli burdens as well as wild type mice (97).  Production of Lcn2 is 
induced by ligation of TLR4, implicating iron regulation as a part of the immune 
response to infection (97).  Murine GeneChip and quantitative reverse transcriptase (RT) 
polymerase chain reaction (PCR) (qPCR) analyses confirmed that Lcn2 mRNA is 
upregulated by the uroepithelium of infected mice (334).  Interestingly, these results were 
obtained in C3H/HeJ mice, indicating a TLR4-independent signaling pathway can 
activate transcription of lcn2 in response to UTI.  Not surprisingly, UPEC has evolved a 
mechanism to counter Lcn2 siderophore sequestration.  Encoded within the iroA gene 
cluster are glycosyltransferases that modify enterobactin in such a way that it cannot be 
bound by Lcn2 (Figure 1.6) (38, 94, 384).  Thus, both the host and UPEC have systems in 
place to manage their own iron stores and to inhibit iron acquisition by the other – a 
molecular arms race for an essential nutrient.   
1.5.6 Antimicrobial peptide (AMP) secretion 
AMPs are short [20-60 amino acid (aa)] positively charged peptides secreted by 
both epithelial and hematopoietic cells that disrupt bacterial membranes and can be 
chemotactic for certain immune cells (395, 466, 467).  Human - defensin-1 mRNA and 
protein was found in kidney tissue, implicating this AMP in host defense against UPEC 
(440).  More convincingly, mice deficient in defb1, a murine
 
homolog of human -
defensin, have a significantly higher incidence of bacteriuria (274).  Murine -defensin is 




Figure 1.6  Chemical structures of enterobactin and one member of the 




(36).  Alpha-defensins are specific to neutrophil granules, and in some cases other innate 
acting leukocytes (369, 467); however, murine neutrophils lack -defensin (80, 369), 
thus the role, if any, of this AMP in UTI is not clear.  The human cathelicidin, LL-37, and 
its murine homolog, cathelin-related AMP (CRAMP), are secreted in response to UPEC 
exposure (63).  Studies using CRAMP-mutant mice revealed that epithelial-derived 
CRAMP is important during the early stages of UTI, while leukocyte-derived CRAMP 
likely functions later when bacteria penetrate the kidney epithelium (63). 
1.5.7 Cytokine and chemokine secretion 
1.5.7.1 Neutrophil-associated cytokine ligands and receptors 
Human C-X-C ligand 8 (hCXCL8, IL-8) is the main chemoattractant for 
neutrophils in humans, and mCXCL1 and mCXCL2 [also known as keratinocyte-derived 
chemokine (KC) and macrophage inflammatory protein (MIP)-2, respectively] are the 
functional mouse homologs of IL-8 (189).  Bladder and kidney cell lines secrete IL-8 in 
response to UPEC (154, 358, 456).  Human and murine studies demonstrated that 
neutrophil migration to the UPEC-infected urinary tract is dependent on IL-8 (4, 5, 144, 
265).  Additionally, mCXCL2 secretion is dependent on TLR4, as it was deficient in 
infected C3H/HeJ mice (147).  hCXCR1 and hCXCR2 are receptors for a number of 
chemokines, including IL-8 (189).  Both are expressed in bladder and kidney biopsies, 
and transmigration studies indicated that hCXCR1 plays a dominant role in IL-8-
dependent neutrophil migration (118).  Consistent with this, children prone to 
pyelonephritis tend to have low hCXCR1 expression and heterozygous hCXCR1 




but unlike TLR4 deficiency, with intact inflammatory signaling that ultimately results in 
tissue damage (Figure 1.7) (324).  Similarly, mice lacking mCXCR2 (the functional 
homolog for hCXCL1) experience subepithelial accumulation of neutrophils, increased 
bacterial titers, and renal scarring after UPEC inoculation (105, 118, 143).  These data 
indicate that normal function of neutrophils, their chemotactic ligands, and their 
chemokine receptors are required for bacterial clearance without post-inflammatory 
sequelae. 
1.5.7.2 Secretion of other cytokines and chemokines in response to UPEC   
Despite ample information on IL-8 in vitro and in vivo, a complete picture of the 
cytokine and chemokine dynamics during UTI was lacking.  In response, a longitudinal 
assessment using a Bio-Plex format was conducted by Ingersoll and colleagues (186).  
Chemokine (C-C motif) ligand 2 (CCL2) [macrophage chemotactic protein (MCP)-1], 
CCL4 [macrophage inflammatory protein (MIP)-1b], CCL5 [regulated on activation 
normal T-expressed and secreted (RANTES)], CXCL1, IL-1 , IL-6, IL-12p40, IL-17, 
tumor necrosis factor- (TNF- ), and granulocyte-colony stimulating factor [G-CSF, 
colony-stimulating factor 3 (csf3)] were all upregulated in bladder homogenates from 
UPEC-infected C57BL/6 mice when compared to phosphate-buffered saline (PBS)-
treated counterparts (186).  These results agreed with patient and cell line data regarding 
upregulation of IL-6 in response to UPEC (155, 156).  In mice, TNF-  expression was 
elevated at one hour post inoculation for rapid mobilization of acute responses (186); this 





Figure 1.7  Genetic susceptibility of mice lacking TLR4 or CXCR2.  In both 
cases, bacterial clearance is delayed; however, the lack of inflammatory signaling 
in mice lacking TLR4 results in asymptomatic carriage whereas the lack of a 
neutrophilic chemokine receptor results in dysregulated inflammatory and 




-  signaling (22).  Generally speaking, expression of most cytokines and chemokines 
weeks (186).  These dynamics correlated well with the peak and resolution of bacterial 
burdens (186).   
Similar to TLR adaptor molecule usage (96), the type of fimbriae expressed also 
seems to influence the repertoire of chemokines secreted.  Specifically, kidney cells 
exposed to type 1 fimbriated-UPEC secrete neutrophil-associated chemokines, while P 
fimbriae-stimulated cells secrete chemokines targeting antigen presenting cell (APC)- 
and Th1-specific cytokines, exemplified by CCL2 and CCL5 expression (119).  In 
addition, IFN-  and IL-4 (signature cytokines of the Th1 and Th2 lineages, respectively) 
and IL-10 [a T regulatory cell (Treg) effector cytokine] knockout mice were tested for 





mice appear to experience infection dynamics similar to wild type, IFN-
-/-
 mice had 
increased incidence and severity of UTI (198), implying a role for IFN-  and Th1-
mediated inflammatory responses to UTI.   
1.5.7.3 IL-17 and host defense against microbes 
One notable exception in the aforementioned study by Ingersoll and colleagues 
was IL-17A (also referred to as IL-17), which was highly upregulated from six hours to 
one week post inoculation, and remained above baseline through the two-week 
experimental duration (186).  Aside from the canonical CD4
+
 Th17 cells, other cell types 
have been found to secrete IL-17A, including cytotoxic T cells,  T cells, natural killer 
(NK)T cells, neutrophils, eosinophils, and monocytes (32).  IL-17A or the Il-17 receptor 




bacterial (142, 187, 363, 376, 438, 465, 471), fungal (68, 178, 343, 442), and even viral 
(141, 177, 209) infection.  Several studies have also demonstrated a role for IL-17A in 
adaptive immune responses (165, 250, 285, 286, 438).  Because of the roles played in 
both arms of the immune system, IL-17A has emerged as an innate-adaptive 
immunomodulatory cytokine.   
IL-17A plays a role in the innate immune response to infection by enhancing 
neutrophil migration to infected tissue.  Specifically, IL-17A acts indirectly by stabilizing 
mRNA transcripts for cytokines involved in granulopoiesis and chemotaxis (148-150, 
163).  Although the exact PAMP that triggers secretion of IL-17A is not defined, 
components of microbial cell wall, host receptors that recognize such components (i.e. 
the mannose receptor), and TLR-related signaling pathways are all implicated (442, 471).  
NF- B activation by IL-17A has been documented (150, 375, 462), as has a synergistic 
upregulation of cytokine expression by IL-17A and TNF-  or IL-1  (12, 148-150, 163, 
375).  This upregulation appears to be mediated by the activity of mitogen-activated 
kinases (MAPKs), namely p38 and extracellular signal-related kinase (ERK) (149, 150, 
163); however, it seems that MAPK effects may be specific to the activation of NF- B, 
while IL-17A effects on mRNA stability may be independent of MAPK signaling (149).  
IL-17A-specific signaling from the IL-17 receptor (IL-17R) was shown to be dependent 
on the adaptor protein NF- B activator 1 (Act1) (58, 148, 243).  Pathogen interference 
with this pathway has already been described (452), reflecting the importance of IL-17A 
signaling in host defense.  Binding sites for the NF- B, CCAATT enhancer-binding 




were overrepresented in IL-17 target promoters (375), indicating that these transcriptions 
factors likely control downstream gene expression initiated by IL-17A signaling.  
1.6 Host factors involved in intracellular UPEC 
1.6.1 Intracellular UPEC and persistence 
Over the past twelve years there has been a growing body of literature revealing 
that UPEC, in addition to its extracellular luminal or adherent lifestyle, appears to have 
three distinct intracellular lifestyle components within the urinary tract (88).  The first is 




 fusiform vesicles which are 
subsequently recycled back to the cell surface and exocytosed (37).  The other two 
pathways both begin with uptake into a membrane-bound compartment which can lead to 
either a quiescent non-replicative existence (89, 280) or escape from compartmental life 
to undergo a highly replicative phase in the cell cytoplasm (200, 278).  While 
internalization via the fusiform vesicle pathway may be a side effect of normal bladder 
function, the latter pathways are perhaps intentional processes undertaken by UPEC to 
establish a persistent reservoir (89, 200, 212, 278, 280, 355).   Indeed, UPEC have been 
shown to exist in the urinary tract for weeks following infection (278, 355), even after 
antibiotic treatment (212).   
After umbrella cells exfoliate in response to UTI, intracellular infection of the less 
differentiated underlying cells is suggested to lead to formation of antibiotic-resistant 
“quiescent intracellular reservoirs” (QIRs) (200).  Induction of urothelial renewal may 
lead to reinfection by UPEC contained in QIRs (282); specifically, cell proliferation and 




to the drastic changes in host cell actin (89, 212, 280).  As an argument against a fecal 
reservoir, housing naïve mice with infected ones did result in transmission of UPEC to 
uninfected mouse bladders –  persistent colonization of the bladder was only seen after 
prior UTI, although transmission of fecal positivity to uninfected animals was noted 
(likely through the practice of coprophagia) (355).  Finally, infection of ten genetically 
distinct mouse strains also revealed that some strains were more susceptible to 
persistence than others, indicating that host hereditary components may also contribute to 
the ability of UPEC to persevere in the urinary tract (172).  
1.6.2 In vivo characterization of intracellular UPEC 
Infected mouse bladder explants monitored by time-lapse fluorescence 
videomicroscopy generated a model for the intracellular UPEC life cycle instigated after 
uptake in a membrane-bound compartment (the non-fusiform vesicle route) (200).  While 
the mechanism of compartmental escape remains undefined, once contained in 
cytoplasmic “intracellular bacterial communities” (IBCs), UPEC can undergo several 
changes in morphology categorized as early, middle (“pod”), and late IBC stages (11, 
200).  In the pods, immunofluorescence microscopy showed expression of antigen 43 and 
type 1 fimbriae, and use of the periodic acid-Schiff reagent indicated the presence of 
polysaccharides, suggesting a biofilm-like state (11).  Late IBCs that escape exfoliation 
with umbrella cells contain filamentous UPEC that are not present in C3H/HeJ mice, 
indicating that this morphological change may be a bacterial stress response to TLR4-
mediated immune activation (200, 278).  This murine background also experienced 




114, 200).  Although kinetics and morphology differences were noted, IBCs were formed 
by different UPEC patient isolates in several additional murine backgrounds, including 
C57BL/6J, CBA/J, and FVB/NJ (114).  Images resembling findings in murine studies 
have been shown in the urine of females suffering from UTI (341); however, all the data 
validating IBCs involves microscopy and therefore must be interpreted with caution.  
Urothelial cells proximal to IBCs in C3H/HeJ mice upregulate transferrin receptor, Lcn2, 
complement system components (C3, factor B, CD55), and lysozyme (334).   Involucrin 
and suprabasin transcripts were also increased indicating that, in addition to gene 
products that function to eradicate bacteria, proteins important for epithelial integrity may 
be an imperative host response in response to intracellular UPEC (334). 
1.6.3 In vitro characterization of intracellular UPEC 
In vitro treatment of either 5637 cells with a small amount of the detergent 
saponin (89) or immortalized pediatric bladder cells with the cholesterol-sequestering 
drug filipin (31) recapitulates some of the observed features of intracellular UPEC in 
vivo.   Additionally, much work has been done using the 5637 bladder epithelial cell line 
to further delineate molecular components and mechanisms surrounding UPEC 
intracellularity (37, 77, 86, 87, 89, 253, 254, 278, 358).  UPEC internalization does not 
require bacterial viability (358), but is dependent on FimH (254).  1 and 3 integrins 
were shown to be receptors for Fim-mediated UPEC internalization, mediated by 
signaling through focal adhesion kinase (FAK) and, in contrast to an earlier study, Src 
family kinases (87, 254).  FimH-dependent uptake requires microtubules, histone 




to the involvement of cytoskeletal proteins, tyrosine kinases, and phosphoinositide 3-
kinase (PI3K) (254), UPEC engulfment has also been reported to be cholesterol- and 
dynamin-dependent and modulated by calcium levels, clathrin, and clathrin adaptors (86).  
Additional work on dynamin revealed that the nitric oxide synthase (NOS) enzyme is 
responsible for chemically modifying dynamin, redistributing it to the membrane for 
bacterial internalization (448).  As hinted by the cholesterol dependence, UPEC 
internalization is often reported to be associated with lipid rafts (24, 204), dependent on 
caveolin-1 and Rho-family GTP binding proteins (77, 253).   The association with lipid 
rafts was confirmed in vivo; UPEC inoculation in the presence of a lipid raft-disrupting 
chemical decreased the number of intracellular bacteria in the murine bladder (77).   
Notably, TLR4 also plays a non-inflammatory role in host defense against UPEC 
by modulating the activity of the observed secretory and vesicular internalization 
pathways.  TLR4-mediated PKA activation suppresses the lipid raft endocytic pathway 
(392), a possible effort to prevent the establishment of persistence reservoirs.  Also along 
these lines, UPEC exocytosis in fusiform vesicles was actually accelerated by TLR4-
mediated recognition of LPS and dependent on the activities of cAMP, Rab27b, caveolin-
1, and the scaffolding protein MyRIP (393). 
1.7 Host response to UPEC-mediated UTI by innate inflammatory cell types 
1.7.1 Neutrophils 
Infected mouse bladders examined histologically display thickening of epithelium 
accompanied by robust infiltration of inflammatory cells and edema in the lamina propria 




the infected urinary tract (5, 147, 191, 374).  Infected individuals often experience an 
inflammatory response involving pyuria, or the presence of white blood cells in the urine.  
Since greater than 95% of the cells present in urine are neutrophils (374), counting 
urinary neutrophils is a quick measure of the innate immune response in mice and an 
indicator of UTI in humans.  Antibody-mediated knockdown of the neutrophil population 
revealed their crucial role in bacterial clearance during UTI, especially within the kidney 
(147).  There does not appear to be a resident population of neutrophils in the bladder 
(167, 356), likely due to the short-lived and tissue-damaging nature of these cells (383).  
Efficient migration of neutrophils requires intracellular adhesion molecule-1 (ICAM-1) 
expression by epithelial cells and 2 integrin (CD11b/CD18) expression by neutrophils 
(4, 356).  G-CSF is also required for the neutrophil response, and unexpectedly, mice 
with neutralized G-CSF are more resistant to UTI (186).  Although 
monocyte/macrophage numbers were similar in anti-G-CSF-treated and wild type mice, 
cytokines important for macrophage activation were upregulated in the knockdown 
animals, potentially leading to accelerated clearance by enhanced phagocytic killing 
(186).  Of note, the electrostatic properties of the P fimbrial tip adhesin may interfere 
with neutrophil binding, allowing UPEC to evade neutrophil killing (40, 410).   
1.7.2 Macrophages and DCs 
Compared to the neutrophil response, relatively little is known about APCs in the 
context of UTI.  In mice, resident CD11c
+
 cells that express low to intermediate levels of 
F4/80 and CD11b macrophage markers were found in the kidney (221), while CD11c
+
 




356).  In spite of macrophage marker expression, CD11c
+
 kidney cells had physical and 
functional characteristics of DCs (221).  At twenty-four hours post inoculation, CD11c
+
 
cells that migrate to the bladder did not express CD8 , Gr-1, or B220, thus were not 
plasmacytoid or lymphoid, but appeared to be CD11b
intermediate
 TNF- - and iNOS-
producing (Tip)-DCs (84).  Infection studies in mice lacking Tip-DCs suggested that they 
are not necessary for the host response to acute UTI (84).  Since Tip-DCs are necessary 
for the generation of mucosal IgA (411), their role may lie in mediating the humoral 
response to UPEC.  Similar to what was observed for DCs, there appears to be a resident 
population of macrophages in bladder tissue that increase by several orders of magnitude 
in response to UTI (85, 167, 186).  Gr-1
high
 monocytes, a population of cells that include 
inflammatory monocytes (IMs) (17, 371) and can give rise to macrophages or DCs, are 
also recruited to the bladder in response to UPEC infection.  Release of these cells from 
the bone marrow was dependent on CCR2 (85), and correspondingly CCL2 is 
upregulated in the bladder response to UTI (186).   
1.7.3 Neutrophil and DC-associated factors 
Some of the factors utilized by neutrophils, macrophages, and DCs for pathogen 
uptake and destruction have been described during UTI.  iNOS generates the 
antimicrobial compound nitric oxide (NO) from L-arginine, and was originally reported 
to be secreted by macrophages (164, 287, 401).  Although iNOS is rapidly upregulated in 
the inoculated bladder (282), iNOS
-/-
 mice are equally as susceptible to UTI as wild type 
mice (198, 318).   Neuronal NOS, endothelial NOS, or myeloperoxidase (MPO) may 






animals may lack a colonization phenotype because there are several factors (Hfq 
and Nsr-regulated genes, polyamines, flavohemoglobin) expressed by UPEC that 
enhance tolerance to reactive nitrogen species in vitro (43, 44, 226, 406), suggesting NO 
production may be an ineffective host defense against UPEC.  With respect to the 
complement system, it appears that UPEC is able to bind C3 to enter host uroepithelial 
cells via the surface receptors Crry or CD46 (242, 396).  Correspondingly, C3
-/-
 mice are 
more resistant to renal damage and infection (396).  As C3 levels are significantly higher 
in the urine of UTI patients (242), UPEC may stimulate C3 production for pathogenic 
means, or at least evolved to exploit this host defense factor.  
1.8 Innate-like lymphocytes (ILLs) in the innate immune response to  
UPEC-mediated UTI  
 Infection studies using severe combined immunodeficient (SCID) mice that lack 
functional B and T cells and nude mice that lack thymically-derived T cells provide 
preliminary evidence of a role for ILLs in acute UTI host defense (175).  Epithelial  T 
cells, B-1 cells, and NKT cells are ILLs: cellular subsets that have relatively invariant 
receptors and reside in specific locations of the body (189).  After a two-day primary 
infection, SCID mice had significantly higher bacterial counts in their bladder and 
kidneys, while nude mice were colonized similarly to wild type animals (175).  The lack 
of a colonization phenotype in nude mice suggests that either antibody responses 
independent of thymus-derived T cell help or extrathymically-produced T cells may play 
a role in innate clearance of UPEC.  The latter suggestion has some experimental support.  
 T cells can be produced extrathymically and rapidly secrete cytokines in response to 




bladder increase in response to UTI (255), and T cell receptor (TCR)
-/-
 mice lacking 
expression of  T cells are more susceptible to UTI than isogenic controls (198).  We go 
on to demonstrate that  TCR
+
 cells express IL-17A during UPEC-mediated UTI, a 
rapid-response by  T cells that may function in concert with other innate factors to 
mediate neutrophil influx for clearance of UPEC.  B-1 cells spontaneously secrete large 
quantities of polyspecific IgM against bacterial and self antigens, and in contrast to 
conventional (B-2) B cells, do not require T cell help (30).  While IgM secreted by B-1 
cells might play a role in innate clearance of UPEC, current evidence suggests otherwise.  
JHD mice, lacking both B-1 and B-2 cells (59, 327), infected and monitored over a 
fourteen-day time period exhibited no significant increases in incidence or severity of 
cystitis (198).  On a final note regarding ILLs, administration of -GalCer, a ligand for 
CD1d-restricted NKT cells, alleviates renal UPEC infection (264).  Consistent with this, 
we have observed a resident population of NK1.1
+
 cells (potentially NK or NKT cells) in 
the bladder of C57BL/6 mice that increases in response to UTI.  Studies using a systemic 
E. coli infection model suggested that, similar to  T cells, NKT cells may act as early 
amplifiers of the innate immune response to UTI by rapid cytokine secretion (283).   
1.9 Adaptive host defenses to UPEC-mediated UTI 
Existing data regarding adaptive immune responses to UPEC are relatively 
limited.  In a seminal study, Thumbikat and colleagues engineered a strain of UPEC to 
express ovalbumin (OVA) to examine mechanisms behind antigen-specific adaptive 









(416), extending the findings of early IHC studies probing T and B cell populations in 
infected bladders (167).  Furthermore, splenocytes, enriched splenic T cells, or serum 
antibodies from previously infected donor mice each protected wild type naïve recipient 
mice against UPEC challenge (Figure 1.8) (416).  This result suggests that protection 
derived from natural infection is antibody-mediated, as UPEC-specific antibody-secreting 
plasma cells could be present in both splenocyte and enriched T cells preparations.  As 
expected, transfers from naïve donor mice did not facilitate enhanced protection to 
recipients (416).  This result is in contrast to a previous murine adoptive transfer study 
where SCID recipients receiving splenocytes from either naïve or vaccinated wild type 
donors exhibited equal levels of enhanced clearance, despite the presence of antigen-
specific plasma cells in the vaccinated donor cells (175).  This result suggests that simply 
reconstituting immunosuppressed mice with lymphoid cells provides the means (likely 
stimulatory cytokines for phagocytic cells) for enhanced clearance.  Conversely, wild 
type recipient mice used in the former study only exhibited enhanced clearance when 
given cells or serum from antigen-educated vaccinated donors (416), indicating that 
enhanced protection in individuals with intact immune systems will only be provided by 
stimulation of an effective adaptive immune response. 
1.9.1 T cells and the adaptive immune response to UPEC-mediated UTI 
T helper (Th) cells are a key component in adaptive immunity and the generation of 
protective responses involving antibodies.  Th cell subsets are characterized by 
transcription factors and cytokines involved in their differentiation and the particular 





Figure 1.8  Passive and adoptive transfer of protection from mice 
vaccinated via the natural route of infection.  Naive mice received 
adoptive transfer of 5 x 106 T cells, 1 x 107 splenocytes, or 200 µl of whole 
serum, and were then challenged with NU14-OVA, a UPEC strain 
expressing ovalbumin, followed by plating of bladder homogenates twenty-
four hours later. Donor cells and serum were derived from mice that were 
infected with NU14-OVA two weeks previously (1°), or that were 





Figure 1.9  Summary of Th cell attributes.  Depicted are the four major classes 
of Th cells, transcription factors responsible for their development, cytokines 
they secrete, and their effector functions.  Also shown are the antibody isotypes 





dichotomy of helper T cell differentiation has been modified by the discovery of other Th 
cell subgroups, namely Th17 and Treg cells.  While IFN-  IL-4, and TGF-  are the 
signature cytokines secreted by Th1, Th2, and Treg cells, respectively, Th17 cells are 
characterized, among other factors, by the ability to secrete IL-21, IL-22,  IL-17A (the 
signature cytokine), and IL-17F (61).  Additionally, ROR t, ROR , and STAT3 are the 
transcriptional factors responsible for development and regulation of the Th17 lineage 
(220), whereas development of the inducible Treg, Th1, and Th2 lineages are primarily 
controlled by FoxP3, T-bet, and GATA3, respectively, among the activity of additional 
transcription factors (32). 
To date, studies have not implicated a skew toward Th1- or Th2-mediated UTI 
immunity (7, 416).  DC phagocytosis of infected apoptotic cells is the key event required 
for DCs to secrete the unusual cytokine milieu (predominately accepted to be TNF-  and 
IL-6) necessary for Th17 development (418).  As previously mentioned, a number of DC 
subsets and UPEC-infected apoptotic cells are present in bladder tissue during UTI.  
Similar to other cell populations, we and others have observed a resident CD8
+
 cell 
population in the bladder that increases in response to infection (416).  We can speculate 
that these are classical cytotoxic T cells or an intraepithelial lymphocyte (IEL) population 
that may exert cytotoxic effects upon UPEC- or virus-infected cells or rapidly secrete 
cytokines to mobilize the innate immune response (1, 153).  Finally, the role of Treg 
subsets in UTI host defense has not been formally examined. 




Despite the lack of detail regarding T cell responses to UTI, there is ample 
evidence for antibody-mediated clearance of UPEC.  Since the 1970s, the genitourinary 
tract has been recognized as part of the secretory immune system (111, 417).  UPEC-
specific antibodies are detected in the urine of infected patients (313) and in the urine or 
serum of animals exposed to UPEC antigens (176, 339, 416, 424).  Urinary IgG and IgA 
from UTI patients are capable of inhibiting UPEC adherence (79, 403, 422).  Patient 
studies have also suggested that antibody responses to pyelonephritis are, in general, 
stronger and last longer than humoral responses to cystitis (107, 205, 206).  In a study 
involving experimental UTI using ten different inbred mouse strains, initial infection led 
to an innate response marked by inflammation, followed by an antibody response to the 
infecting organism (172).  There was a modest correlation between bacterial colonization 
and inflammation; however, and a positive correlation between splenic antibody-forming 
cells and bladder and kidney infection levels was detected (172).  In Chapter 2, we 
describe analysis of murine urine and serum samples collected before and after 
vaccination with OMP iron receptors, allowing identification of immunological correlates 
of mucosal vaccine-induced protection against UTI (7).  Specifically, levels of either 
urinary IgA or serum IgG (relative to serum IgM, denoted the “class switch index”) 
inversely correlated with bladder colonization in vaccinated mice (7).  Presumably 
urinary IgA plays a direct role in UPEC clearance from the bladder mucosa, while IgG 
may be a marker for class switching by B cells or also play a direct role in mucosal 
bacterial clearance.  That stated, as previously mentioned, analysis of bacterial burdens in 
JHD mice, which cannot produce antibodies (59), suggested no role for the humoral 




antibody-mediated protection by B-2 cells (canonical B cells) would likely play a role in 
memory responses, beckoning re-evaluation of these mice in UPEC-reinfection and 
vaccination-challenge models.   
1.10 Urothelial regeneration in response to UPEC infection 
One of the consequences of UPEC infection is exfoliation of the superficial facet 
cell layer that lines the surface of the bladder lumen (14, 82, 108, 262, 277, 278, 298).  At 
this juncture, the host not only needs to rid the invading bacterial onslaught, but repair the 
damaged uroepithelium, as the impermeability of this barrier is crucial for protection 
from toxic substances and pHs found in urine.  Mysorekar and colleagues have conducted 
a number of studies to understand the molecular events and players involved in urothelial 
regeneration (281, 282).  Microarray analysis revealed that genes involved in cell 
differentiation, proliferative and immediate-early responses, apoptosis, stress response, 
signal transduction, and cell-cell contact are generally upregulated in response to UPEC 
infection, as compared to mock infection or bladders experiencing cell non-inflammatory 
exfoliation by chemical treatment (281, 282).  Importantly, cytokines, chemokines, 
signaling molecules, and transcription factors involved in inflammation are highly 
upregulated and may also contribute to uroepithelial regeneration (281, 282).  
Regeneration itself appears to be a function of uroepithelial stem cells present in the basal 
and mesenchymal layers of the uroepithelium, and depends on downstream signaling 
mediated by downregulation of bone morphogenic protein 4 (Bmp4) though the Bmp4 
receptor 1a (281).  Studies of the gut epithelium unveiled macrophages act as “cellular 




epithelial progenitors via direct contact (323).  Whether or not macrophages play a 
similar role in the urinary tract remains unknown.   
1.11 Summary 
From epidemiology studies delineating risk factors to cellular molecular studies 
concretely characterizing roles of particular immunological facets in UTI, research in the 
field is critical to ameliorate the societal and economic costs associated with this disease 
of morbidity.  While many general concepts regarding the immune response to UTI are 
understood, molecular details of these responses are only beginning to be discovered and 
appreciated.  Such details are likely going to be the key in the development of a 
successful vaccine for use in humans or more effective and directed treatments in lieu of 
antibiotic therapy.  The results presented in this dissertation add to the current understand 
of both the innate and the adaptive immune response to UTI.  Regarding adaptive 
immune mechanisms playing a role in protection against UPEC-mediated UTI, potential 
vaccine candidates and their corresponding immunological correlates of protection are 
tested and determined, respectively, in Chapter 2.  In Chapter 3, the role of the innate-
adaptive immunomodulatory cytokine IL-17A is defined in the context of both primary 
and secondary UTI.  Speculations about and future directions stemming from these 






Chapter 2  
Mucosal immunization with iron receptor antigens protects against UTI 
2.1 Abstract 
 Uncomplicated infections of the urinary tract, caused by UPEC, are among the 
most common diseases requiring medical intervention. A preventive vaccine to reduce 
the morbidity and fiscal burden these infections have upon the healthcare system would 
be beneficial.  Here, the results of a large-scale selection process that incorporates 
bioinformatic, genomic, transcriptomic, and proteomic screens to identify six vaccine 
candidates from the 5379 predicted proteins encoded by uropathogenic E. coli strain 
CFT073 is described.  The vaccine candidates; ChuA, Hma, Iha, IreA, IroN, and IutA, all 
belong to a functional class of molecules that is involved in iron acquisition, a process 
critical for pathogenesis in all microbes.  Intranasal immunization of CBA/J mice with 
these outer membrane iron receptors elicited a systemic and mucosal immune response 
that included the production of antigen-specific IgM, IgG, and IgA antibodies.  The 
cellular response to vaccination was characterized by the induction and secretion of IFN-
γ and IL-17A.  Of the six potential vaccine candidates, IreA, Hma, and IutA provided 
significant protection from experimental infection.  In immunized animals, class-
switching from IgM to IgG and production of antigen-specific IgA in the urine represent 
immunological correlates of protection from E. coli bladder colonization.  These findings 




tract infections and demonstrate how targeting an entire class of molecules that are 
collectively required for pathogenesis may represent a fundamental strategy to combat 
infections. 
2.2 Introduction 
2.2.1 Epidemiological statistics, treatment of UTI, and the need for a vaccine 
 UTI caused by UPEC is a considerable public health issue.  In addition to 
symptoms of acute cystitis and pyelonephritis caused by UTI, a number of more serious 
conditions are often associated with these infections.  Upper UTIs in young children can 
cause permanent kidney damage.  An estimated 57% of children with acute 
pyelonephritis develop renal scarring (246).  As with other significant pathogens, 
increased resistance to antibiotics by UPEC poses a treatment issue (128).  Even with 
treatment, recurrent infections frequently occur, with same-strain episodes making up 
between 25-100% of recurrent UTI cases [reviewed in (196)].  Consequently, these imply 
that a vaccine to prevent UTI would alleviate this source of morbidity and economic 
burden.  Indeed, a number of groups have sought to stimulate protective immunity 
against UPEC.  For example, immunization with the type 1 fimbrial adhesin, FimH, 
conjugated to its periplasmic chaperone, FimC, reduced murine bladder colonization by 
99.9%, as well as provided protection in a primate model (235, 236).  Additionally, 
subunit vaccines based on several other surface-exposed molecules have been shown to 
induce at least some immune response in immunized animals (122, 227, 293, 339, 349).  
However, although much research has focused on the development of a vaccine against 




2.2.2 A new strategy to identify novel UPEC vaccine candidates 
 Large-scale reverse vaccinology approaches offer an alternative to traditional 
vaccine design.  Pioneered by successful work using Neisseria meningitidis, this 
technique applies genomic and bioinformatic methods to identify novel vaccine targets 
(315).  Recently applied to extraintestinal pathogenic E. coli (ExPEC), a pathotype to 
which UPEC belongs, a subtractive hybridization study identified surface-exposed 
antigens specific to ExPEC and found that several of these proteins protected immunized 
mice from lethal sepsis (78).  Due to the limited success of previous UTI vaccine design 
strategies, we hypothesized that a functional vaccinology approach – utilizing “omics” 
technologies to identify “PASivE” vaccine candidates – would identify vaccine targets of 
UPEC in an unbiased manner that could elicit protective immunity.  Described here is the 
use of previously established genomics and proteomics data to identify six pathogen-
associated OM iron receptors (ChuA, Hma, Iha, IreA, IroN and IutA) that are Pathogen-
specific, Antigenic, Surface-exposed, In vivo-Expressed and therefore ideal putative 
UPEC vaccine targets.  Each of these 71-84 kDa proteins is predicted to form a 
transmembrane beta-barrel in the OM, with a series of loops extending extracellularly 
(51).  Facilitating import of specific iron sources, these receptors mediate uptake of 
siderophores, secreted bacterial iron-chelating molecules, or host heme-derived iron.  
Because iron acquisition is necessary for bacterial pathogenesis and it is well known that 
the urinary tract is an iron-limited environment, iron acquisition via these receptors is 
crucial for UPEC infection (419).  Consequently, deletion of the siderophore receptor 




IroN, or aerobactin receptor IutA all decrease the fitness of UPEC in the murine urinary 
tract (136, 195, 345, 348, 419). 
 This Chapter describes the use of an unbiased, rational vaccinology approach to 
identify suitable UPEC vaccine candidates; the results implicated a class of molecules 
involved in iron acquisition.  Intranasal immunization with these UPEC OM iron 
receptors provides protection from UTI.  Additionally, antigen-specific antibody and 
cytokine responses are generated in response to vaccination with iron receptor proteins, 
of which, the former correlated with protection.  Therefore, this class of molecules is 
promising as protective vaccine targets against UPEC and, because of their conserved 
function of iron acquisition for pathogenesis, could potentially be adopted for the 
development of vaccines against other Gram-negative bacterial infections.  
2.3 Materials and Methods 
2.3.1 Bacterial strains and culture conditions 
 Escherichia coli CFT073, a prototypic UPEC strain, was isolated from the urine 
and blood of a patient with acute pyelonephritis (270) and has been fully sequenced and 
annotated (450).  E. coli strain 536 was isolated from a patient with acute pyelonephritis 
(135).  Unless otherwise noted, bacteria were cultured in Luria broth containing 
appropriate antibiotics (100 g/ml ampicillin, 25 g/ml kanamycin, and/or 20 g/ml 
chloramphenicol) at 37°C with aeration. 
2.3.2 Murine model of ascending UTI 
 Mice were maintained in specific pathogen-free conditions and all experiments 




and Care of Animals at the University of Michigan.  Female CBA/J mice were 
transurethrally inoculated as previously described (138).  Six- to eight-week old mice 
were used for these studies and animals were ≤15 weeks old at the conclusion of all 
experiments.  For manipulation, mice were anesthetized with an i.p. injection of 100 mg 
ketamine, 10 mg xylazine per kg body weight.  Prior to inoculation, overnight E. coli 
CFT073 cultures were harvested by centrifugation (3000 x g, 30 min, 4 C) and 
resuspended in PBS to an OD600 of 4.0, equivalent to 4x10
9
 colony-forming units 
(CFU)/ml.  Bacterial suspension (50 l/mouse) was delivered transurethrally using a 
sterile 0.28 mm inner diameter polyethylene catheter connected to an infusion pump 
(Harvard Apparatus), with total inoculum of 1x10
8
 CFU/mouse.  When necessary, mice 
were euthanized using a lethal dose of isoflurane and appropriate organs were harvested 
for further analysis.  For determination of CFUs, organs were harvested from euthanized 
animals at 48 hours (h) post-inoculation and homogenized in PBS with a GLH 
homogenizer (Omni International).  Bacteria in tissue homogenates were enumerated by 
plating on Luria-Bertani agar containing 0.5 g/L NaCl using an Autoplate 4000 spiral 
plater (Spiral Biotech).  Colonies were enumerated using a QCount automated plate 
counter (Spiral Biotech).  Blood was collected as necessary from anesthetized mice by an 
infraorbital bleed using 1.1 to 1.2 mm Micro-Hematocrit Capillary Tubes (Fisher) and 
serum was separated using Microtainer Serum Separator Tubes (Becton Dickinson).   
2.3.3 Antigen purification 
 Genes encoding the selected antigens were PCR-amplified from CFT073 genomic 




Recombinant protein expression from pBAD (Hma, IutA, ChuA) was induced in E. coli 
TOP10 cultured to OD600 = 0.8 by addition of L-arabinose to 100 μM for 4 h.  Proteins 
expressed from pET (Iha, IreA) were over-expressed in E. coli BL21(DE3) pLysS 
cultured in Terrific broth (12 g/L tryptone, 24 g/L yeast extract, 2.3 g/L KH2PO4, 12.5 
g/L K2HPO4, 4% glycerol) to OD600 = 1.0 at 37°C and induced overnight with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG).  Induced cultures were harvested by 
centrifugation (8,000 × g, 4°C, 10 min), resuspended in 10 mM HEPES, pH 7, and 100 U 
Benzonase nuclease (Sigma).  Bacteria were lysed by two passages though a French 
pressure cell (20,000 psi) and the lysate was cleared by centrifugation (8,000 × g, 4
o
C, 10 
min).  Bacterial membranes were pelleted from the cleared lysate by ultracentrifugation 
(112,000 × g, 4
o
C, 30 min) and the membrane pellet resuspended in 5 ml 100 mM 
NaH2PO4, 10 mM Tris-HCl, 8 M urea, 1% ASB-14, pH 8.0.  His6-tagged proteins were 
purified on nickel-nitriloacetic acid-agarose columns (Qiagen) using urea- or imidizole-
based methods according to the manufacturer’s instructions (The QIAexpressionist).  
Eluted purified proteins were renatured by dialysis at 4°C into a final solution containing 
0.05% Zwittergent in PBS, pH 7.5 and quantified using the BCA protein assay (Pierce).  
LPS was tested for in purified protein preparations using the Limulus Amebocyte Lysate 
PYROGENT Single Test Vials (Cambrex).   
2.3.4 Peptide synthesis 
 Putative extracellular loops of IroN and IutA were predicted using the PRED-
TMBB program (http://biophysics.biol.uoa.gr/PRED-TMBB/).  30-mer peptides 




GGCYLIGNKDLDPE; IutA: VDDIDYTQQQKIAAGKAISADAIPGGSVD) were 
synthesized to ≥96% purity by Invitrogen.  
2.3.5 Vaccination 
 Purified antigens were chemically cross-linked to cholera toxin (CT) (Sigma) at a 
ratio of 10:1 using N-succinimidyl 3-(2-pyridyldithio) propionate (Pierce) according to 
the manufacturer’s recommendations.  Peptide antigens were dissolved in 1 mM EDTA 
in PBS, mixed with reduced CT, and incubated at 4 C for 18 h.  All immunizations were 
administered intranasally in a total volume of 20 μl/animal (10 μl/nare).  Animals 
received a primary dose on day 0 of 100 μg crosslinked antigen (containing 10 μg CT) or 
10 μg CT alone.  Two boosts of 25 μg antigen (crosslinked to 2.5 μg CT) or 2.5 μg CT 
alone were given on days 7 and 14, and mice were challenged as described above. 
2.3.6 Tissue culture  
 Single-cell suspensions (1.5×10
6
 cells/ml) were made from spleens by forcing 
organs though 40 m Cell Strainers (BD Falcon).  Red blood cells were lysed for 2 min 
using 8.02 mg/ml NH4Cl, 0.84 mg/ml NaHCO3, 0.37 mg/ml EDTA in distilled water.  
Final suspensions were made in RPMI (supplemented with L-Glutamine, Gibco) with 1% 
sodium pyruvate, 1% L-glutamine, 1% penicillin/streptomycin, 1% non-essential amino 
acids, 10% fetal bovine serum (FBS), 0.001% 50 mM -mercaptoethanol.  Splenocytes 
were cultured with either medium alone or with 1 g/ml purified antigen.  After 
incubation of cells at 37
o








 RNA was isolated from pelleted splenocytes using TRIzol Reagent (Invitrogen) 
according to the manufacturer’s instructions.  RNA was quantified using the ND-1000 
Spectrophotometer (NanoDrop) and 1 g was used for cDNA synthesis.  cDNA was 
synthesized from 1 g RNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems).  Oligo dT primers (0.5 g/ l stock) and RNase inhibitor (10 U/ l 
stock) used in the reaction were obtained from Invitrogen.  The cDNA reaction mix 
consisted of (per 10 reactions) 81 l RNase-free water, 30 l 10x buffer, 6 l oligo dT 
primers, 12 l dNTP mix, 6 l RNase inhibitor, and 15 l Multiscribe RT.  The cDNA 
reaction conditions were: 25
o
C for 10 min, 37
o
C for 120 min, and 85
o
C for five sec in a 
PTC-200 thermal cycler (MJ Research).  The qPCR reaction mix consisted of (per 1 
reaction) 8.75 l RNase-free water, 12.5 l 2x Taqman Universal PCR Master Mix 
(Applied Biosystems), 1.0 l 20x target primers and FAM probe (Applied Biosystems),  
0.75 l 20x control GAPDH primers and VIC probe (Applied Biosystems), and 2.0 l 
cDNA.  The qPCR reaction conditions were: 50
o
C for two min, 95
o
C for 10 min, and 55 
cycles of 95
o
C for 15 sec followed by 60
o
C for one min in a Mx3000P thermal cycler 
(Stratagene).  Fluorescence was read at 60
o
C at the end of each cycle.  qPCR reactions 
were conducted in duplicate wells with appropriate no template and no RT controls for 
cDNA and qPCR reactions.  Data were analyzed with MxPro Software (Stratagene) and 
were expressed using the comparative Ct method (2
- Ct
). 




For indirect serum ELISAs, EIA/RIA medium binding 96-well ELISA plates 
(Corning) were coated at room temperature (rt) overnight with 5 g/mL purified protein 
(for serum) or 10 g/mL purified protein (for urine) diluted in carbonate buffer, pH 9.8 
(2.33 mg/mL Na2CO3, 2.86 mg/mL NaHCO3, 0.2 mg/mL MgCl).  Non-specific binding 
sites were blocked with blocking buffer (10% FBS, 0.04% NaN3 in PBS) at rt for 1 h.  
1:256 dilutions of mouse serum in blocking buffer were applied to wells at rt anywhere 
from 2 h to overnight.  Isotype-specific secondary antibodies conjugated to alkaline 
phosphatase were diluted 1:2000 in Tris buffer, pH 8.0 (17.8 mg/mL Trizma HCl, 10.6 
mg/mL Tris base, 10 mg/mL bovine serum albumin (BSA), 0.2 mg/mL MgCl, 0.2 
mg/mL NaN3) and bound to wells at rt for at least 4 h to overnight.  As a note for total 
immunoglobulin (Ig) detection, a 1:2000 dilution of goat anti-mouse Ig was mixed with 
1:4000 dilutions of goat anti-mouse IgA and IgM to ensure all serum antibodies were 
detected.  Goat anti-mouse IgA, IgG, and IgM were obtained conjugated to alkaline 
phosphatase from Southern Biotech.  Alkaline phosphatase substrate, p-nitrophenyl 
phosphate (1 mg/mL; Sigma), was diluted in carbonate buffer and applied to wells at rt 
until color developed (10 to 30 min).  The reaction was stopped by addition of 0.2 N 
NaOH and read with a Quant plate reader (Bio-Tek Instruments, Inc.) at a wavelength 
of 405 nanometers (nm).  For all steps, 100 L was applied to each well and plates were 
washed by flooding all wells four times with wash buffer (0.05% Tween 20 in PBS) 
between all steps. 
To detect IL-17A and IFN-  cytokines, a sandwich ELISA was performed.  




from R&D Systems.  96-well ELISA plates were coated with 50 L of 5 g/mL capture 
antibody diluted in borate-buffered saline (7.0 mg/mL NaCl, 3.1 mg/mL H3BO3, 0.64 
mg/mL NaOH) overnight at 4
o
C.  Non-specific binding sites were blocked with blocking 
buffer (2% BSA in PBS) at 37
o
C for 1 h.  Dilutions of purified IL-17A, IFN- , or test 
samples were made in dilution buffer (0.05% Tween 20, 2% FBS in PBS) and 50 L 
applied to wells at 37
o
C for 1 h.  Biotinylated detection antibodies were diluted to either 
0.5 g/mL or 0.25 g/mL for IFN-  and IL-17A, respectively, in dilution buffer and 
applied to wells at 37
o
C for 45 min.  Streptavidin-HRP (Southern Biotech) was diluted 
1:5000 in dilution buffer and 100 L was applied to wells at 37
o
C for 30 min.  OPD 
Easy-tablets (2 mg/tablet, Acros Organics) were diluted (4 tablets, 5 L H2O2  in distilled 
H2O) and 100 L applied to wells at rt until color developed (5 to 20 min).   The reaction 
was stopped by addition of 100 L 6 N H2SO4 and read with a plate reader at a 
wavelength of 490 nm.  Between all steps, plates were washed by flooding all wells four 
times with wash buffer. 
2.3.9 Statistical analysis 
 All graphing and statistical analyses were done using GraphPad Prism 5.  
Significance was determined using Mann-Whitney tests.  Correlates of protection were 
determined using the Pearson correlation coefficient with linear regression to generate a 
best fit line.  All statistics were conducted using 95% confidence intervals where 





2.4.1 Candidate antigen selection   
 To identify bacterial proteins that could be used as vaccine targets against UPEC 
infection, a functional vaccinology approach was utilized, combining both genomics and 
proteomics techniques.  To begin, criteria defining UPEC vaccine targets were 
established and data from previously-described studies assembled to identify proteins 
meeting these criteria.  Of the 5379 predicted proteins in E. coli pyelonephritis strain 
CFT073, only 6 (Table 2.1) met all 5 of our established PASivE criteria.   
 Transcriptomic and proteomic data were evaluated to identify candidates meeting 
the in vivo expression and antigenicity criteria.  Data from an in vivo transcriptome study 
indicated that genes encoding iron acquisition system components were among those 
most highly upregulated in RNA isolated from the urine of experimentally infected 
CBA/J mice (386).  When all genes were ranked in order of expression level in vivo, 
these iron acquisition genes, specifically OM iron receptors, were among the top 18% 
most highly expressed in the murine urinary tract (Table 2.1).  Similarly, when OM 
proteins (OMPs), which are partially surface-exposed, were isolated from CFT073 
cultured in human urine ex vivo and compared with OMPs isolated from bacteria cultured 
in Luria broth in vitro, these iron receptors were the most highly induced proteins (8).  
Further, the vaccine candidates listed in Table 2.1 comprised 6 of the top 7 human urine-
induced OMPs.  In addition to bacteria isolated from urine, bladder cell-associated UPEC 
has been observed to express OM receptor, both in vitro (137) and in vivo (334).  Finally, 




































  (P) (P) (AS) (ivE) (ivE) (ivE) 
chuA c4308 87 30 + 7.06 95.0 27.8 
hma c2482 69 17 + 6.56 94.5 14.8 
iha c3610 45 37 + 18.9 89.1 5.87 
ireA c5174 20 17 + 23.3 95.2 7.81 
iroN c1250 71 33 + 22.7 82.7 7.63 
iutA c3623 65 17 + 5.57 97.0 49.2 
a
 Table courtesy of Erin Hagan. 
b
 Transcript fold change in the urine of experimentally infected mice as compared to growth in LB (386) 
c 
Of 5379 genes ranked in order of in vivo transcript microarray signal intensity (386) 
d 
Protein fold change following growth in pooled filter-sterilized human urine as compared to growth in LB 
(8) 
e 
Reacts with sera from mice chronically infected with E. coli CFT073 (137) 
f 





reacted with antisera from mice chronically infected with UPEC strain CFT073, 
indicating that these proteins elicited a humoral response during experimental UTI (137).   
 As UPEC represent a subset of strains that are genetically distinct from 
commensal E. coli, a vaccine directed against UPEC should specifically target pathogenic 
strains.  Toward this end, a comparative genomics hybridization study identified 131 
genes that were present in all UPEC isolates analyzed (n=10), but none of the fecal- 
commensal strains (n=4) (248).  Among these UPEC-specific genes, two –  chuA and 
hma – encoded OM heme receptors,.  Furthermore, dot blot analysis of a collection of 
UPEC and fecal-commensal E. coli isolates identified several of these iron OMP genes 
(chuA, hma, iroN, and iutA) as present more frequently among pathogens than non-
pathogens (137).  Even genes that were not statistically more frequent among 
uropathogens (iha and ireA) were nonetheless present at relatively low frequencies in 
commensals.  Of the 5379 predicted proteins in UPEC strain CFT073, 6 candidate 
antigens, all OM iron receptors, emerged from our series of genomics and proteomics 
studies as uniformly highly ranked PASivE vaccine targets (Table 2.1). This screening 
process strongly suggested that broadly targeting an entire class of molecules involved in 
iron acquisition could be an effective strategy to develop a protective UTI vaccine.      
2.4.2 Vaccination confers protection against experimental UTI 
 The 6 iron receptor vaccine candidates, ChuA, Hma, IutA, IreA, Iha, and IroN, 
were expressed and purified as 6xHistidine affinity-tagged recombinant proteins (Figure 





Figure 2.1  Purification and CD spectrum of OM iron receptors.  (A)  
Example purification of IreA (arrow).  Numbers represent the elution fraction 
and buffers C, D, and E have decreasing pH.  The majority of IreA elutes off 
the column in fractions D2-4 and E1-2.  (B)  Purified Iha, IreA, and Hma 
(arrows).  (C)  Far UV CD spectral analysis of purified Hma (800 g/ml) 
following buffer exchange and renaturation.  Spectrum was measured from 
195 to 250 nm at 25°C using a Jasco Co. (Tokyo, Japan) J-810 Rev. 1.00 




dichroism (CD) spectrum of refolded purified Hma displayed a trough at 218 nm, which 
is characteristic of a β-sheet-rich conformation (Figure 2.1C).  The six purified protein 
antigens were each biochemically cross-linked to the CT adjuvant at a ratio of 10:1 
(antigen:CT) and mice were intranasally inoculated with either an antigen-CT complex or 
CT alone.  Following primary immunization (day 0) and booster doses (days 7 and 14), 
the animals were transurethrally challenged with UPEC strain CFT073 and protection 
was assessed at 48 hpi by determining CFUs in the urine, bladder, and kidneys.  The 
vaccination schedule is outlined in Figure 2.2.   
 Of the 6 candidates, 3 conferred protection against experimental challenge with 
UPEC (Figure 2.3B, D, and E).  The heme receptor, Hma, protected mice against 
colonization of the kidney.  Hma-vaccinated mice demonstrated nearly a 3-log reduction 
in median CFU/g in the kidney (P = 0.008) and 13/20 mice had undetectable levels of 
bacteria (<100 CFU/g) in the kidneys (Figure 2.3B).  The putative siderophore receptor 
IreA showed significant protection and demonstrated a 3-log reduction in median CFU/g 
in the bladder (P = 0.035) (Figure 2.3D).  For IreA, 9/15 vaccinated mice had 
undetectable levels of bacteria in the bladder.  The siderophore receptor for aerobactin, 
IutA, conferred significant protection against UPEC challenge in both the bladder and 
kidneys.  Mice vaccinated with full-length IutA displayed 1-log CFU/g reduction in both 
the bladder (P = 0.009) and kidneys (P = 0.007) (Figure 2.3E).  This showed that 
mucosal immunization in the nares generates a protective effect at distal sites, the bladder 
and kidneys.  Not all antigens selected as candidates provided protection against 






Figure 2.2  Vaccination schedule for OM iron receptor antigens.  Mice 
were vaccinated and manipulated according to the outlined schedule.  
Blood and urine were collected before and after vaccination for antigen-
specific antibody analysis while splenocytes were harvested after 
vaccination and both before and after challenge for analysis of cellular 





Figure 2.3  Immunization with OM iron receptor antigens.  Vaccinated 
animals (n = 15-20 mice per experiment, 2 experiments combined) were 
transurethrally challenged with 1×10
8
 CFU of E. coli CFT073 and colonization 
was measured 48 hpi.  Symbols represent CFU/g tissue or /ml urine of individual 
mice and bars indicate median values.  Clear bars, mock vaccinated with CT 
alone; gray bars, vaccinated with purified (A) ChuA, (B) Hma, (C) Iha, (D) IreA, 
or (E) IutA, or (F) peptides corresponding to the extracellular loops of IroN or 
IutA.  The dotted line indicates the 100 CFU/gram tissue limit of detection.  
Infections and sacrifices conducted in collaboration with Chris Alteri, Erin Hagan, 




protection against challenge (Figure 2.3A and C).  With the exception of ChuA, which 
was lethal in 11/30 mice (surviving mice were not protected), all of the full-length protein 
and peptide vaccines were well tolerated in immunized mice and no animals died 
following vaccination. Of note, full-length IroN was never successfully cloned and 
expressed for efficacy trials. 
 Since a significant reduction in post-challenge CFU was observed for Hma and 
IreA vaccinated mice, these antigens were tested to determine if similar levels of 
protection could be generated following heterologous challenge with another UPEC 
isolate.  Mice were immunized as described in Figure 2.2 with Hma, IreA, or CT alone 
and CFUs were determined at 48 hpi with UPEC strain 536.  In these experiments, Hma 
vaccinated mice were significantly protected from heterologous challenge and displayed 
>10-fold reduction in median CFU/g in the bladder (P = 0.0287) (Figure 2.4).  
Vaccination with IreA significantly protected mice from challenge with UPEC strain 536 
and these mice demonstrated a similar log-fold decrease in median CFU/g in the kidneys 
(P = 0.0379) (Figure 2.4).   
 Peptides (30 aa) corresponding to portions of the extracellular loops in both the 
salmochelin siderophore receptor IroN (aa 491-520) and aerobactin receptor IutA (aa 
467-498) were also assessed to determine their use as potential immunogens.  
Extracellular loops were selected based on their predicted topology to direct an antibody 
response against surface-exposed residues.  These peptides also represent highly 
conserved loops within the salmochelin and aerobactin receptors; the IroN peptide has 
>90% identity to 37 siderophore receptor sequences including urinary tract isolates 536, 





Figure 2.4  Immunization with Hma and IreA reduces kidney 
colonization by E. coli 536.  Vaccinated animals (n=10 mice per 
experiment, 2 experiments combined) were transurethrally challenged with 
1×10
8
 CFU of E. coli 536 and colonization was measured 48 hpi.  Symbols 
represent CFU/g tissue or /ml urine of individual mice and bars indicate 
median values.  Clear bars, mock vaccinated with CT alone; gray bars, 
vaccinated with purified Hma or IreA.  The dotted line indicates the 100 
CFU/gram tissue limit of detection.  Experiment conducted by Chris Alteri 




receptor sequences present in various pathogenic E. coli, including UPEC and ExPEC 
isolates UMN026 (240), IAI39, and S88 (316).  Mice were inoculated as previously 
described with peptide mixed with CT or CT alone and protection was assessed at 48 hpi 
following infection with UPEC strain CFT073.  These peptides failed to elicit significant 
protection in the urine, bladder, or kidneys of mice, however, there was nearly a 2-log 
reduction in CFU/g in the kidneys for both IroN (P = 0.053) and IutA (P = 0.078) 
peptides, demonstrating a strong trend towards protection (Figure 2.3F).  These results 
imply that peptides may be suitable for development of a UTI vaccine but maybe more 
efficacious if cross-linked to or fused in a carrier molecule.  Together, these findings 
show that targeting members of an entire functional class of molecules involved in iron 
acquisition is an effective strategy to identify protective vaccine candidates that 
significantly reduce bacterial colonization during ascending UTI following experimental 
challenge with UPEC. 
2.4.3 Splenocytes from vaccinated mice upregulate transcripts for several 
proinflammatory cytokines 
 Proinflammatory cytokines are crucial for orchestrating protective immune 
responses against pathogens.  To gain insight on what cytokines and cell types might be 
important for protection, the relative quantities of a panel of cytokine transcripts were 
analyzed in our CT control- and OMP antigen-vaccinated mice by qPCR analysis.  
Splenocytes were isolated from protein vaccinated and adjuvant (CT)-only controls and 
cultured with or without increasing concentrations of OMP fraction in vitro.  At the time, 
the crude OMP extract (containing the vaccine candidates) was used for in vitro 




cells were harvested and prepared for qPCR analysis.  Figure 2.5 shows dose-dependent 
IFN- transcript upregulation by splenocytes from mice vaccinated with both full-length 
OM iron receptors and peptide (IroN and IutA) loops.  Splenocytes from IreA- and Hma-
vaccinated (protected) mice had the highest upregulation of IFN-  while only the highest 
concentration of peptide stimulation (100 g/ml) fostered significant upregulation of 
IFN- transcript from splenocytes taken from peptide-vaccinated mice.  Splenocytes from 
mice vaccinated with CT only did not upregulate IFN- in response to in vitro 
stimulation, indicating that vaccination with OM iron receptors (or antigenic peptides) 
stimulates the production of antigen-specific immune cells capable of responding to 
subsequent antigen exposure.  Note that splenocytes taken from IreA- and Hma-
vaccinated (protected) mice showed the strongest IFN-  responses.  In addition to IFN-
transcript, we tested upregulation of other pertinent cytokine transcripts in response to 
OM iron receptor vaccination and in vitro restimulation.  Of the panel of cytokines tested, 
only IL-6 transcript was consistently upregulated by splenocytes from all of the 
vaccinated animals and not the CT controls (Figure 2.6).  Lastly, peptide antigens IutA 
and IroN elicited a strong TNF-  response upon stimulation of splenocytes from 
vaccinated mice in vitro. 
2.4.4 Splenocytes from vaccinated mice upregulate IL-17A transcript  
in an antigen-dependent manner 
 At the time these assays were being performed, information on the importance of 






Figure 2.5  Splenocytes from vaccinated mice upregulate IFN-  transcript in 
response to antigen stimulation.  Splenocytes purified from mice vaccinated with 
recombinant Iha, IreA, Hma or peptides representing loops from IroN and IutA 
were restimulated with the OM fraction of E. coli CFT073 or the corresponding 
purified peptides, respectively (n=2 samples per condition per concentration).  
Bars indicate increasing concentrations of stimulant used (from left to right: 0.1 





Figure 2.6  Splenocytes from vaccinated mice upregulate other cytokine 
transcripts in response to antigen stimulation.  Splenocytes purified from 
mice vaccinated with recombinant Iha, IreA, Hma or peptides representing loops 
from IroN and IutA were restimulated with the OM fraction of E. coli CFT073 or 
the corresponding purified peptides, respectively (n=3 samples per condition).  
For these experiments, splenocytes from full-length receptor-vaccinated mice 
were stimulated with 10 g/mL OM fraction while splenocytes from peptide-




immune response to pathogens was rapidly emerging.  In response to this, the 
upregulation of IL-17A transcript was also tested in the vaccinated mice.  Coinciding 
with this, purification techniques were improved and larger yields of purified iron 
receptors were generated, facilitating in vitro stimulation of splenocytes with the purified 
antigen used for vaccination (rather than crude OMP extract).  As shown in Figure 2.7, 
IL-17A transcript was the only proinflammatory transcript significantly upregulated 
compared to both unstimulated controls and to Hma-stimulated cells from CT-vaccinated 
animals (P = 0.0051).  Significant upregulation of IL-17A transcript was also observed 
when analyzing antigen-stimulated splenocytes from mice vaccinated with the other iron 
receptor vaccine candidates (combined Hma studies shown, Figure 2.8A).  Notably, the 
most protective vaccine against UPEC bladder colonization, IreA, showed the largest 
increase in IL-17A transcription (when compared to splenocytes from CT control mice), 
128-fold, P = 0.029 (Figure 2.8A).   
 Testing splenocytes from mice vaccinated with different antigens revealed a 
trend: IL-17A transcript responses by OM iron receptor vaccinated mice were 
significantly different from those of CT control mice (Figure 2.8A), whereas IFN-  
transcripts appeared to be equally upregulated by splenocytes from both control and 
vaccinated mice (Figure 2.8B).  This trend extended to other LPS-responsive 
proinflammatory genes (i.e. IL-6 and TNF- ), suggesting that splenocytes were 
responding to contaminating LPS in the purified iron receptor preparations, and that IL-
17A transcripts were not subject to this innate LPS- responsiveness.  Additional facts 
support this notion.  First, purified OM iron receptor preparations all tested positive for 





Figure 2.7  Splenocytes from Hma-vaccinated mice upregulate 
cytokine transcripts in response to stimulation with Hma in vitro.  
Splenocytes purified from mice intranasally vaccinated with 
recombinant Hma were restimulated with 1 g purified Hma (n=2-7 
samples per condition).  Note the use of a log2-transformed y-axis.  






Figure 2.8  Splenocytes from vaccinated mice only upregulate IL-
17A transcripts in an antigen-specific manner in vitro.  Splenocytes 
taken from vaccinated mice 2 days post challenge were stimulated with 
corresponding antigen in vitro (n=4-10 samples per experiment, 1 or 2 
experiments combined).  After 6 hours incubation, RNA was isolated 
and (A) IL-17A or (B) IFN-  transcript levels were quantified by qPCR.  
IroN and IutA represent data corresponding to extracellular loop 
peptides.  Each symbol represents an individual animal and bars 




these experiments, purification protocols moved from a urea-based method to an 
imidizole-based method, and the level of cytokine transcripts upregulated non-
specifically by splenocytes from CT-vaccinated mice shifted with this transition.  One 
last piece of evidence suggesting that splenocytes were upregulating IFN-  transcript 
non-specifically (in response to LPS) is that splenocytes that were stimulated with the 
peptide preparations, which were ultra-pure and did not test positive for LPS, only 
upregulated IFN-  transcripts in an antigen-dependent fashion (Figure 2.8B).  
Surprisingly, OM preparations used for stimulation of cells in Figure 2.5, Figure 2.6, and 
Figure 2.7 did not result in a similar trend, suggesting that the purification scheme used in 
the latter experiments (Figure 2.8), which was imidizole-based rather than urea-based, 
either enriched for LPS or fostered contamination with LPS.  Thus, the upregulation of 
IFN-  and IL-17A transcripts in response to purified LPS was directly tested; the results 
of this experiment are shown in Figure 2.9.  Indeed, IFN-  transcripts are upregulated 
similarly by splenocytes from both CT-treated and antigen- (ChuA in this representative 
experiment) vaccinated mice in response to either ChuA or LPS (Figure 2.9, left four 
columns).  In contrast, only when splenocytes from ChuA-vaccinated mice were 
stimulated in vitro with purified ChuA was IL-17A transcript generated (Figure 2.9, right 
four columns).  These results demonstrate that, in this system, LPS does not stimulate 
upregulation of IL-17A transcript and antigen-specific stimulation is necessary to initiate 
IL-17A transcription, suggesting the involvement of CD4
+
 Th17 memory cells. 
2.4.5 Splenocytes from vaccinated mice secrete IFN-  and IL-17A  
in an antigen-dependent manner 






Figure 2.9  Splenocytes from vaccinated mice upregulate IFN-  
transcripts in a non-specific response to LPS and IL-17A transcripts 
in an antigen-specific response to OM iron receptor.  Splenocytes 
taken from CT-control or ChuA-vaccinated mice 2 days post challenge 
were stimulated with ChuA or LPS in vitro (n=2-4 samples per 
condition).  After 6 hours incubation, RNA was isolated and IFN-  and 
IL-17A transcript levels were quantified by qPCR.  Bars and error 




investigated.  Secretion of two major proinflammatory cytokine mediators, IFN-  and IL-
17A, were measured from the splenocytes of mice immunized with adjuvant alone (CT), 
IreA (a protective antigen), or Iha (a non-protective antigen) following vaccination.  Cells 
were analyzed both pre- and post-challenge (days 21 and 23, respectively, Figure 2.2) to 
gauge the immune response to in vivo antigenic stimulation (i.e., UPEC challenge).  
Splenocytes were cultured in vitro in the presence of 1 g/ml of the purified antigen used 
for immunization.  Splenocytes from Iha-vaccinated and IreA-vaccinated mice collected 
both before (-) and after (+) challenge demonstrated significant antigen-specific secretion 
of IFN-  and IL-17A when compared to the corresponding splenocytes from CT control 
mice (P < 0.05, bars not shown) (Figure 2.10A and B).  Supernatants from unstimulated 
splenocytes from both CT-treated and antigen-vaccinated mice had undetectable levels of 
both IFN-  and IL-17A.  Interestingly, splenocytes derived from Iha- and IreA-vaccinated 
mice post-challenge secreted less pro-inflammatory cytokines than pre-challenge cells (P 
< 0.003) (Figure 2.10 A and B).  Both IFN-  and IL-17A secreting splenocytes were 
significantly decreased post-challenge (P <0.003) in IreA-vaccinated mice (Figure 
2.10B), whereas only IL-17A secreted splenocytes were significantly decreased (P = 
0.0007) in mice vaccinated with Iha (Figure 2.10A).  In other words, a decrease in both 
IFN-γ and IL-17A secretion from vaccinated mice post-challenge as compared to pre-
challenge was only observed following immunization with a protective antigen (IreA), 
suggesting that IFN-  or potentially Th1-mediated responses may play a role in 
protection.  Overall, these results indicated that vaccination with OM iron receptors 





Figure 2.10  Antigen-specific splenocytes from vaccinated mice secrete 
IFN-  and IL-17A.  Splenocytes harvested from (A) Iha-vaccinated or (B) 
IreA-vaccinated without challenge (-) or 2 days after transurethral challenge 
with E. coli CFT073 (+) were stimulated with the corresponding antigen in 
vitro (n=5-10 samples per condition).  Cytokines were measured in culture 
supernatants by ELISA.  Each symbol represents an individual animal and 




two important pro-inflammatory cytokine mediators; unfortunately, no significant 
correlation was found between cytokine production and reduction in CFU post-challenge.  
Lastly, unlike transcript upregulation, IFN-  was only secreted in the splenocyte 
supernatants when cells were exposed to specific antigen, not LPS or LPS-contaminated 
antigen preparations.  This finding reveals antigen-specific regulation of proinflammatory 
immune responses at the level of translation and or secretion. The mechanism behind this 
specificity remains to be tested. 
2.4.6 Vaccinated mice excrete antigen-specific IgA in urine 
 To evaluate the humoral immune response at the primary site of infection – the 
bladder mucosa – levels of antigen-specific IgA were measured in urine by ELISA.  To 
account for variability in the amount and concentration of urine from each mouse, 
collections were pooled for use in an indirect ELISA to measure antigen-specific IgA.  
Urine from IreA- (Figure 2.11A) and IutA-vaccinated (Figure 2.11B) cohorts, which had 
significantly decreased bladder colonization upon challenge, had the highest fold 
increases in IgA (34-fold and 6.2-fold, respectively) post-vaccination.  Antigens that did 
not generate significant decreases in colonization in the bladders of vaccinated mice had 
more modest fold-increases in urine IgA post-vaccination (2.0-fold for ChuA, and 1.7-
fold for Iha) (Figure 2.11D and E).  Correspondingly, peptide antigens representing 
extracellular loops of IroN and IutA did not significantly protect from infection in the 
bladder, and IgA was at background levels in the urine of these animals (Figure 2.11F).  
Hma, which was protective in the bladder when challenged with strain 536, but not 





Figure 2.11  Mice produce antigen-specific urinary IgA in response to 
intranasal immunization.  Urine from (A) IreA-vaccinated, (B) IutA-vaccinated, 
(C) Hma-vaccinated, (D) Iha-vaccinated, (E) ChuA-vaccinated, (F) peptide-
vaccinated, and corresponding CT control mice was collected prior to vaccination 
(pre) and after vaccination but before transurethral challenge with UPEC strain 
CFT073 (post).  Pooled samples (n=5-10 mice per group) were plated in 
appropriately coated ELISA plates and probed for antigen-specific IgA.  
Absorbance reflects relative quantity of IgA.  Error bars indicate the mean +/- 




findings demonstrate that vaccination with, IreA and IutA, which provide significant 
protection in the bladder from experimental challenge with UPEC strain CFT073 (Figure 
2.3), generates production of antigen-specific IgA that is secreted in urine. 
2.4.7 Vaccinated mice produce antigen-specific serum antibodies 
 To evaluate the systemic humoral immune response to our vaccine candidates, the 
levels of serum antigen-specific antibodies generated by vaccinated mice were compared 
to those of CT control mice.  Serum was collected by infraorbital ocular bleed before 
vaccination and after vaccination prior to transurethral challenge with UPEC strain 
CFT073 (Figure 2.2).  Note that collections were also taken after challenge (day 23) in 
some experiments; the relative antigen-specific antibody measurements were not 
different from those on day 21.  For each protein and loop peptide antigen tested, there 
was a significant increase of antigen-specific IgG in post-vaccination serum compared to 
the corresponding pre-immune serum (P = 0.0002) (Figure 2.12A-F).  In most cases, 
there was no difference in IgG levels between the pre- and post-vaccinated sera from CT 
control mice.  Additionally, all post-vaccination sera had significantly higher levels of 
IgM than pre-vaccination sera (P < 0.05) (Figure 2.12A-F).  Although both IgG1 and 
IgG2a increased from pre- to post-vaccination, there was no definitive skew toward 
production of IgG1 or IgG2a by any antigen (Figure 2.13).  This phenomenon is not 
unusual for protein antigens, as they can stimulate production of both Th1 and Th2 cells 
by virtue of their broad MHC class II peptide repertoire (67).  Serum IgA or IgE was 






Figure 2.12  Antigen-specific serum IgM and IgG is produced by vaccinated 
mice.  Serum from the indicated antigen-vaccinated mice and corresponding CT 
control-treated mice was collected prior to vaccination (pre) and after vaccination 
before transurethral challenge (post) (n=5-10 mice per experiment, representative 
experiments shown).  Each symbol represents an individual animal and bars 





Figure 2.13  Antigen-specific serum IgG2a and IgG1 is produced by vaccinated 
mice.  Serum from the indicated antigen-vaccinated mice and corresponding CT 
control-treated mice was collected prior to vaccination (pre) and after vaccination 
before transurethral challenge (post) (n=5-10 mice per experiment, representative 
experiments shown).  Each symbol represents an individual animal and bars 




vaccinated mice generate target-specific antibodies in response to intranasal 
immunization with iron-receptor antigens. 
2.4.8 Antibody class-switching and mucosal IgA correlates with protection 
 IgG and IgM are often monitored to determine the level of class switching 
undergone by B cells.   In our studies, all vaccinated animals demonstrated significant 
increases in both serum IgG and IgM from pre- to post-vaccination.  However, Hma-, 
IreA-, and IutA-vaccinated (protected) animals displayed more dramatic IgG increases 
than IgM when compared to ChuA-, Iha-, and peptide loop antigen-vaccinated 
(unprotected) animals (compare Figure 2.12B, D, and E to Figure 2.12A, C, and F).  This 
finding suggested that these animals have been sufficiently stimulated to class switch to 
more effective antibody isotypes.  To more quantitatively assess this trend and the 
relationship of serum IgG and IgM to protection from UTI, we first calculated a “class 
switch index” using the data from all of the immunized mice.  The class switch index is 
the ratio of the median change in sera IgG to the median change in sera IgM for each 
group of vaccinated mice.  To account for non-specific antibody increases, the median 
changes in sera IgG and IgM of CT-treated mouse cohorts were subtracted from the 
corresponding antigen-vaccinated group values.  The class switch indices were then 
plotted against the normalized post-challenge median bladder CFU/g for each individual 
study to determine if any relationship existed between antibody class-switching and 
protection from cystitis.  Because infectivity can vary between experiments, the median 
CFU/g from each antigen-vaccinated group was divided by the median CFU/g of the CT 




median CFU/g values were log10 transformed for comparison on a linear scale.  This 
analysis demonstrated that there was a significant correlation between the class switch 
index and the CFU/g in the bladder (P = 0.0014) (Figure 2.14A), suggesting that a 
decrease in bladder colonization may be attributed to the relative amount of antibody 
class-switching from IgM to IgG in mice vaccinated with protective antigens.  No 
significant correlation was found between antibody class-switching from IgM to IgG and 
CFU/g in the kidneys.  However, as predicted, there is also a strong correlation between 
the amount of antigen-specific IgA in urine and protection from UPEC infection in the 
bladder (Figure 2.14B); specifically, increases in urine IgA corresponded to decreases in 
bladder CFU (P = 0.0165). These findings show that antibody class-switching and 
urinary IgA are each an immunological correlate of protection against UTI caused by E. 
coli. 
2.4.9 Passive and adoptive transfer of protection 
 The fact that the class switch index correlated with protection suggested that 
either IgG itself may mediate protection, or isotypes other than IgM (IgA, for instance) 
may mediate the protective response to UPEC infection of the urinary tract.  To further 
establish the immune factor(s) involved in protection by intranasal vaccination with 
UPEC antigens, we conducted pilot passive (sera) and adoptive (cellular) transfer 
experiments.  Groups of 10 CBA/J mice were vaccinated with either or Hma or IreA 
(protective antigens) as outlined in Figure 2.2, and subsequently their serum was 
harvested by cardiac puncture and pooled for i.p. administration to 10 naïve recipient 





Figure 2.14  Isotype class-switching and urinary IgA correlates with 
vaccine-mediated protection from infection.  (A) The class switch index 
[( IgGVAC - IgGCT) / ( IgMVAC - IgMCT), where VAC indicates antigen 
vaccinated mice and CT indicates adjuvant control mice] was plotted against 
the normalized bladder CFU (group median CFUVAC / group median CFUCT) 
for each vaccination experiment (n = 203 mice total).  Thus, each individual 
point reflects the collective data from an experiment involving at least 10 
vaccinated and 5 CT mice.  In most cases, experiments were repeated twice.  
Lower normalized CFU values indicate enhanced bacterial clearance after 
challenge, where higher class switch indices represent superior B cell 
activation.  (B) Normalized bladder CFU values from each vaccination 
experiment are plotted against the median change in absorbance of antigen-
specfic IgA detected in the urine ( IgAVAC).  Pearson correlation coefficient 




sera to transfer to naïve mice.  In addition to the sera, we collected spleens from CT 
control or iron receptor antigen-vaccinated animals.  After lysing the red blood cells, 
2.5x10
6
 splenocytes from each of the three groups (pooled from 4 spleens) were 
administered to 10 naïve mice by intravenous tail vein injection (in 100 l PBS per 
animal).  At the time of transfer, mice receiving either sera or splenocytes from CT-
treated, IreA-vaccinated, or Hma-vaccinated animals were transurethrally challenged 
with 1x10
8
 CFU of UPEC strain CFT073.  After 48 hours, recipient animals were 
sacrificed and colonization of their bladders and kidneys was assessed.  While none of 
the mice receiving sera or splenocytes from IreA- or Hma-vaccinated animals had 
statistically significant protection when compared to mice receiving sera or splenocytes 
from CT-treated animals, there were some trends toward protection exhibited by “IreA 
recipient mice” (Figure 2.15A and B).  Specifically, naïve mice receiving splenocytes 
from IreA-vaccinated animals showed a trend toward protection in the bladder, and naïve 
mice receiving sera from IreA-vaccinated animals showed a trend toward protection in 
the kidney.  One interpretation of these results is that antigen-specific IgA-secreting 
plasma cells in the splenocyte population afforded some protection in the bladder, while 
antigen-specific IgG contained in the sera from vaccinated animals afforded some level 
of protection in the kidney tissue.  Additional experiments involving passive transfer of 
higher volumes of sera or adoptive transfer of either higher numbers of splenocytes or 
plasma cells purified from the spleens and inguinal lymph nodes of vaccinated mice will 
further establish whether or not antigen-specific antibodies not only correlate with 





Figure 2.15  Transfer of immunity from iron receptor antigen-vaccinated 
animals to naïve recipients.  Either sera or splenocytes from CT control or iron 
receptor antigen-vaccinated animals (n=10 each) were transferred to naïve 
recipients (n=10 each) as described in the text.  (A)  Colonization of mice 
receiving splenocytes from adjuvant-treated or iron receptor-vaccinated animals, 
indicated on the x-axis.  (B)  Colonization of mice receiving sera from adjuvant-
treated or iron receptor-vaccinated animals, indicated on the x-axis.  Note the P-






 UTIs caused by UPEC represent a significant healthcare burden that could be 
alleviated by the development of a protective vaccine.  Toward this aim, a multi-pronged, 
functional vaccinology approach was used, and this approach uniformly singled out one 
class of molecules, those involved in iron acquisition, as PASivE protein targets.  The 
screening process selected six vaccine candidates from the 5379 predicted proteins 
encoded within the E. coli CFT073 genome.  The six vaccine candidates meet the criteria 
for PASivE vaccine candidates.  They were conserved among UPEC strains (137, 248), 
antigenic (137), predicted to be surface-exposed and present in the bacterial OM (8, 137), 
transcriptionally upregulated in vivo (386), and induced during culture in human urine 
(8).  These vaccine targets, ChuA, Hma, Iha, IreA, IroN, and IutA, are all OM -barrel 
proteins that function as receptors for iron-containing compounds. Of these, we found 
that intranasal immunization with Hma, IreA, or IutA generates an antigen-specific 
humoral response, antigen-specific upregulation of IL-17A transcript and secretion of IL-
17A and IFN-γ, and provides significant protection against experimental infection with 
UPEC. 
2.5.2 Protection and physiology 
 Significant protection was observed in mice vaccinated with IutA, Hma, or IreA 
(Figure 2.3).  While protection by IreA and Hma appeared to be site-specific in response 
to challenge with CFT073 (IreA in the bladder and Hma in the kidney, Figure 2.3B and 




(Figure 2.4), perhaps due to differences in bacterial expression of IreA and Hma during 
infection.  Alternatively, with respect to IreA, reduction in the level of bacterial 
colonization within the bladder may have resulted in reduced numbers of bacteria 
ascending to the kidneys, potentially accounting for the modest reduction in bacteria seen 
in the kidneys in the IreA-vaccinated mice following challenge with either UPEC strain 
CFT073 or 536 (Figure 2.4).   
 In contrast to the bladder protection seen with IreA, Hma significantly reduced 
the number of bacteria colonizing the kidneys and, in over half of the animals, prevented 
kidney colonization completely in response to challenge with CFT073 (Figure 2.3).  The 
kidney-specific protection of the Hma vaccine may reflect the biological function of Hma 
for UPEC during colonization of the urinary tract; UPEC that are unable to produce Hma 
have reduced fitness only within the kidney during experimental UTI (136).  This result 
suggests that the immune response may perturb the normal function of this OM heme 
receptor, perhaps by antibody interference with ligand-binding domains or selective 
immune targeting of bacteria that exhibit tissue-specific expression of Hma.   
2.5.3 Protection and cytokines 
 To assess cellular responses to immunization, both antigen-specific upregulation 
of proinflammatory transcripts and antigen-specific secretion of IFN-γ and IL-17A, 
known to be critical for mediating anti-bacterial activities within the host, were analyzed.  
Production of IFN-γ has been previously shown to be important for the control of 
infection within the urinary tract (198) and IL-17A has been shown to promote the 




transcripts were upregulated significantly, only IL-17A upregulation was shown to be 
antigen-dependent in this system (Figure 2.8 and Figure 2.9).  IL-17A has been recently 
appreciated as an important mediator to control infection by Salmonella, Listeria, 
pathogenic Mycobacterium, E. coli, and Klebsiella (142, 363, 376, 438, 464).  With 
regard to secretion, however, both IFN- γ and IL-17A were produced from splenocytes 
originating from IreA and Iha immunized mice in response in vitro stimulation (Figure 
2.10).  The fact that splenocytes obtained from vaccinated mice post-challenge showed a 
reduction in antigen-specific cytokine secretion compared to splenocytes obtained from 
mice pre-challenge suggests that antigen-specific lymphocytes may be homing from the 
spleen to the site of infection.  Further, the post-challenge reduction in both antigen-
specific cytokines tested was only significant for the IreA vaccine, which generates a 
protective response in the bladder. 
2.5.4 Protection and antigen-specific antibodies 
 Mucosal immunization is considered the most effective means to develop a UTI 
vaccine and the Mobley Lab has shown previously that intranasal immunization with 
MR/P fimbria is effective in protecting mice against UTI caused by P. mirabilis, an agent 
of complicated UTI (244).  Because local immunization of the urethra is not practical, the 
migration of immune cells between mucosal sites can be exploited during intranasal 
inoculation with antigen (207).  We reasoned that intranasal immunization would 
generate a distant mucosal response in the genitourinary tract against UPEC in vaccinated 
animals.  Consistent with this, we observed that the two vaccines, IreA and IutA, which 




production of secretory IgA detectable in their urine (Figure 2.11).  Conversely, antigens 
that did not induce protective immunity within the bladder did not generate a similar 
increase in the level of IgA.  Based upon these findings, relative levels of IgA in the urine 
significantly correlated with protection in the bladder.  That is, when examining all of the 
vaccine candidates and bacterial counts within the bladder, there is a direct relationship 
between a reduction in CFU in the bladder and increased IgA in the urine (Figure 2.14B).  
This immunological correlate suggests that a mucosal response and vaccine that 
generates IgA is sufficient to provide protection from UPEC colonization in the bladder.  
This finding is consistent with other studies that have shown that antibodies specific for 
the infecting E. coli strains leads to resolution of cystitis and that oral immunization with 
OM proteins generates an antigen-specific IgA mucosal response against UPEC (173, 
238). 
 The finding that IgA in the urine is produced in response to intranasal 
immunization indirectly shows that class-switching of antibody isotypes is occurring in 
vaccinated animals.  Analysis of serum antibodies from immunized mice shows that 
antigen-specific IgM is produced in response to all the vaccine candidates tested.  
Further, antigen-specific IgG is markedly increased in response to each vaccine when 
compared to pre-immune sera (Figure 2.12).  For the Hma and IutA vaccines, which 
provided significant protection in the kidney, it is possible that circulating IgG or antigen-
specific plasma cells migrate to the kidney to contribute to reduction of bacterial 
colonization.  Interestingly, the vaccines that significantly protected mice against UPEC 
infection, Hma, IreA, and IutA, displayed a dramatic increase in antigen-specific IgG 




value that significantly correlated with protection from bacterial colonization in the 
bladder (Figure 2.14A).   
 It is notable that both CT-treated and antigen-vaccinated mice experience 
increases on antigen-specific IgM, with increases in antigen-specific IgM being more 
dramatic in the antigen vaccinated mice (Figure 2.12).  Increases in the control mice may 
be a result of CT stimulation of the immune system, whereas in the case of the antigen-
vaccinated mice serum increases, naïve B cells that encounter antigen by ligation with 
surface IgM undergo proliferation (453).  This proliferation results a clonal population of 
B cells specific for the iron receptor of interest and capable of secreting more antigen-
specific IgM.   In animals vaccinated with non-protective antigens, these cells are clearly 
not receiving additional signals (chemokines, for example) that are necessary for 
migration to lymphatic germinal centers and class-switching.  Hence we observe more 
antigen-specific IgM in the serum of non-protected animals, and antigen-specific IgG in 
the serum of protected animals, indicating that class-switching of antibody isotypes is 
indicative of a protective immune response.  The class switch index could potentially be 
further refined by the inclusion of total antibody (antigen-specific and non-specific) to 
account for this variable in the measurement of serum antibody.   
 Whether antibodies targeting OM iron-related receptors neutralize UPEC by 
interfering with iron acquisition or provoke a bactericidal immune response (i.e., 
opsonization or activation of complement) is a topic to be investigated.  Because of their 
physiological locales in the body, it is likely that IgA directly neutralizes UPEC, as 
phagocytes are not in excess in the mucosa, and IgG either opsonizes bacteria in the 




UPEC can evade the activity of these antibodies if the iron receptors are truly 
functionally redundant, as their expression could be modified to obtain iron in the case of 
neutralization or evade the immune system in the case of opsonization or complement 
activation.  These ideas are also based on the assumption that there is no inherent killing 
property elicited by the antibody binding in itself, which the literature suggests otherwise 
(98).  In any case, deciphering between these strategies using in vitro assays is an 
important next step to better understand what types of host response are necessary to 
overcome UPEC infection in vivo.     
2.5.5 PASivE vaccine candidates in context of previous UPEC vaccination studies 
 There has been limited success to develop an efficacious UTI vaccine that would 
provide protection from infection by UPEC.  Immunization with Solco-Urovac, a vaccine 
formulation that is comprised of inactivated uropathogenic bacteria, generates urinary 
IgA (288) and vaginal immunization with this vaccine provides protection that lasts eight 
to twelve weeks in humans (429).  If administered more frequently, vaccination with 
Solco-Urovac can increase time to recurrence to six months (171).  This suggests this 
vaccine might be useful to prevent recurrent UTIs in susceptible populations; however, 
the frequency of administration poses a problem with the general target population.   One 
of the vaccine candidates we identified and tested, IroN, has been used previously to 
immunize mice, and similar to our results with IroN, was shown to generate antigen-
specific IgG but not IgA (349).  In contrast to our findings, IroN was previously found to 
protect mice against renal infection.  This difference may be accounted for by the fact 




extracellular loops mixed with CT given intranasally versus denatured IroN without 
adjuvant given subcutaneously (349).  Lastly, using a lethal challenge model of 
extraintestinal pathogenic E. coli infection, it was found that vaccination with IroN, but 
not ChuA, increased survival in immunized mice (78).  The results presented here are 
consistent with ChuA being non-protective (and unfortunately lethal); however, 
protection from UTI was not afforded by IroN vaccination. The discrepancy may be due 
to the ability of epitopes in the IroN sequence to stimulate class-switching to IgG, which 
would presumably be protective systemically, rather than mucosal IgA antibody, which 
likely mediates protection in the bladder mucosa. 
2.5.6 Conclusions 
 Despite these advances, a UTI vaccine that confers long-term protection against 
uncomplicated UTIs is currently lacking.  The rational large-scale screening process we 
described identified six surface-exposed OM receptors for iron compounds as PASivE 
vaccine candidates.  Iron acquisition is well known to be a common trait necessary for 
bacterial pathogenesis, and by targeting receptors involved in this process, it may be 
possible to disrupt this critical function thereby neutralizing UPEC.  Intranasal 
inoculation with three of six vaccine candidates (IreA, Hma, and IutA) provided 
protection from challenge with UPEC and this study provides the basis for the 
development of a subunit vaccine that would incorporate these protective antigens to 
provide broader efficacy within the urinary tract and across uropathogenic isolates.  
Importantly, this work shows that focusing on an entire class of proteins that are involved 




fundamental strategy that could be generally adopted during the development of vaccines 
against pathogens.  Administered together, the antigens may afford sterilizing immunity 
in both the bladder and the kidney.  Lastly, this work also yielded immunological 






Chapter 3  
The innate immune response to Uropathogenic Escherichia coli involves IL-17A  
in a murine model of UTI 
3.1 Abstract 
 UPEC strains express a number of virulence and fitness factors that allow 
successful colonization of the mammalian bladder.  To combat this, the host has distinct 
mechanisms, not only to prevent adherence to the bladder wall, but to detect and kill 
UPEC in the event of colonization.  In this study, we investigated the role of IL-17A, an 
innate-adaptive immunomodulatory cytokine, during UTI using a murine model.  
Splenocytes, isolated from mice infected by the transurethral route, robustly expressed 
IL-17A in response to in vitro stimulation with UPEC antigens.  Transcript expression of 
IL-17A in the bladders of infected mice correlated with a role in the innate immune 
response to UTI, and -positive cells appear to be a key source of IL-17A production.  
While IL-17A appears to be dispensable for the generation of a protective response to 
UPEC, its importance in innate immunity is demonstrated by a defect in acute clearance 
of UPEC in IL-17A
-/- 
mice.  This clearance defect is likely a result of deficient cytokine 
and chemokine transcripts and impaired macrophage and neutrophil influx during 
infection.  These results show that IL-17A is a key mediator for the innate immune 





Uncomplicated UTI occurs in otherwise healthy individuals that lack any urinary 
anatomical abnormalities.  The fact that recurrence of uncomplicated UTI is so prevalent 
argues against the thought that an acquired immune response if formed in response to 
natural infection.  Alternatively or in addition, high recurrence rates also suggest that 
UPEC are highly heterogeneous group of pathogenic strains.  The importance of the 
innate immune response has been recognized in governing an effective adaptive immune 
response.  When UPEC adheres to the uroepithelium, thereby establishing itself in the 
urinary tract, a robust innate immune response is generated.  TLRs have been shown to 
be important for UPEC recognition and immune mobilization (10, 374, 469).  A number 
of secreted factors such as AMPs, THP, cytokines, and chemokines are detected in the 
mammalian bladder upon infection (63, 166, 186, 352, 354, 404).  Among cellular 
infiltrate, neutrophils are the most abundant early responders in infected bladders (147).  
Additionally, macrophages (167), DCs (84), and ILLs such as  T cells (198) have been 
implicated in innate host defense to UPEC-mediated UTI.  Despite this knowledge, the 
role of each of these factors in the generation of a sterilizing recall response is not 
understood, and there are likely other undescribed factors that also regulate this process. 
IL-17A or the IL-17R has been shown to play a critical role in autoimmune 
disease (32, 261) and in bacterial (142, 187, 363, 376, 438, 465, 471), fungal (68, 178, 
343, 442), and even viral (141, 177, 209) infection.  Because of the roles played in both 
arms of the immune system, IL-17A has emerged as an innate-adaptive 
immunomodulatory cytokine.  Regarding the innate immune response to infection, IL-




transcripts for cytokines involved in granulopoiesis and chemotaxis in cells treated with 
IL-17A have enhanced stability (148-150, 163).  Aside from being the signature cytokine 
secreted by CD4
+
 Th17 helper cells, other cell types have been reported to secrete IL-
17A, including cytotoxic T cells,  T cells, NKT cells, neutrophils, eosinophils, and 
monocytes (32).  Although the exact PAMPs that trigger secretion of IL-17A are not 
defined, components of microbial cell wall, host receptors that recognize such 
components (i.e., the mannose receptor), and TLR-related signaling pathways are 
implicated (442, 471).   
In an effort to characterize the immune response to known UPEC antigenic OM 
proteins (137), we discovered that IL-17A was secreted by in vitro stimulated splenocytes 
derived from UPEC iron receptor-vaccinated mice (Figure 2.10) (7).  Given the 
importance of IL-17A in controlling mucosal infection (76), the role of IL-17A during the 
innate and adaptive immune response to UTI was formally investigated.  In the murine 
model, IL-17A is upregulated by in vivo sensitized secondary lymphoid tissue cells in 
response to in vitro stimulation, yet IL-17A appears to be dispensable for the generation 
of protective immunity.  IL-17A is also upregulated in the bladder in response to acute 
infection, and both -positive cells and IMs are a major source of secreted IL-17A in the 
bladder tissue.  Lastly, IL-17A appears to play a role in regulating the innate immune 
response to UTI; mice lacking IL-17A exhibit both deficient cytokine transcript 





3.3 Materials and Methods 
3.3.1 Animals 
3.3.1.1 Strains 
For these studies, C57BL/6 mice were used instead of the CBA/J model because 
knockout mice used were in this background.  Of note, the CBA/J mouse model of UTI 
typically involves ascension of bacteria from bladder to the kidneys (138), whereas 
C57BL/6 mice usually exhibit colonization confined to the bladder, with more modest 
ascension to the kidney (172, 198).  The factor(s) involved in this phenotype are not 
known.  C57BL/6 wild type mice TCR 
-/-
 mice deficient in   TCR expression in all 
adult lymphoid and epithelial organs (188) were purchased from Jackson Laboratories 
(Bar Harbor, ME).  Breeding pairs of IL-17A
-/-
 mice were obtained as a gift from 
Yoichiro Iwakura (University of Tokyo) (285).  IL-17R
-/- 
mice were obtained as a gift 
from Weiping Zou (University of Michigan).  All experiments were conducted when 
animals were 6 to 15 weeks old, and C57BL/6 wild type mice with birth dates within one 
week of the knockout mice (all in the C57BL/6 background) were used. 
3.3.1.2 Manipulation 
All infections (including sensitizations and challenges) consisted of 5x10
7
 CFU 
per mouse were administered as described in 2.3.2.  CFU was also determined as 
described in 2.3.2, and in some experiments, homogenates were centrifugated (16,100 x 
g, 10 min, 4°C) for collection and storage (-20ºC ) of supernatants for ELISA. 




E. coli CFT073 was described in 2.3.1.  EFC4 is a fecal strain isolated from a 
healthy woman (270).  For whole cell lysate preparation, a single colony of E. coli strain 
CFT073 was inoculated into 250 ml sterile human urine (pooled from 5 healthy donors) 
and cultured statically at 37°C until late stationary phase.  Bacterial cells were harvested 
by centrifugation (8,000 x g, 5 min, 4°C), washed, resuspended in 10 ml PBS, and 
incubated at room temperature with 2 l benzonase solution (10 U/ l, Sigma) for 30 min.  
Bacterial lysis and protein quantitation was done as described in 2.3.3.  Lysate was 
cleared by centrifugation (8,000 x g, 5 min, 4°C) and sterilized using a 0.22 m filter 
(Millipore). 
3.3.3 Tissue culture 
Spleens (1.5x10
6 
cells/well) or the inner inguinal (lumbar) lymph nodes (5x10
5
 
cells/well), responsible for draining the pelvic viscera, were harvested, made into single 
cell suspensions, and cultured as described in 2.3.6.  Lymph nodes from the same groups 
of animals were pooled and plated in replicate wells.  Cells were cultured with medium, 5 
g/ml -CD3 [clone 145-2C11, a gift from Dr. Cheong-Hee Chang (University of 
Michigan)], or 25 g/ml E. coli CFT073 whole cell lysate, and incubated at 37°C, 5% 
CO2 for 72 h at which point supernatants were harvested and stored at -20°C for ELISA. 
3.3.4 Kinetic MPO assay 
 Groups of 10 mouse bladders were homogenized in 1 ml 2x Homogenization 
Buffer (in ddH2O: 0.5 g HTAB, 0.1 ml EDTA, 43.9 ml 1.0 M monobasic potassium 
phosphate, 6.2 ml 1.0 M dibasic potassium phosphate, pH 6.0) and kept on ice.  0.1 ml of 




(15,700 x g, 15 min, 4°C), and 0.01 ml of supernatant was aliquotted into 96-well plates.  
0.140 ml of Assay Buffer (in ddH2O: 4.39 mL 1.0 monobasic potassium phosphate, 0.615 
ml 1.0 M dibasic potassium phosphate, 0.0833 ml H2O2, 0.834 ml ODH reagent) to each 
sample, mix briefly, and read absorbance at 460 nm immediately using a kinetic setting 
with collections every 10 sec for 3 min.  Homogenization buffer alone was used as a 
black, and the slopes (A460/min) were used to report MPO Units.  Control and infected 
mouse lungs from Thomas Moore (University of Michigan) were used as negative and 
positive controls, respectively. 
3.3.5 ELISAs 
Cytokine ELISAs were performed as described in 2.3.8.  For detection of MPO in 
bladder homogenates, a Mouse MPO ELISA Kit (Hycult Biotechnology) was used.  
Tissue homogenate preparation and ELISA protocol were done according to 
manufacturer’s instructions.  
3.3.6 RNA isolation, cDNA synthesis, and PCR 
3.3.6.1 qPCR 
For qPCR analyses, RNA was isolated from bladder tissue using TRIzol Reagent 
(Invitrogen) according to the manufacturer’s instructions.  cDNA synthesis, qPCR 
reactions, and subsequent analysis were done as described in 2.3.7.  For G-CSF, forward 
(5’-tcc ctg gag caa gtg agg aa-3’) and reverse (5’-gct tgt agg tgg cac aca act g-3’) primers 
were designed using Taqman Probe and Primer Design Software (Applied Biosystems).  
This qPCR reaction consisted of: 9.5 l RNase-free water, 12.5 l 2x SYBR Green PCR 




transcripts were normalized to that of GAPDH (2
- Ct
, where Ct equals the cycle 
threshold of test gene minus the cycle threshold of GAPDH). 
3.3.6.2 RT-PCR 
For RT-PCR analyses, RNA was isolated from bladder tissue using the RNeasy 
Mini Kit (Qiagen) according to the manufacturer’s instructions.  Genomic DNA was 
removed from the samples using TURBO DNA-free (Ambion) according to the 
manufacturer’s instructions.  cDNA was synthesized from 1 g of DNase-treated RNA 
using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) using 
gene-specific primers for common  and  chains [C  (256), C  (326)] according to the 
manufacturer’s instructions.  PCR for  and  variable chain transcripts was conducted 
using 2 l C  or C -generated cDNA, respectively, and either Taq Polymerase 
(Invitrogen) or Phire Hot Start DNA Polymerase (Finnzymes) according to the 
manufacturer’s recommendations with a melting temperature of 54ºC (with the exception 
of V 5 and V 8, which were amplified with a melting temperature of 51ºC).  Primer sets 
used were as follows: V 1.1 with J 4 (460); V 1.2 with C  (255); V 2-4 (121) and V 5 
(5’-cct act tct agc ttt ctt gc-3’) with J 1 (5’-ctt acc aga ggg aat tac tat gag-3’); V 1-3 and 
5-8 (460), and V 4 (255) with J 1 (326). Nomenclature used is according to Garman 
(113).  As with qPCR, RT-PCR reactions were conducted with appropriate no template 





Bladder tissue was harvested at necropsy and fixed in 10% neutral buffered 
formalin for 24 h.  Histology was performed by the Pathology Cores for Animal Research 
in the Unit for Laboratory Animal Medicine at the University of Michigan.  
Histopathological assessment was performed by pathologist Dr. Ingrid Bergin, VMD, 
MS, DACLAM, DACVP.  Tissues were trimmed and processed by standard histological 
methods and were stained with hematoxylin and eosin.  Light microscopic 
histopathological assessment was performed blinded to the group assignment of the 
samples.  The presence or absence of inflammation and the predominating type and tissue 
distribution of inflammatory cells was qualitatively assessed.  Additional points assessed 
were the presence/absence of bacteria, subjective assessment of bacterial quantity and 
distribution, and mucosal changes.  
3.3.8 Neutrophil counts 
 Urine was collected by massaging the mouse abdomen while holding the urethra 
over a sterile Eppendorf tube.  Urine was mixed 10:1 with Turk’s stain (0.05 mg/ml 
crystal violet, 3% glacial acetic acid in distilled water) and neutrophils were enumerated 
using a hemacytometer. 
3.3.9 Cellular staining and flow cytometry 
 Bladders, isolated from euthanized mice, were cut into small pieces with a 
scalpel.  Tissue was digested for 50 min at 37°C with agitation in 0.5% heat inactivated 
FBS, 20 mM HEPES pH 7, 0.057 Kunitz units/ l DNase I (Sigma), and 1 mg/ml 
collagenase A (Roche) in RMPI medium, with repeated passage through an 18½ gauge 




Erythrocyte-lysed homogenates were filtered through 40 micron cell strainers and washed 
once with flow cytometry buffer (1% FBS, 0.01% NaN3 in PBS).  After enumeration by 
hemacytometer, cellular suspensions were treated with mouse anti-CD16/CD32 (clone 
2.4G2, eBioscience) for 10 min to block Fc receptors.  Surface markers were stained for 
30 min, and cells were fixed overnight in a 4% formalin solution.  For intracellular 
staining, fixed cells were permeabilized with 1% FBS, 0.1% saponin in PBS, and stained 
for 60 min.  Data were acquired using a BD FACSCanto flow cytometer and BD 
FACSDiva software, and analyzed using FlowJo v7.2.4 (Tree Star, Inc.).  Mouse anti-
CD4-FITC (clone GK1.5), anti- -TCR-FITC (clone eBioGL3), anti-F4/80-FITC (clone 
BM8), anti-IL-17A-PE (clone eBio17B7), anti-CD8a-PE (clone 53-6.7), anti-CD4-PE-
Cy7 (clone GK1.5), anti-Ly-6G(Gr-1)-PE-Cy7 (clone RB6-8C5), anti-CD45R(B220)-
APC (clone RA3-6B2), anti-MHC Class II(I-A/I-E) (clone M5/114.15.2), anti-CD8a(Ly-
2)-APC-Cy7 (clone 53-6.7), and anti-CD11b-APC-Cy7 (clone M1/70) used staining and 
calibration controls were obtained from eBioscience. 
3.3.10 Statistics 
 Graphing and statistical analyses were done using GraphPad Prism 5.  Data were 
represented as mean or median values based on the D'Agostino & Pearson omnibus 
normality test.  Where applicable, the Mann-Whitney test, Paired t-test, or Fisher’s exact 
test was used to determine statistical significance with two-way analysis of variance and 






3.4.1 Adaptive immune responses and IL-17A 
3.4.1.1 IL-17A is secreted by spleen and lymph node cells from C57BL/6 mice  
in response to transurethral infection with UPEC 
To determine if lymphoid cells taken from infected mice secrete IL-17A in 
response to stimulation with UPEC antigens in vitro, wild type C57BL/6 mice were 
inoculated the transurethral route with either UPEC strain CFT073 or PBS according to 
the outlined schedules (Figure 3.1).  Cells harvested from the spleen and the inner 
inguinal lymph nodes were stimulated in vitro with medium alone, -CD3 monoclonal 
antibody (mAb, as a positive control), or UPEC strain CFT073 whole cell lysate and 
incubated for 72 h before harvesting supernatants for ELISA.  Seventy-two hours was 
chosen because it was the peak of cytokine secretion from spleen and lymph node cells in 
dose dependence experiments (Figure 3.1C).  Figure 3.1C also demonstrates that whole 
cell lysate was a superior stimulation agent compared to whoel killed bacterial cells.  As 
expected, splenocytes treated with -CD3 mAb had high expression of IL-17A, 
regardless of whether they originated from PBS- or CFT073-treated animals, and 
unstimulated cells from either treatment group did not secrete IL-17A (Figure 3.1A).  
However, in response to in vitro stimulation with UPEC whole cell lysate, only the 
splenocytes from UPEC-infected mice showed significant secretion of IL-17A compared 
to unstimulated controls (P=0.0147)  (Figure 3.1A).  Additionally, inner inguinal lymph 
node cells from UPEC-infected mice secreted significantly higher amounts of IL-17A in 
response to in vitro lysate stimulation than lymphoid cells from PBS-treated animals 




Figure 3.1  Spleen and inner inguinal lymph node cells from C57BL/6 mice 
receiving UPEC infection secrete IL-17A.  (A)  Mice were sensitized 
transurethrally with either PBS (open symbols) or UPEC (filled symbols) on days 
0, 14, and 28, and were sacrificed on day 33.  Upon sacrifice, splenocytes from 
individual animals (n=10) were stimulated with medium alone, 5 g/ml -CD3 
mAb, or 25 g/ml whole cell lysate from UPEC strain CFT073 for 72 h.  Each 
symbol represents an individual animal while bars represent the median values in a 
representative experiment.  (B)  Mice were sensitized transurethrally with either 
PBS (open bars) or UPEC (filled bars) on days 0 and 7 and sacrificed 2 days after 
the second sensitization, day 9.  Pooled inguinal lymph node cells from each group 
of animals (n=6) were plated in replicate wells and stimulated as in (A).  Bars and 
error represent the mean ± SEM of triplicate ELISA wells in a representative 
experiment.  n.d., not detectable.  (C)  Time-dependence of experiments shown in 




stimulates adaptive secretion of IL-17A from in vivo-sensitized cells from both systemic 
and local lymphoid origins. 
3.4.1.2 IL-17A is not necessary for the  
adaptively-acquired protective immune response to UTI 
 Because IL-17A was secreted in response to UPEC antigens (Figure 3.1) and the 
role that IL-17A plays in bacterial vaccination models (165, 250), we wanted to 
determine whether IL-17A is required for the generation of a protective immune response 
to UTI.  To do this, a reinfection model based on one presented by Thumbikat et al. was 
utilized (416).  Wild type and IL-17A
-/-
 mice were transurethrally infected once (1x), 
twice (2x), or not at all (N), prior to a 48 h challenge infection with UPEC (Figure 3.2).  
Both wild type sensitization groups had significantly fewer bacteria in their bladders 
when compared to wild type naïve mice (P=0.0193 for 1x and P=0.0016 for 2x compared 
to N) (Figure 3.2), consistent with a previously published study (416).  Sensitized IL-
17A
-/-
 mice also exhibited a similar pattern of accelerated clearance (P=0.0071 for 1x and 
P=0.0062 for 2x compared to N) (Figure 3.2).  Of note, a primary infection with UPEC is 
typically cleared from the urinary tract by day 7 post infection (Figure 3.3B).  These 
results demonstrate that both wild type and IL-17A
-/-
 mice experience enhanced clearance 
in response to a secondary infection, and suggest that IL-17A is not required for the 







Figure 3.2  IL-17A is not necessary for the protective (re-challenge) 
response to UTI.  Cohorts of wild type and IL-17A
-/- 
mice (n=11-12 each, 
2 experiments combined) were sensitized by the transurethral route with 
UPEC strain CFT073 once (1x), twice (2x), or not at all (N for naïve) on 
the indicated days.  Subsequently, all mice were challenged with CFT073 
on day 28.  Bladder colonization levels 48 h post challenge for wild type 
(filled symbols) and IL-17A
-/-
 (open symbols) mice are shown.  The dotted 
line indicates the 100 CFU/gram tissue limit of detection.  Each symbol 






Figure 3.3  IL-17A transcript dynamics in response to acute infection.  Mice 
were transurethrally inoculated with UPEC strain CFT073 and bladders were 
collected at specified time points for analysis of (A) cytokine transcript levels by 
qPCR (n=5-18 per time point, several experiments combined), (B) bladder CFU 
(n=3-55 per time point, several experiments combined), (C) IL-17A protein in 
bladder homogenate (n=9-10 mice per time point, 2 experiments combined), and 




3.4.2 Innate immune responses and IL-17A 
3.4.2.1 IL-17A transcript is upregulated  
in response to acute bladder infection by UPEC 
 Since there was no overt defect in the generation of protective immunity in IL-
17A
-/- 
mice, we sought to determine if IL-17A played a role in the innate response to UTI.  
To do this, we first examined IL-17A transcript dynamics during acute infection.  Mice 
were inoculated transurethrally with UPEC and their bladders were collected for qPCR 
analysis at 7 time points during a 28-day period.  UPEC-infected mice demonstrated a 
dramatic increase in IL-17A mRNA with median values peaking at 48 hpi (Figure 3.3A), 
suggesting a role for IL-17A in the innate immune response to UTI.  As depicted in 
Figure 3.3B, peak levels of IL-17A transcript expression coincide with CFU dynamics in 
the infected C57BL/6 bladder, a phenomenon that is further examined in the next section.  
To see if protein expression reflected transcript dynamics, bladders from infected mice 
were probed for secreted IL-17A by ELISA.  Surprisingly, IL-17A protein levels did not 
mirror transcript expression, as the amount of IL-17A detected in infected murine bladder 
homogenates increased over time, with a significant increase over baseline at 28 days 
post infection (dpi) (P = 0.005) (Figure 3.3C).  This time point corresponds to the 
resolution of infection in the majority of animals, as measured by the lack of CFU counts 
in the bladder (Figure 3.3B).  These data demonstrate that IL-17A transcript is highly 
upregulated at 2 days post bladder inoculation, and that significant protein levels are 
detectable after the infection has been cleared.    
 To put the dynamics of IL-17A transcript expression into perspective, RNA 




analyzed for IFN-  and IL-4 transcript expression over time.  These particular transcripts 
were chosen because they are the signature cytokines of the Th1 and Th2 cell subsets.  
While IL-17A transcripts peak at 2 dpi and remain above baseline throughout the 
experimental duration, IFN-  transcription appears to peak around 7 dpi, coinciding with 
the infiltration of adaptive immune cells (Figure 3.3D).  IL-4 transcript peaks similarly to 
IL-17A; however, unlike IL-17A, IL-4 transcript expression is back to baseline by day 28 
post infection (Figure 3.3D).  These results indicate that transcription of IL-17A is 
acutely upregulated in response to infection, and expression appears to correlate with the 
innate immune response to UTI.  
3.4.2.2 Innate expression of IL-17A appears to depend on UPEC colonization 
 The results in Chapter 2 revealed that expression of IL-17A transcript by 
splenocytes from UPEC antigen-vaccinated mice was not sufficiently stimulated by 
exposure to LPS (Figure 2.9).  Moreover, the exact molecular ligand that triggers 
activation of the signaling pathway responsible for secretion of IL-17A during acute 
bacterial infection is not established.  Perhaps TLR4 recognition of FimH (16, 275), or a 
different TLR-PAMP interaction such as TLR2 recognition of peptidoglycan components 
(441) or lipopeptide recognition by an unknown receptor (185), may trigger IL-17A 
secretion in response to UPEC.  Another alternative, however unlikely considering the 
paradigm of conserved PAMPs recognized by innate PRRs, is that there is a UPEC-
specific ligand that triggers transcription of IL-17A in the bladder in response to UTI.   
 Indeed, studies on TLR11 were not able to pinpoint the exact ligand for TLR11; 




IL-17A expression was specific to UPEC, C57BL/6 mice were infected with either UPEC 
or fecal strain EFC4.  EFC4 does not have the capacity to robustly colonize the murine 
urinary tract (270) (Figure 3.4A), and therefore cannot be considered an uropathogenic 
strain.  While both strains stimulated similar upregulation of IFN-  transcripts at 6 hpi 
(0.25 dpi), 2 dpi, and 7 dpi, it appeared that only mice infected with uropathogenic strain 
CFT073 upregulated IL-17A transcripts over time (Figure 3.4B).  However, while the 
levels did not increase with time, infection EFC4 did result in upregulation of IL-17A 
transcripts over baseline, as no IL-17A transcripts are detected in naïve animals (Figure 
3.4B).  This result suggested that colonization is likely necessary for robust upregulation 
of IL-17A transcripts that increase in the initial days of infection.   
3.4.2.3  T cells are a significant source of IL-17A  
during acute UTI in the mouse model 
3.4.2.3.1 qPCR for IL-17A in infected wild type and TCR -/- mice 
 The cell type(s) responsible for the high amount of IL-17A transcript generated in 
response to UPEC-mediated UTI needed to be identified.  Since TCR
-/-
 mice are more 
susceptible to UTI (198) and  TCR-positive cell populations are known to express IL-
17A in the context of bacterial infection (142, 249, 363, 376, 438), we wanted to see if 
TCR
-/-
 mice had a deficiency in IL-17A transcript expression during bladder infection.  
Wild type C57BL/6 and TCR 
-/-
 mice were inoculated transurethrally with PBS or 






Figure 3.4  Robust upregulation of IL-17A may be UPEC-specific or depend on 
efficient bladder colonization.  (A)  Mice (n=5-6 per inoculum) were transurethrally 
infected with the indicated inoculums of EFC4 and bladder CFU was analyzed at 48 hpi.   
Figure and experiment done by Sara Smith.  (B)  Mice were transurethrally infected with 
UPEC strain CFT073 or fecal isolate EFC4 (n=5 per strain).  At 0.25, 6, or 7 days dpi, 
bladders were harvested for qPCR analysis.  Values of 1x10
-9
 were given to mice that had 




mice exhibited significant upregulation of IL-17A compared to PBS-treated controls, 
which were undetectable.  However, the median value of IL-17A expression was 3.7-fold 
higher in the wild type mice (1.16x10
-3
 relative to GAPDH for wild type compared to 
3.1x10
-4
 for TCR 
-/-
 mice) (Figure 3.5).  These results demonstrate that mice deficient in 
the  TCR tend to have lower expression of IL-17A than wild type mice at 48 hpi, 
suggesting that  T cells are a source of the IL-17A secreted in response to UPEC 
bladder colonization.
3.4.2.3.2 Intracellular staining and flow cytometric analysis of  
IL-17A-producing  T cells 
Because TCR 
-/-
 mice express less IL-17A in response to experimental UTI, we 
sought to quantify the level of IL-17A expression by T cells in infected wild type 
animals by flow cytometry.  Bladders were isolated from PBS- or UPEC-inoculated wild 
type C57BL/6 mice at 48 hpi and made into single cell suspensions for staining and flow 
cytometric analysis.  For comparison, the expression of IL-17A by CD4
+
 cells was also 
analyzed.  To best represent the level of IL-17A expression in vivo, these cells were not 
stimulated in vitro prior to staining and analysis by flow cytometry.  While the number of 
infiltrating CD4
+
 cells was an order of magnitude higher than that of  TCR
+
 cells, 
increases in both populations were statistically significant (P=0.0021 and P=0.0229, 
respectively) (Figure 3.6A).  Each population was then interrogated for IL-17A positivity, 
as depicted by representative plots (Figure 3.6B).  Only TCR
+
 cells exhibited 
statistically significant increases in IL-17A positivity after UPEC infection (P=0.0225) 
(Figure 3.6C).  In addition, the median frequency of  TCR
+





Figure 3.5  IL-17A transcript dynamics in wild type and  TCR
-
/- 
mice.  Wild type (filled symbols) and  TCR
-/- 
(open symbols) 
mice (n=9 each, two experiments combined) were inoculated 
transurethrally with UPEC and sacrificed at 48 hpi for analysis of 
bladder mRNA by qPCR.  Each symbol represents an individual 





Figure 3.6   T cells are a source of IL-17A during acute UTI.  Bladders from 
mice treated transurethrally with PBS (open symbols, n=7, 2 experiments 
combined) or UPEC strain CFT073 (filled symbols, n=9, 2 experiments combined) 
were collected at 48 hpi, made into a single cell suspension, and stained (without in 
vitro stimulation) for flow cytometry.  Forward- versus side-scatter (FSC vs. SSC) 
plots were gated to include all CD4
+
 and  TCR
+
 cells as determined by 
backgating.  CD4
+
 and  TCR
+
 gates were then interrogated for IL-17A positivity 
individually based on unstained and singly-stained bladder control samples.  (A)  









(right) cells also staining positive for IL-17A from representative 
PBS-treated (top) and UPEC-infected (bottom) animals.  (C)  The total number of 
CD4
+
 and  TCR
+





cells in PBS treated and UPEC-infected animals.  In (A), (C), and 





for IL-17A was ~5%; in some animals, up to 12% of the  cell population expressed IL-
17A when compared to PBS group (P=0.0317) (Figure 3.6D).  These results indicate that 
at 48 hpi, -positive T cells are responsible fora portion of the upregulated IL-17A 
transcripts seen in UPEC-infected mouse bladders. 
3.4.2.3.3 Expression of IL-23R in the murine bladder 
 Recently, it has been shown that responsiveness to IL-23 is important for the 
expression of IL-17A by  T cells in a non-TCR-dependent fashion (402).  To see if IL-
23R was expressed in the bladder and thus could be mediating a role in IL-17A 
expression by  T cells in response to UTI, we quantified IL-23R expression in bladder 
tissue by qPCR.  IL-23R transcript was detected in the bladder of C57BL/6 wild type 
mice (Figure 3.7A).  Additionally, unlike the inducible expression of IL-23R by 
peritoneal exudates cells in response to i.p. infection with E. coli (376), expression levels 
in untreated animals were not significantly altered after UTI (Figure 3.7A) and were 
similar in wild type and IL-17A
-/-
 mice (Figure 3.7B).  These results indicate that the IL-
23R is present in the bladder tissue of mice and may mediate rapid expression of IL-17A 
in response to UTI. 
3.4.2.3.4 Expression of  TCR variable chains in the murine bladder 
In addition to IL-23R expression, we wanted to examine and  variable chain 
expression in the bladder during UTI.  Bladders from C57BL/6 mice that were 
transurethrally infected with CFT073 for 48 h were harvested and prepared for RT-PCR.  




Figure 3.7  IL-23R and all of the known  and  TCR variable chains are 
expressed in the murine bladder.  Wild type mice were left uninfected or 
transurethrally infected with UPEC.  (A and B)  At 24 or 48 hpi, bladders (n=5 
each) from wild type of IL-17A
-/- 
mice were harvested for RNA isolation and 
analysis of IL-23R expression by qPCR.  Each symbol represents an individual 
animal while bars represent the median values.  (C)  Bladders were harvested for 
RNA isolation and analysis of  and variable chain expression by RT-PCR.  The 
presence of two products in the V 1 lane may reflect the junctional diversity 






chain, and PCR using 5’ V  with 3’ J  or C  primers and 5’ V  specific primers with 3’ 
J  specific primers was performed on the respective products.  We did not detect a 
preference for V  or V  chain expression in the murine bladder in response to UTI; that 
is, we detected expression of all known V  chains [with the exception of the V 1.3 
pseudogene (55)] and V  chains in the bladder tissue of infected mice (Figure 3.7C), 
indicating that any or all of the  T cells expressing these variable chains could be 
responsible for the expression of IL-17A during UTI.   
3.4.2.4 CD11b+ Gr-1+MHC Class II+ inflammatory cells also produce 
 IL-17A in response to UTI 
 While TCR
-/-
 mice appeared to have deficient upregulation of IL-17A transcript 
in response to UTI, these mice still had some residual expression (Figure 3.5), indicative 
of an additional source of IL-17A.  To investigate what additional cells could be 
producing IL-17A, intracellular staining and flow cytometry was used.  Similar to the 
experiments done with  T cells, cells were harvested and prepared directly from the 
mouse (no in vitro restimulation) to best represent populations of cells producing large 
amounts in vivo.  Using this methodology, it was concluded that CD8
+
 (which includes 
cytotoxic T cells and IELs), B220
+ 





 (including activated macrophages) cells were each not a significant 
source of IL-17A during UPEC-mediated UTI.  However, upon investigation of the 
neutrophil population, another cell type was found to express high amounts of IL-17A.  
Figure 3.8 depicts the gating strategy on representative flow plots from PBS-mock treated 




   







 inflammatory cells.  C56BL/6 mice were 
transurethrally infected with UPEC strain CFT073 or mock infected with PBS for 
48 h before bladders were harvested and prepared for flow cytometric analysis.  
Shown is the gating strategy of a representative PBS-mock treated mouse (left side) 
and an UPEC-infected mouse (right side).  FSC versus SSC plots were gated to 
include most myeloid cells as determined by backgating.  Each successive row is 
the cell population gated in the previous row, and the arrows in the third row 








 and MHC Class 
II
-
.  This cell population does not express IL-17A during the steady-state or in response to 







cell population appears express high amounts of IL-17A in response to UPEC-mediated 





cells both positive and negative for MHC Class II (P =0.0286) 
(Figure 3.9A), only the MHC Class II
+
 population significantly expressed IL-17A in 















 cells (P = 0.0294) (Figure 3.9B).  As 






 cell population expresses IL-17A in 
response to UPEC in the bladder (Figure 3.9C), these inflammatory myeloid cells are also 
a significant source of IL-17A in response to UTI. 
3.4.2.5 IL-17A plays a role in defending the urinary tract  
from acute UPEC colonization  
 To examine the role of IL-17A in innate control of UTI, bladder and kidney 
homogenates from wild type and IL-17A
-/-
 mice were cultured at the reported peak of 
bacterial colonization in C57BL/6 mice, 24 hpi (186).  At this time point, IL-17A
-/- 
mice 
had a 3-fold higher median CFU/gram bladder tissue (Figure 3.10).  By 48 hpi, the peak 
of IL-17A transcript expression in the bladder (Figure 3.3A), this trend increased 10-fold 
to a 35-fold higher median CFU per gram tissue in the bladders of IL-17A
-/- 
mice (Figure 
3.10).  While these trends were reproducible, we sought to investigate later time points, 
presuming the colonization phenotypes resulting from the lack of IL-17A may be 
exacerbated.  Indeed, at both 72 and 96 hpi, IL-17A
-/-











 inflammatory cells expressing IL-
17A.  C56BL/6 mice (n=4) were transurethrally infected with UPEC strain 
CFT073 or mock infected with PBS for 48 h before bladders were harvested 




 cells positive and 












 cells also positive for IL-17A in PBS 
treated and UPEC-infected animals.  Each symbol represents an individual 





  Figure 3.10  IL-17A is necessary for clearance of acute UTI.  Wild type (WT, 
filled symbols) and IL-17A
-/- 
(open symbols) mice were infected transurethrally 
with UPEC strain CFT073.  At 24, 48, 72, and 96 hpi mice were sacrificed and 
bladder homogenates were plated on LB agar to determine the bacterial burden 
(n=14-19 mice per group per time point, 2 or 3 experiments combined).  The 
dotted line indicates the 100 CFU/gram tissue limit of detection.  Each symbol 




bacteria colonizing their bladders (P < 0.05) (Figure 3.10).  Of note, the naïve group of 
mice in the adaptive immune experiments also demonstrated a significant difference in 
colonization, with the IL-17A
-/-
 having a higher bacterial load at 48 hpi (P = 0.0303) 
(Figure 3.2).  These results indicate that IL-17A
-/- 
mice are more susceptible to cystitis 
than wild type mice. 
3.4.2.6 IL-17A is necessary for proinflammatory transcript upregulation in 
response to UTI 
 Given that IL-17A mediates inflammatory responses largely by influencing 
mRNA levels of cytokines and chemokines posttranscriptionally (148-150, 163), we 
wanted to determine if such effects were present in the context of UTI.  Wild type and IL-
17A
-/-
 mice were inoculated transurethrally with UPEC and their bladders were collected 
at 48 hpi for transcript analysis by qPCR.  We measured mRNA levels of a panel of 
chemokines, the antimicrobial effector protein inducible NO synthase (iNOS), and 
cytokines previously shown to be affected by IL-17A expression (110).  At 48 hpi, the 
peak of IL-17A transcript expression in the infected murine bladder, transcripts for all of 
the genes investigated were expressed at a significantly lower level in IL-17A
-/-
 mice 
compared to their wild type counterparts (Figure 3.11).  Of note, expression of the AMP 
-defensin was not found to significant change in response to infection in either genetic 
background.  These results indicate that animals lacking IL-17A
-/-
 signaling are not able 






Figure 3.11 Proinflammatory transcript upregulation in response to acute 
UTI is defective in IL-17A
-/-
 mice. Wild type (filled symbols) and IL-17A
-/-
 
(open symbols) mice were inoculated transurethrally with UPEC strain CFT073.  
Mice (n=7-12, 1 or 2 experiments combined) were sacrificed at 48 hpi and their 
bladders were harvested for qPCR analysis of (A) chemokines CXCL2, CXCL10, 
CCL5, CCL20, and iNOS (NOS2) and (B) cytokines IL-4, IL-6, IFN- , TNF- , 
and G-CSF.  Each symbol represents an individual animal while bars represent the 
median values. 




3.4.2.7 Infected wild type and IL-17A-/- exhibit qualitatively similar responses to 
UTI when examined histologically 
 Since IL-17A
-/-
 mice had decreased cytokine and chemokine expression, we 
decided to examine the bladders of wild type and IL-17A
-/-
 histologically to see if there 
were any gross pathological differences or qualitative differences in inflammation.  
Longitudinal sections of bladders from wild type and IL-17A
-/-
 mice that were either 
uninfected or infected for 48 h (the peak of IL-17A expression) were H&E stained and 
visualized microscopically at low (Figure 3.12) or high (Figure 3.13) magnification.  The 
sections revealed similar histopathological effects in response to UTI both backgrounds.  
More specifically, bladders from the uninfected mice were histologically within normal 
limits, without inflammation or other alteration (Figure 3.12A, C, E, G).  Bladders from 
the infected mice, however, had expansion of the lamina propria by edema fluid 
accompanied by perivascular and interstitial inflammation (Figure 3.12B, D, F, H, black 
filled arrowheads).  These occurrences ranged from mild to severe in both wild type and 
IL-17A
-/-
 mice.  Additionally, umbrella cell sloughing was also apparent in the infected 
animals [compare apical surface of the transitional epithelium in Figure 3.12E and G to 
that in Figure 3.12F and H].  Inflammatory infiltrates consisted of primarily neutrophils; 
although, sometimes a mixed monocytic and neutrophilic infiltrate was observed (Figure 
3.13A-F).  Occasional intraepithelial inflammation was also noted in both backgrounds 
(Figure 3.12H and Figure 3.13B, open arrowhead).  Small numbers of adherent bacteria 
were observed in slides from infected animals (Figure 3.13E, on UC; Figure 3.13F, “B” 
with arrow) while larger numbers of both adherent and intraluminal bacteria were present 
in sections from IL-17A
-/-





Figure 3.12  Wild type and IL-17A
-/-
 exhibit similar histological profiles in 
response to UTI.  Wild type (A, B, E, F) and IL-17A
-/-
 (C, D, G, H) mice were 
left untreated (A, C, E, G) (n=1 each background) or infected with UPEC for 48 h 
(B, D, F, H) (n=3 each background).  (A-D)  40x magnification, bar=500 m;  
(E-H)  200x magnification, bar=100 m. L=lumen, TE=transitional epithelium, 
LP=lamina propria, BV=blood vessel, M=muscularis, UC=umbrella cell, 
B=bacteria, open arrowhead= intraepithelial inflammation, closed arrowheads= 





Figure 3.13  Wild type and IL-17A
-/-
 exhibit similar histological profiles in 
response to UTI.  Wild type (A, C, E) and IL-17A
-/-
 (B, D, F) mice were infected 
with UPEC for 48 h (n=3 each background).  Subsequently, bladders were 
harvested and prepared for histological examination.  Shown are representative 
images of the transitional epithelium (A and B), lamina propria (C and D), and 
bacteria present in the bladder (E and F).  All images: 600x magnification, bar=20 
m.  L=lumen, TE=transitional epithelium, BV=blood vessel, UC=umbrella cell, 




arrowhead), indicative of a decreased ability to eliminate bacteria and consistent with 
higher bacterial loads in the knockout animals (Figure 3.10).  Also depicted is a 
sloughing umbrella cell with adherent UPEC (Figure 3.13E, UC) and inflammatory cells 
accompanying luminal UPEC (Figure 3.13B, arrowhead).  Collectively, histological 
analysis did not reveal any gross pathological defects that could explains the clearance 
defect exhibited by IL-17A
-/-
 animals. 
3.4.2.8 IL-17A is required for optimal macrophage and neutrophil infiltration in 
response to UTI 
3.4.2.8.1 Indirect measures of MPO 
 Neutrophils are the first cell type to migrate to the bladder in the event of UTI, 
and they are crucial for controlling infection at early time points (5, 147, 374).  Since no 
qualitative differences in neutrophil numbers were seen histologically, a more 
quantitative approach was needed to determine the neutrophil response in wild type and 
IL-17A
-/-
 mice was taken.  The levels of MPO, a neutrophil-associated enzyme, in mouse 
bladders were indirectly probed using both a kinetic assay and ELISA.  While detectable, 
the signal for enzymatic activity of MPO in infected mouse bladders (pooled groups of 
10) was extremely weak (Figure 3.14A).  Moreover, while ELISA was able to detect 
MPO in a single mouse bladder, MPO data collected by ELISA was highly variable and 
inconsistent, and there was no significant difference in MPO levels at 6, 24, or 48 hpi in 
infected wild type and IL-17A
-/-
 bladders (Figure 3.14B).  Given the aforementioned 
complications, it was concluded that indirect measurement of MPO by either kinetic 
assay or ELISA was not a reliable approach to determine neutrophil numbers in UPEC-





Figure 3.14  Measurement of MPO levels in the murine bladder by 
kinetic assay and ELISA.  (A)  Wild type mice were transurethrally infected 
with varying amounts of CFT073 and sacrificed at 6 hpi.  Ten bladders were 
pooled for each condition and prepared for kinetic ELISA assay.  (B)  Wild 
type and IL-17A
-/-
 mice (n=5-17 each background, 1 to 3 experiments 
combined) were transurethrally infected with UPEC strain CFT073.  At 6, 24, 
and 48 hpi, their bladders were harvested for MPO-specific ELISA.  
Concentrations were calculated using a standard curve.  Each symbol 




3.4.2.8.2 Direct neutrophil urinalysis 
 In lieu of indirect MPO analysis, more direct quantitative assays were employed 
to determine the neutrophilic infiltrate in wild type and IL-17A
-/-
 mice.  One quick way to 
quantitatively measure neutrophil recruitment to the bladder is to directly count the 
neutrophils in urine using a hemacytometer; the peak of this measurement occurring at 6 
hpi in both mice and humans (4, 147).  At this time point, IL-17A
-/-
 mice had 
significantly fewer neutrophils in their urine (P=0.0480) (Figure 3.15).  Additionally, IL-
17A
-/-
 mice lacked a population of “high-responder” mice present in the wild type cohort; 
these animals had greater than 1.5x10
6
 neutrophils per ml present in their urine at 6 hpi 
(compare 45% of wild type animals to 17% of IL-17A
-/-
 animals, P = 0.0262) (Figure 
3.15).  Since IL-17A transcript and protein are detectable in the bladder at this early (6 h) 
time point (Figure 3.3A) (186), these results indicate that IL-17A may be important for 
very early neutrophil migration to the bladder in response to UPEC infection. 
3.4.2.8.3 Flow cytometry for neutrophils and macrophages 
 To investigate the innate cellular response to UTI in the absence of IL-17A at a 
later time point (48 hpi), we quantified the number of macrophages and neutrophils in 
wild type and IL-17A
-/-
 mice localized to the bladder tissue using flow cytometry.  












 cells.  Representative plots showing the gating strategy for macrophages and 
neutrophils in wild type and IL-17A
-/-
 bladder cells are shown (Figure 3.16A and C).  




Figure 3.15  Early neutrophil infiltration is deficient in IL-17A
-/-
 mice.  
Wild type (filled symbols) and IL-17A
-/-
 (open symbols) mice were 
transurethrally infected with UPEC strain CFT073.  At 6 hpi, urine was 
collected from live mice (n=30-31, 5 experiments combined).  Cells in the 
excretion were stained and neutrophils were counted by hemacytometer.  Each 
symbol represents an individual animal while bars represent the median values.  





Figure 3.16  Macrophage and neutrophil infiltration is deficient in IL-17A
-/-
 
mice in response to UTI.   Wild type (filled symbols) and IL-17A
-/-
 (open 
symbols) mice were infected with UPEC strain CFT073 via the transurethral route.  
Mice (n=14 per background, two experiments combined) were sacrificed at 48 hpi.  













 population was 
further interrogated for MHC Class II negatively to enumerate neutrophils.  (A)  




 cells from wild type (left) 
and IL-17A
-/-




 cells.  




 cells from wild type (left) 
and IL-17A
-/-
 animals (right).  The bottom plots show MHC Class II expression by 







 cells.  In (A) and (C) numbers are the percent of the parent population and 
in (B) and (D) each symbol represents an individual animal while bars represent 







(P=0.0031) (Figure 3.16D) cell populations were significantly lower in IL-17A
-/-
 mice as 




 cells likely represent a monocyte or 
macrophage population that has not undergone activation (Figure 3.16A), which 






mice.  Moreover, the presence of the MHC Class II
-
 cell population in the IL-17A
-/-
  mice 
suggests that there is not a defect in macrophage migration to the bladder in response to 
infection, but a defect in macrophage activation, which could potentially be due to 
inadequate expression of IFN-  in this background (Figure 3.11B).   Uninfected mice 
were not examined in this particular study, as knockout mice were limited and the 





 population in PBS-treated animals in Figure 3.8).  These data reveal that IL-17A plays 
an important role in the recruitment of neutrophils to the bladder, and potentially 
activation of macrophages, in response to UPEC infection. 
3.4.3 IL-17R-/- mice lacking the receptor for IL-17A display enhanced clearance of 
UPEC during experimental UTI 
 Due to impaired proinflammatory cytokine and cellular responses, mice lacking 
IL-17A
-/-
 appear to have an inability to clear UPEC-mediated UTI as well as their wild 
type counterparts (Figure 3.10).  Among the 5 IL-17 cytokine family members, IL-17F 
has the highest degree of amino acid homology to IL-17A (~50%) (184, 217).  IL-17F 
has also been shown to function similarly to IL-17A in terms of stimulating neutrophil 
recruitment during infection, albeit with less efficiency (184, 217).  Given the role of IL-
17A in clearance (Figure 3.10) and the redundant function of IL-17A and IL-17F, one 




to UPEC-mediated UTI than IL-17A
-/-
 mice.  IL-17A and IL-17F both signal though IL-
17R (or IL-17RA) (257, 381, 421), and another IL-17R family member, IL-17RC, is 
necessary for optimal signaling (421).  Since we had access to IL-17R
-/-
 mice, the 







have since been generated by a group in Japan (187)].  IL-17R
-/- 
mice were 
transurethrally infected with CFT073 and sacrificed at 48 hpi to determine the bladder 
and kidney bacterial burden.  Surprisingly, mice lacking IL-17R
-/-
 were more resistant to 
UPEC-mediated UTI than wild type mice, as both their bladders and kidneys had 
significantly less bacteria (P = 0.0065 and P = 0.0479, respectively) (Figure 3.17A).  
Upon examination of the cellular infiltrate in these animals, no statistically significant 











) populations (Figure 3.17B); however, there was a 
trend toward deficient infiltration of phagocytes in the receptor knockout mice.  These 
results suggest an additional unanticipated level of regulation in signaling by the IL-17 
ligand and receptor family members, as a lack of signaling through IL-17R results in an 







Figure 3.17  IL-17 receptor knockout (IL-17R
-/-
) mice are less susceptible 
to UTI than wild type animals.  Wild type and IL-17R
-/-
 mice were 
transurethrally infected with CFT073.  (A)  Bladder and kidney CFU (n=17-
18 each background, 3 experiments combined) was enumerated at 48 hpi.  
(B)  Bladders were harvested for examination of cellular infiltrate by flow 
cytometry (n=5-6 each background).  FSC versus SSC plots were gated to 
include all positive neutrophil and macrophage events in the infiltrating cell 
population.  Each symbol represents an individual animal while bars 






With the exception of ABU (449), the bladder mucosa has been widely accepted 
as a sterile environment.  Mammalian hosts employ a number of mechanisms to keep this 
niche microbe-free, as infection by bacterial and fungal pathogens can lead to serious 
clinical consequences.  Here we characterized the role of the cytokine IL-17A during UTI 
using a murine model.  IL-17A was upregulated specifically in response to UPEC 
antigens by secondary lymphoid tissue cells from UPEC-infected C57BL/6 mice.  IL-
17A transcripts were also highly upregulated in the bladders of acutely infected mice,  






 inflammatory monocyte (IM) cells being major 
sources.  Although no role for IL-17A in infection-induced protection was observed, we 
noted a deficiency in bladder neutrophil influx during the very early stages of acute 




mice also had impaired 
proinflammatory transcript expression and fewer macrophages and neutrophils 
infiltrating the bladder tissue days after UTI.  Taken together, these results define IL-17A 
as an important factor in the innate immune response to UPEC-mediated UTI.  
3.5.2 Adaptive immunity and IL-17A 
Although the presence of pathogen-specific antibodies in the urine and serum of 
infected humans and experimental animals has been documented for decades (434), the 
cascade of immunological events that occurs during the generation of adaptive immunity 
during UTI has not been established.  Although cells from UPEC-sensitized mice highly 




vaccine-induced protective immunity (Figure 3.2).  This result is in contrast to 
vaccination models for Streptococcus pneumoniae, Bordetella pertussis, and 
Pseudomonas aeruginosa, where IL-17A was required for a protective immunity (165, 
250, 321).  As the immune system features redundant pathways, it is unclear if there is a 
compensatory factor acting in bladder or lymphoid tissue or if the downstream effects of 
IL-17A are indeed not necessary for a protective response to UTI.   
3.5.3 Innate immunity and IL-17A 
3.5.3.1 Dynamics and stimulants of IL-17A transcription during UTI 
 In addition to secretion in a recall response setting, IL-17A is upregulated in an 
innate fashion (Figure 3.3A).  Similarly, airway IL-17A peaked innately in response to 
intranasal infection with Chlamydia muridarum, another mucosal pathogen, and this was 
dependent on bacterial replication (471).  In experimental UTI, IL-17A upregulation was 
also shown to be either UPEC-specific or dependent on the ability of UPEC to 
successfully colonize the urinary tract, as transurethral inoculation of a fecal strain EFC4 
does not induce IL-17A transcript to the levels of the uropathogenic strain (Figure 3.4B).  
As shown in Figure 3.3A and B, expression dynamics of IL-17A during the first week of 
infection superimposes with bladder colonization by UPEC.  Using either gDNA or 
cDNA as a template, PCR could be conducted on samples from individual mice to 
determine if there is a direct correlation between the level of bacterial infection (as 
measured by the amount of fimH in semi-quantitative or qPCR, for example) and 
expression of IL-17A mRNA by the host.  The apparent dose-dependency of this 




expression) supports the latter idea that upregulation of IL-17A in response to UTI is 
colonization-dependent and stimulated by recognition of PAMPs, not pathogen-specific 
motifs.  As a future study, it would be interesting to determine which of these 
suppositions is accurate by stimulating primary bladder cells with E. coli strains EFC4 
and CFT073 in vitro and assessing IL-17A transcript upregulation or secretion by qPCR 
or ELISA, respectively.  However, this type of approach will exclude the cells that 
migrate to the bladder in response to infection to secrete IL-17A (Figure 3.9B).  
Alternatively, EFC4 and CFT073 lysates or killed cells could be transurethrally instilled 
into mice to determine if stimulation with strain-specific antigens is sufficient for 
migration of IL-17A-secreting cells and secretion of IL-17A.  Additional strains that are 
known to colonize or not colonize the urinary tract (“uropathogenic” to different extents) 
could also be tested to shed light on this topic.  While the more likely explanation for 
stimulation of IL-17A transcription by CFT073 and not EFC4 has to do with the ability to 
colonize the urinary tract, at this time one cannot rule out the possibility of a UPEC-
specific ligand that stimulates IL-17A.   
3.5.3.2 The discrepancy between IL-17A transcript and IL-17A protein expression 
A recent study by Ingersoll and colleagues surveyed cytokines and chemokines in 
the bladder of mice during a two-week experimental UTI (186).  While most of the 
protein levels examined peaked around two dpi and returned to near baseline levels after 
a week, IL-17A peaked accordingly but remained elevated (relative to control mice) 
throughout the experiment (186).  Our IL-17A transcript data was consistent with these 




17A protein in bladder homogenates from infected mice, a different pattern of expression 
was detected: low, but detectable, baseline levels in uninfected animals that steadily 
increased in response to infection throughout the duration of the experiment (Figure 
3.3C).  These results differed from the transcript data in that: 1) transcript levels are 
completely undetectable in the absence of infection, and 2) transcript levels demonstrate 
a signature spike in expression at two dpi while in protein steadily increases over time.  
The methodology used in the study by Ingersoll et al. negates comparison with the 
protein data in Figure 3.3C, as they used cytokine bead arrays rather than ELISA and 
expressed the data as a ratio compared to mock-treated animals rather than as calculated 
concentrations using a standard curve.  This fact aside, the protein data we generated 
(Figure 3.3C) may not correlate with our transcript data (Figure 3.3A) due to rapid 
receptor-ligand internalization and subsequent degradation of IL-17A during the early 
time points.  This phenomenon has been demonstrated for other cytokines (361).  While 
receptors for IL-17A are expressed ubiquitously (217), the lack of the additional 
inflammatory cell infiltrate at later time points may hasten this process, allowing protein 
levels to linger and appear to increase over time.  Alternatively, detergent was not used 
during homogenization of the bladder tissue, thus intracellular IL-17A may not have been 
detected due to incomplete cell lysis in the absence of a cellular disruption agent.  
Regardless, it is not known if IL-17A persists in the bladder longer than 28 dpi, or if the 
presence of IL-17A is beneficial or deleterious to host tissue, as residual IL-17A could 
conceivably aid in either priming the urinary tract in the event of reinfection or lead to 




3.5.4 Cell types responsible for upregulation of IL-17A during UTI 
3.5.4.1  T cells 
A number of cell types have been shown to secrete IL-17A (32).  Unlike classical 
 T cells, which recognize antigen that is processed and presented in the context of self 
MHC molecules,  T cells harbor the ability to directly recognize cognate antigen, 
allowing for rapid production of effector molecules (55, 62).  Therefore, because of the 
early upregulation of IL-17A in the bladder (Figure 3.3A) (186), we reasoned that CD4-
positive Th17 cells are not the principal source of IL-17A.  Despite being in the T cell 
minority (Figure 3.6A), intracellular staining and flow cytometric analyses demonstrated 
that  T cells were a major source of IL-17A during UTI (Figure 3.6B-D).  We also 
confirmed expression of IL-23R transcript in the bladder tissue of infected mice (Figure 
3.7A), an important factor in secretion of IL-17A by  T cells (402).   
It was previously reported that the main IL-17A-producers in the liver after L. 
monocytogenes infection were γδ T cells of Vγ4 and/or Vγ6 type(s) (142).  Even more 
rapid production of IL-17A by γδ T cells was reported in a murine E. coli i.p. infection 
model, and in this model, the responsive γδ T cells were found to be mainly the Vγ6Vδ1-
expressing subset (376).  Thus, we wanted to investigate if similar repertories of γδ T 
cells are involved in UTI host defense.  As antibodies for the known  and  variable 
chains were not readily available, RT-PCR was performed on RNA collected from 
UPEC-infected mouse bladders.  Using previous established primer sets, all the variable 
chains probed were found to be expressed in the bladder (Figure 3.7C).  Follow-up 
studies include qPCR analyses to quantitatively determine expression levels of the 




determine expression of IL-17A by  T cell subsets.  On a final note, TCR 
-/-
 mice were 
still able to generate some IL-17A transcript over background (Figure 3.5), demonstrating 
that additional cell types make IL-17A in the bladder of UPEC-infected mice.   
3.5.4.2 CD11b+Gr-1+MHC Class II+ inflammatory myeloid cells 
Indeed, upon exploring the capability of neutrophils to secrete IL-17A in this 






cells to upregulate IL-
17A in response to infection (Figure 3.8 and Figure 3.9).  This cell population is only 
present in the bladder in significant numbers after mice have been infected with UPEC 
(Figure 3.9A) and may represent an IM population (17, 371).  Approximately 15% of this 
cell population makes IL-17A, translating to a median of 4x10
3
 bladder cells (roughly 
0.8% of the total cells in the bladder) (Figure 3.9B and C).  Aside from their ability to 







cells during UTI is unclear and warrants further investigation.  In total, 
these results suggest that -positive cells and an uncharacterized inflammatory myeloid 
population secrete IL-17A in response to UPEC infection.   
3.5.5 IL-17A and control of bacterial infection 
3.5.5.1 The role of IL-17A in controlling bacterial burdens 
In the context UTI, IL-17A appears to play a role in optimal restriction of 
bacterial burden, especially at time points after the peak of IL-17A expression in wild 
type mice (Figure 3.10).  Infection models for L. monocytogenes, disseminated E. coli, K. 
pneumoniae, oral and systemic Candida albicans, oral T. gondii, C. muridarum, Bacillus 




invading organism (68, 142, 178, 210, 376, 379, 465, 471).  This collection of data 
demonstrates the breadth and versatility of IL-17A-mediated pathways in handling 
various classes of microbes.  In contrast, IL-17A has been shown to be dispensable for 
clearance in infection models for systemic S. enterica serovar Enteritidis and pulmonary 
M. bovis bacille
 
Calmette-Guérin (363, 364, 438).  The factors determining whether or 
not IL-17A signaling is important for clearance in a particular infection model are not 
clear.  They may depend on anatomical location, inherent qualities of the infectious 
agent, or innate immune signaling in response to pathogen recognition.  Lastly, mice 
treated with IL-17A neutralizing antibody experience exacerbated bacterial loads in the 
liver and peritoneal exudates in response to i.p. infection with E. coli (376), suggesting 
that this background may generally lack the ability to control infection with E. coli.  
Other routes of infection with E. coli (for example, gut infections with enterohemorrhagic 
or enteropathogenic strains) or UTI caused by other uropathogens (for example, 
Klebsiella, Pseudomonas, Proteus, or Enterococcus species) need to be examined to 
determine if the lack control of UPEC-mediated UTI by mice unable to signal through 
IL-17A is specific to the bacterium or to the biological niche. 
3.5.5.2 The role of IL-17A in regulating cytokine and chemokine expression 
IL-17A has a well-documented role in regulating cytokine, chemokine, and 
antimicrobial expression (110).  Thus, it was not surprising that proinflammatory bladder 
transcripts probed in infected IL-17A
-/-
 mice were not expressed as well as in wild type 
counterparts (Figure 3.11).  The lack of chemokines important for the infiltration of 




CCL20) may each or all contribute to the defect in bacterial clearance seen in the IL-17A
-
/-
 animals.  Additionally, cytokines crucial for activation and mobilization of innate 
immune responses (IL-6 and IFN- ) were also lacking in this background.  While 
deficiency in these transcripts may be the result of inadequate stimulation of epithelial 
cells and resident macrophages, lower iNOS levels may be a reflection of impaired 
neutrophil infiltration in the IL-17A
-/-
 mice (Figure 3.15 and Figure 3.16D).  
Unexpectedly, IL-4 was also significantly lower in the bladders of IL-17A
-/-
 mice.  IL-4 
is a canonical Th2 cytokine (291), and given that IL-4
-/-
 mice do not have an acute UPEC 
clearance defect (198), a function in UTI immunity has not been defined.  Nonetheless, 
the role of IL-4 in B cell activation (219) suggests that IL-4 may be upregulated to 
stimulate B cell antibody generation in an adaptive response to UTI.  In total, it appears 
that there is a general inflammatory defect in IL-17A
-/-
 mice, and that genes of both 
appreciated and unknown importance are affected by the absence of IL-17A during UTI.   
3.5.5.3 The role of IL-17A and recruitment of neutrophils and macrophages 
Since IL-17A orchestrates neutrophil recruitment to infected tissue, there is 
precedence for an innate immune mechanism involving rapid secretion of large amounts 
of IL-17A to bolster neutrophil killing of UPEC (147, 217).  We could not detect any 
qualitative differences in inflammatory cell recruitment by histological examination of 
bladders from wild type and IL-17A
-/-
 mice (Figure 3.12 and Figure 3.13), nor was 
quantitation of MPO a sensitive enough assay to reveal differences in neutrophil 
infiltration between wild type and IL-17A
-/-
 mice (Figure 3.14B).  However, when 
counted directly in the urine, a lack of early neutrophil infiltrate in IL-17A
-/-




apparent (Figure 3.15).  This result was potentially due to both impaired neutrophil exit 
from the bone marrow and migration to the bladder tissue, as growth factor G-CSF and 
neutrophil-specific chemokine transcripts were both decreased in infected IL-17A
-/- 
animals.  Interestingly, antibody-mediated knockdown of G-CSF rendered mice more 
resistant to UTI, and the authors of that study suggested that macrophage activation status 
may be responsible for this surprising phenotype (186).  Although deficient in G-CSF 
expression, IL-17A
-/-
 mice do not exhibit an enhanced clearance phenotype, possibly 
owing to the pleiotropic effects of IL-17A deficiency or signaling by residual G-CSF.   
We also examined neutrophil levels in wild type and IL-17A
-/-
 mice at later time 
points during infection.  Macrophages were included in the analysis to see if their total 
numbers varied similarly to neutrophils.  Upon UPEC infection, numbers of both cell 
populations increased several fold over PBS mock-infected mice; however, both 
neutrophil and macrophage counts were lower in the IL-17A
-/- 
mice (Figure 3.16B and 
D).  These data reveal that the defect IL-17A
-/-
 mice exhibit in UPEC clearance may be 
due to less macrophages and neutrophils present in the bladder to execute bacterial 
clearance. 
3.5.6 The unexpected clearance phenotype exhibited by IL-17R-/- mice 
While one may expect that removing a particular ligand or its corresponding 
receptor from a system would yield the same phenotype, redundancy and broad 
functionality of the immune system appears to meddle with the simplicity of this concept.  
In this work, IL-17A
-/-
 mice and IL-17R
-/-
 mice were found to have opposing phenotypes 




while the receptor knockouts more efficiently eliminated UPEC (Figure 3.10 and Figure 
3.17A).  Unfortunately, we only had access to a small group of IL-17R
-/-
 mice for a 
follow-up analysis of inflammatory cell infiltration by flow cytometry, which was 
inconclusive (Figure 3.17B).  With no knowledge of UTI-specific cytokine or cellular 
responses in the IL-17R
-/- 
animals, we will make predictions regarding the hyperclearance 
phenotype based on the literature.  Similar to IL-17R
-/-
 animals, we mentioned in section 
3.5.5.3 that mice treated with an anti-G-CSF antibody and infected transurethrally with 
UPEC exhibited enhanced bacterial clearance (186).  Mice lacking G-CSF did, however, 
also have increased levels of cytokines and chemokines that influence macrophage 
activity and recruitment (186).  Moreover, mice lacking both IL-17A and IL-17F had 
increased amounts of several proinflammatory cytokines in response to Citrobacter 
rodentium infection (187).  These results suggest that signaling though IL-17R may 
negatively regulate expression of proinflammatory cytokines.  In support of this, IL-17R
-
/-
 mice infected with Helicobacter pylori had a marked increase in gastric B cells, plasma 
cells, and lymphoid follicles, indicating that IL-17R signaling down-regulates the chronic 
mononuclear inflammation elicited by H. pylori infection (6).  Therefore, a lack of 
signaling through IL-17R may result in an exacerbated upregulation of proinflammatory 
cytokines in UPEC-infected IL-17R
-/-
 mice, and this milieu may incite enhanced UPEC 
killing by both myeloid and lymphocytic cellular infiltrate.  It is possible that in the IL-
17A
-/-
 mice, residual signaling by IL-17F keeps this hyperinflammatory phenotype in 
check, at the cost of both deficient proinflammatory responses and bacterial clearance.  
To this end, some in vitro studies were conducted where RAW or primary bone marrow 




analyzed for their ability to engulf and destroy UPEC.  While having issues with 
repeatability, these experiments did hint at an inhibitory role for the IL-17 family of 
cytokines.   
IL-17R can interact with several members of the IL-17 cytokine family leading to 
differential signaling cascades and biological outcomes.  As mentioned earlier, both IL-
17A and IL-17F have been shown to interact with IL-17R when in a complex with IL-
17RC, leading to varying levels of signaling and cellular responses (421).  Furthermore, 
in a complex with the IL-17RB receptor, IL-17R has been shown to be able to bind to IL-
25, resulting in the induction of IL-5 and IL-13, a Th2 skewing milieu (335).  In the 
absence of IL-17R, Th2-type immune responses may be inhibited, allowing Th1-type 
responses (and activation of proinflammatory responses and phagocytosis by the 
corresponding cytokines) to predominate, materializing as a hyperclearance phenotype.  
There also may be a cellular component to this regulation, as IL-17R is highly expressed 
on hematopoietic cells, while the other IL-17R family members and their splice variants, 
like IL-17RC, are highly expressed on non-hematopoietic cells (224).  The lack of IL-
17R expression on immune cells may negate inhibitory signaling received via this 
receptor, leaving these cells unchecked in their bactericidal functions.  All told, there 
appears to be an intricate balance of signaling necessary for optimal clearance of UPEC.  
Mice experiencing enhanced bacterial clearance due to hyperinflammatory responses 
may also sustain permanent damage to the epithelia or chronic inflammation.  Future 
studies examining the inflammatory responses of IL-17R
-/-
 mice during UTI should 





Collectively, these data demonstrate that IL-17A plays a role in the innate 
immune response to experimental UTI in a mouse model.   As many of the genes 
influenced by IL-17A have similar function during UTI in mice and men (324), we 
expect that IL-17A also plays a role in controlling the bacterial burdens early during UTI 
in humans.  IL-17A accomplishes such control by enhancing the presence of mRNA 
transcripts important for the infiltration of neutrophils and other inflammatory mediators.  
The presence of such cell types is crucial to the defense of the urinary tract from 





Chapter 4  
Discussion and Future Directions 
4.1 Overview and Primary Findings 
 UPEC induces a robust innate immune response that involves, among other 
facets, cytokine and chemokine secretion and immune cell infiltration.  While it has been 
observed that both transurethral infection with live UPEC and intranasal vaccination with 
UPEC antigens afford mice with an acquired immune response that results in accelerated 
clearance, little has been established regarding the nature of adaptive immune effectors 
(i.e. specific T cell subsets and antibody isotypes) and innate mediators of this acquired 
immune response.  In this work, the efficacy of UPEC OM iron receptor antigens as 
mucosal vaccine candidates was determined; in this process immunological correlates of 
protection were established, a significant contribution to field of UTI vaccinology.  Both 
the relative levels of urinary IgA in the bladder and relative levels of antigen-specific IgG 
in the serum are linked to protection from UPEC-mediated UTI.  Additionally, the role of 
IL-17A was evaluated in the innate and adaptive host response to UTI.  While 
upregulated in both arenas, infections in IL-17A
-/-
 mice revealed that IL-17A, while 
dispensable for the formation of acquired immunity, was necessary for optimal control of 
the innate immune response to UPEC in the bladder.  IL-17A was shown to be secreted 
by  T cells and an IM population.  The presence of IL-17A was required for 




macrophage migration to the bladder, events that likely result in the clearance defects 
exhibited by IL-17A
-/- 
mice.  Taken together, these findings contribute significantly to the 
understanding and of innate and adaptive immune responses during UTI. 
4.2 Development of a vaccine against UPEC-mediated UTI 
4.2.1 A new approach to identifying UPEC vaccine candidates 
Conventional vaccinology approaches targeting bone fide virulence factors of 
UPEC, namely FimH of type 1 fimbriae, have generated promising data in animal models 
(235).  Regardless of these efforts, there is no licensed vaccine available for prevention of 
UTI humans in the United States.  This result is likely due to the challenge of targeting a 
relatively heterogeneous group of pathogenic strains in a unique physiological niche.  A 
new approach was necessary to identify novel vaccine targets suitable for animal trials.  
Despite the advances afforded by reverse vaccinology, an in silico genomics-based 
approach to vaccine development (54), it was not practical at the time due to a lack of 
high-throughput methods to test for protection.  A more optimal approach to UPEC 
vaccine discovery would be one that is broad and unbiased, yet has some aspect of 
selectivity to narrow the list of candidates.  An example of this has been employed in 
Pneumococcal vaccinology (117).  Applied to UPEC, we thought it would be useful to 
target only PASivE candidates, UPEC proteins that are pathogen-specific, antigenic, 
surface-exposed, and in vivo expressed.  These particular traits are attractive because they 
ensure that the targets are not widely expressed by commensal E. coli, are accessible to 
and recognized by the host immune system, and are synthesized specifically in vivo and 




4.2.2 The “omics” screening approach  
to identify PASivE UPEC vaccine candidates applied 
Somewhat to our surprise, the six top ranking PASivE vaccine candidates (those 
that repeatedly ranked highest in all the screens) all belong to the same functional class of 
proteins.  The hits were all membrane proteins involved in iron acquisition, a process 
critical for microbial pathogenesis.  Other, lower-ranked targets identified by these 
studies included metabolic transporters, putative adhesins, and hypothetical proteins that 
may represent novel virulence factors.  While not representative of a class of critical 
virulence factors, these candidates still warrant testing in the murine model.  Intranasal 
immunization of CBA/J mice with three of the six OM iron receptors provided significant 
protection from experimental infection.  There were no apparent characteristics hinting at 
why some of the OMP iron receptors were protective and some were not.  Putative 
reasons may include the solubility of the proteins (affecting APC uptake) or the presence 
of preferential epitopes for antigen presentation in some aa sequences and not others.  
Alternatively, each of the iron receptors may have similar potential in stimulating 
efficacious acquired immunity; however, temporal and quantitative expression of these 
receptors by UPEC may dictate the ability of antigen-specific antibodies to interfere with 
iron uptake or target bacteria for destruction. 
4.2.3 Immune responses to OM iron acquisition receptors 
 With regard to cytokine responses, all six candidates similarly induced 
transcription and secretion of proinflammatory cytokines and chemokines.  In addition, 
regardless of protective effect, systemic humoral responses were elicited by all 




dramatically was the robustness and magnitude of these responses.  Both antigen-specific 
class-switching from IgM to IgG and production of antigen-specific IgA in the urine were 
found to represent immunological correlates of protection from E. coli bladder 
colonization.  The discovery of immunological correlates of protection is a significant 
contribution to UTI vaccine research, as a reverse vaccinology approach can now be 
applied to identify additional vaccine candidates.  Rather than conducting challenges on 
large numbers of animals, larger pools of vaccine candidates can be screened on a small 
group of animals and be evaluated for efficacy by their class switch indices and ability to 
generate antigen-specific IgA in urine. 
4.2.4 Targeting a class of functionally redundant virulence factors  
in a multivalent vaccine 
 The results of the “omics” approach to identify PASivE vaccine candidates clearly 
indicated the importance of iron uptake in uropathogenesis.  By default, these results 
brought forth the idea of targeting an entire class or classes of molecules important for 
virulence.  Given the absolute requirement of iron and the presumed functional 
redundancy of proteins involved in its acquisition, in hindsight, targeting iron uptake 
systems as a whole should have been considered an obvious approach.  Indeed, a 
multivalent vaccine that contains several antigens, each targeting a difference iron uptake 
system, would presumably curb bacterial evasion of host iron sequestration and is 
therefore more inclined to generate sterilizing immunity.   
 While potent immunologically, the OMP iron receptors themselves are not 
attractive vaccine candidates because of their biochemical nature: they are relatively large 




purification.  Rather than combining each protein candidate in its entirety, this current 
theme may evolve to incorporate potent antigenic motifs from each target in an inert 
carrier protein backbone.  Additionally, we predict that the lengthy extracellular loops 
that protrude beyond the LPS and capsule layers contain the antigenic epitopes that are 
recognized by the host immune system.  The fact that mice vaccinated with synthetic 
peptides representative of the extracellular loop sequences demonstrates a trend toward 
protection accompanied by some, admittedly modest, antigen-specific immune responses 
supports this prediction.  These modest immune responses may be due to inefficient 
uptake of soluble peptides by APCs, resulting in poorer antigen processing and 
presentation (237) – a process that could be improved by delivery in more formulations 
that facilitate optimal modes of phagocytosis for antigen presentation.   
 Regardless of whether the loops actually contain aa sequences of interest, epitopes 
from IreA, Hma, and IutA (protective candidates) must be mapped and cloned for 
combinatory administration in a multivalent platform.  To do this, splenocytes from mice 
immunized with the protective candidates need to be harvested and fused to myeloma 
cells.  Hybridoma supernatants can then be evaluated for secretion of specific antibody by 
ELISA, and hybridomas
 
secreting OMP iron receptor-specific antibody cloned (by 
limiting dilution
 
or plating in soft agar), expanded, and preserved in frozen stocks.  Once 
mAbs are isolated, they can be evaluated for antimicrobial activity in a number of in vitro 
assays and in mice for their ability to passively protect naïve donors from transurethral 
challenge with UPEC.  After identification of biologically relevant clones, the epitopes of 
interest can be mapped by screening overlapping synthetic peptides corresponding to the 




sequences representing other parts of the protein should also be analyzed.  It is also 
possible that the epitopes of interest may be discontinuous conformational epitopes, in 
which case a much more laborious effort involving predictions based on crystal structures 
and screening point mutations may be necessary.  Testing the reactivity of the mAbs of 
interest against unfolded and re-folded protein will also help discern if the epitopes of 
interest are conformation-dependent.  After this extensive effort, potent epitopes from the 
different receptors can be cloned and expressed in combination or combined in another 
type of platform or evaluation of efficacy in mouse trials.  
 Other systems that could potentially be used in a multivalent vaccine strategy are 
proteins involved in adherence or effector secretion.  Capsular and O-antigens are also 
likely multivalent vaccine targets; however, their heterogeneity approaches a realm where 
vaccine design is impractical, if not impossible.  Thus, the next horizon in vaccine 
development may involve the identification of genes previously unknown to be 
responsible for essential virulence phenotypes and combination of the respective gene 
products into a single cocktail for vaccination.   
4.2.5 Testing routes and adjuvants 
 The testing phase presents a new challenge for UPEC vaccinology.  As discussed, 
the field should advance towards a multi-subunit vaccine directed against PASivE 
proteins.  Additionally, being a mucosal pathogen, the vaccine must be administered with 
an appropriate adjuvant.  The involvement of TLRs in the immune response to UTI and 
current knowledge of their ability to incite innate and direct adaptive responses make 




mucosal adjuvants and variations in vaccination routes and schedules must be tested in an 
effort to generate UPEC-specific local and systemic antibodies (238, 317) and optimize 
production of immunological memory, not tolerance (57, 260).  To this end, animal trials 
must be used to address these issues and also to distinguish details regarding the 
molecular and cellular factors that play a role in the adaptive immune response to UTI.  
There is considerable work to be done to better understand the mechanisms of protective 
immunity against UPEC in the bladder.  Specifically, available knockout mouse strains 
could be used to systematically evaluate the role of various receptors (CD series), 
cytokine and chemokine ligands and receptors (e.g., CXC or CC families), innate 
signaling molecules (e.g., MyD88, TRIF, TRAM, “3d” mice lacking intracellular TLRs) 
and cell types (for example, CCR2
-/-
 mice lack IMs) in controlling UPEC-mediated UTI 
and eliciting potent adaptive and memory immune responses.  Ideally, the field can 
acquire insights on UTI immunity at a level suitable to rationally develop a much-needed 
vaccine that elicits sterilizing immunity against UPEC in the human urinary tract. 
4.2.6 Recurrent UTI and immunological memory 
 Despite immunity to natural infection, reinfection is a rampant problem.  There is 
much controversy in the field as to the cause of reinfection.  Same-stain reinfection has 
been documented, indicative of a reservoir (191, 277, 461).  The source of this reservoir, 
however, is debatable, and there appears to be two main schools of thought.  The first is 
that UPEC strains exist in the gut among benign fecal flora and fecal contamination of 
the vaginal meatus and the urethra result in reinfection.  The second is that, during the 




involves the formation of QIRs that foster reemergence of UPEC and symptomatic 
infection upon an uncharacterized epithelial damage event (280).  While either or both of 
these theories may be partly or entirely accurate, the simple fact of the matter is that if 
clonal reinfection is occurring, lasting effective immunity is not generated by natural 
infection.  As it has been demonstrated in the mouse model, an adaptive immune 
response is generated during natural infection, the longevity of which is unknown.  The 
fact that same-strain reinfections have been documented in patients indicates that while 
exposure of the bladder mucosa to UPEC antigens may stimulate an adaptive immune 
response, this response is not lasting.  The results of the SolcoUrovac trials also support 
this conclusion, as ceasing the administration of uropathogenic antigen vaginal 
suppositories correlates with recurrence of UTI in patients (427, 429).  Since there was no 
“official” adjuvant used in the Solco trials (it is assumed that the sample preparations 
were ripe with LPS and other TLR stimulants), it is possible that administration with a 
more effective (perhaps non-TLR-based) adjuvant may stimulate lasting effects.  Support 
for this idea is found in the Salmonella literature, as there is a report documenting the 
generation of acquired humoral and cellular immunity independent of TLR4, TLR2, and 
MyD88 signaling (368).  Ultimately, the appropriate adjuvant would be one that 
stimulates the activation of dendritic cells in such a way to mobilize production of a 
protective immune response.  Regardless of adjuvant choice, the resonating idea is the 
use of multivalent vaccine formulations containing epitopes from PASivE candidates.  
Ideally, potent administration of a few tailored targets (rather than an thousands of 
antigens found on whole cells, some in limiting concentrations) will increase the 




4.2.7 Outlook on vaccination 
While treatments have been proposed to expel intracellular UPEC from the 
bladder (37, 280), an E. coli reservoir harboring potential UPEC strains will always be 
present in the intestine (194, 272, 461).  From epidemiology studies delineating UTI risk 
factors to cell and molecular studies characterizing the host response during UTI, 
research in the field is critical to ameliorate the societal and economic costs associated 
with this disease of morbidity.  While many general concepts regarding the immune 
response to UTI are understood, many molecular details are only beginning to be 
discovered and appreciated.  Such details are likely going to be the key in the 
development of a successful vaccine for use in humans or more effective and directed 
treatments in lieu of antibiotics.   
4.3 Determining the role of IL-17A during UTI 
4.3.1 Adaptive immunity: If IL-17A isn’t important, what is? 
 Given the identification of humoral correlates of protection in a vaccine setting 
and the vast literature documenting the antibody response to UPEC, the role of the 
humoral response in clearance of UPEC infection is obvious.  What is not clear is the Th 
cell population that mediates activation of B cells and development of antibody-secreting 
plasma cells.  Chapter 2 highly implicated Th17 cells in mediating the immune response 
to intranasal vaccination with UPEC antigens.  Since these experiments were conducted, 
literature has emerged indicating that both the cholera toxin adjuvant and the intranasal 
route of vaccination stimulate Th17-mediated immune responses (239, 473), indicating 




the Th cell response.  Thus, it is not surprising that, in Chapter 3, IL-17A was found not 
to be necessary for the formation of an effective adaptive immune response to natural 
(transurethral) infection.  Considering IL-17A is the signature cytokine of the Th17 
subset of T cells, this result could suggest that Th17 cells do not play a role in acquired 
immunity to UTI.  Despite this notion, Th17 cells are known to secrete a number of other 
cytokines (i.e., IL-21, IL-22) that may play a role in adaptive immunity to UTI.  
Moreover, both DCs and infected apoptotic cells are present in the infected mouse 
bladder.  This is pertinent information as DC phagocytosis of infected apoptotic cells is 
the cellular event that triggers secretion of the cytokine milieu (TGF-  and IL-6) that 
promotes development of the Th17 lineage, indicating that Th17 cells have potential to 
develop in the bladder in response to UPEC infection.  Future studies to test the role of 
Th17 cells in UTI may involve evaluating IL-22
-/-
 mice in the protective model of UTI.  
Regarding the Th1/ Th2 dichotomy, in response to intranasal vaccination, no Th1 or Th2 
skewing was evident upon examination of indicative antibody isotypes (IgG2a verses 
IgG1).  Nonetheless, cytokine secretion dynamics by splenocytes from protected and 
non-protected animals suggested that Th1 cells were involved for acquired UTI 
immunity.  To help discern which Th subsets contribute to the formation of humoral 
responses to UTI, it would be useful to purify CD4
+
 cells from the bladders of in vivo-
stimulated (infected) and UPEC-antigen vaccinated mice to probe Th cell skewing in 
response to repeated transurethral infection with UPEC.  Evaluating adaptive immune 
responses in both IL-6 and IL-12p35 knockout mice, which would not be able to generate 




to orchestrate the recall response to UTI.  This facet of the adaptive immune response 
needs to be delineated both during natural infection and during mucosal vaccination.   
4.3.2 Innate UTI immunity 
4.3.2.1 Cytokine responses and IL-17A in the context of UTI 
 Upon infection with UPEC, the bladder epithelium mobilizes in every sense of the 
term.  Umbrella cells undergo apoptosis and slough from the surface; meanwhile, a 
robust cytokine and chemokine response accompanied by edema and cellular 
inflammation fill the bladder epithelium and underlying lamina propria.  While IL-17A 
was shown to be necessary for an optimal innate response to infection, IL-17A
-/-
 animals 
were still able to mount a response, albeit a subpar one, highlighting the functional 
redundancy of the innate immune system.  The fact that, amongst this redundancy, IL-
17A
-/-
 mice still exhibit a clearance defect further illustrates the importance of IL-17A in 
controlling bacterial infection in the bladder.  This defect is probably attributable to the 
fact that expression of IL-17A is intimately linked to the neutrophil recruitment (217).  
Neutrophils have been both indirectly and directly shown to be critical for control of 
UPEC infection in the mammalian bladder (5, 147, 191, 374).  What’s more, the 
downstream effectors of IL-17A signaling (i.e., IL-8, G-CSF, AMPs) have also been 
shown to be important in UTI host defense, thus the investigation of IL-17A in UTI was 
an obvious next step.   
4.3.2.2 Role of IMs during UTI 
 In the process of exploring the role of IL-17A in the host response to UTI, it was 










 cells, or IMs, make IL-17A in response to infection.  The involvement of  T cells in 
UTI host defense was heavily supported by the literature and therefore an immediate 
beacon of interest.  In addition to being required for optimal clearance of a primary UTI 
episode (198), a large majority of the  T cells present in the bladder (migration was 
marginal, most of this small population was resident) during infection were making IL-
17A.  On the other hand, similar to the neutrophil population, IMs are not present in the 
bladder at high numbers, but migrate from the bone marrow in response to UTI.  In the 
case of the  T cells, the majority of a minority cell population is making IL-17A, which 
translates to hundreds of cells, whereas with the IMs, a fraction of a majority cell 
population is making IL-17A, which translates to thousands of cells.  This IM population 
was detected purely by coincidence and as a result of ample numbers and robust synthesis 
of IL-17A, as neutrophils were actually the cell population being probed.  Therefore, two 
very different cell lineages, ILLs and myeloid cells, make IL-17A in response to UPEC-
mediated UTI. 
 Monocytes are largely divided into two subsets, those involved in homeostasis 
(surveillance) and those involved in inflammation (17).  Aside from the fact that they 
migrate in large numbers to the inflamed bladder and they make IL-17A, the function of 






 cells – in the context of UTI is 
unknown.  In the future, it would be useful to further characterize this cell type.  First, 
they should be probed by flow cytometry for expression of CD115, CCR2, CD62L, and 
CX3CR1 surface markers to further confirm the identity of this population as that of IMs 
(17, 371).  They should also be interrogated for Ly-6G (Gr-1) and Ly-6C expression, as 




has been described in the L. monocytogenes literature that these IMs can develop into 
Tip-DCs, suggestive of a function in the secretion of NO and TNF-  (372).  Tip-DCs are 
not present in mice lacking CCR2, and transurethral infection of CCR2
-/-
 mice 
demonstrated that Tip-DCs are dispensable for UPEC clearance from the urinary tract 
(84).  This result also suggests that the IM population may also not be necessary for the 





are more susceptible to UPEC infection, these results may suggest that secretion of IL-
17A by the  T cell population is more critical than secretion by the IM population.  
Alternatively, by virtue of their ability to phagocytose pathogens and present antigens, 
IMs and Tip-DCs may play a role in the adaptive immune response to UTI, justifying 
testing of CCR2
-/-
 mice in the reinfection model. 
4.3.2.3 Turning off the innate immune response to UTI:  
regulators and therapeutic potential 
 While deciphering the dynamics of and players in IL-17A upregulation is 
important to understanding the host response to UTI, what is even more crucial (and 
perhaps underappreciated) is the cessation of IL-17A expression and signaling in 
inflamed tissue.  Indeed, IL-17A has been implicated in several autoimmune diseases 
including rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis, 
and asthma (220).  As demonstrated in this study, IL-17A is a potent inflammatory 
cytokine, further illustrated by the fact that transcript is not expressed basally in the 
steady state.  Treg cells have emerged as the counterbalance to the Th17 subset (296).  
These cells secrete inhibitory cytokines such as IL-10, IL-35, and TGF- , and 




dependent (65).  Suppression of the robust inflammatory response generated by UPEC 
infection and the presumable role that Treg cells play in this process should be a topic of 
future inspection.  Related to this topic, the cause of interstitial cystitis is unknown and 
could potentially link to uncontrolled expression of IL-17A and chronic inflammation in 
response to UTI.  Due to its role in regulating inflammatory responses to infection and 
correlation with autoimmune disease, IL-17A has gained much attention over the last ten 
years as a target of anti-inflammatory therapeutics.  While beneficial in the realm of other 
diseases, treatment with antibodies or inhibitors that block the activity of IL-17A may 
render a patient more susceptible to bacterial cystitis.  Nonetheless, considerations of the 
level of morbidity in autoimmune disease relative to UTI may negate this risk.   
4.4 Closing statements 
 Modeled experimentally in mice, the role of the proinflammatory cytokine IL-
17A is defined with respect to the innate and adaptive immune response in the natural 
route of infection.  Regarding adaptive immune mechanisms playing a role in protection 
against UPEC-mediated UTI, potential vaccine candidates and their corresponding 
immunological correlates of protection were tested and determined, respectively. The 
results presented in this dissertation significantly contribute to the current understanding 
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